Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 1of 113
CLINICAL PROTOCOL
AN8-WEEK, RANDOMI ZED, CONTROLLED, EXAMINER -BLIND, 
CLINICAL STUDY TO EVALUATE THE EFFICACY OF A STANNOUS 
FLUORIDE TOOTHPASTE FOR THE RELIEF OF DENTIN 
HYPERSENSITIVITY IN A POPULATION OF DENTIN 
HYPERSENSITIVITY SUFFERERS
Protocol Number: [ADDRESS_798488] Name: 0.454percent ( %)weight/weight ( w/w) 
stannous fluoride ( SnF 2) toothpaste
[LOCATION_002] (US) Investigational 
New Drug (IND) Number:N/A
European Clinical Trials Database (EudraCT) Number:N/A
Other Regulatory Agency Number:N/A
Phase: N/A300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
This document contains confidentiality statements that are not relevant for this publicly
available version
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 2of 113
Sponsor Information
Sponsor Name & Legal 
Registered AddressHaleon ([LOCATION_006]) 
The Heights,
Building [ADDRESS_798489] Floor,
Weybridge ,
Surrey,
KT13 0NY,
[LOCATION_008] ([LOCATION_006])
Sponsor Contact [CONTACT_602999],
Weybridge,
Surrey,
KT13 0DE,
[LOCATION_006]300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 3of 113
Document History
Document Version Summary of Changes 
Original Protocol 1.0 N/A
Protocol 2.0 C orrection of an administrative error relating to the DHEQ 
endpoints and analysis.
Section 1.1. Synopsis, Objectives and Endpoints and Section 
3. Study Objectives and Endpoints: DHEQ-related endpoints.
Section [ADDRESS_798490] on Everyday Life ( Q1-3) corrected to Section [ADDRESS_798491] on Everyday Life ( Q7-9).
12.3.2. Secondary Endpoint Analyses, DHEQ- 48:
Section [ADDRESS_798492] on Everyday Life: Q1 , Q2& Q3 (separate 
scores) corrected to Section [ADDRESS_798493] on Everyday Life: Q7, Q8 
& Q9 (separate scores)
Amendments incorporate all revisions to date, including amendments made at the request of the 
country health authorit y, institutional review board ( IRB), etc.  300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 4of 113
Investigator Protocol Agreement Page
•I confirm agreement to conduct the study in compliance with the protocol and any 
amendments according to the current International Conference on Harmonisation Good 
Clinical Practice (ICH GCP) guidelines , and applicable medical device regulation s.
•I acknowledge that I am responsible for overall study conduct. I agree to personally 
conduct or supervise the described study.
•I agree to ensure that all associates, colleagues and employees assisting in the conduct of 
the study are informed about their obligations. Mechanisms are in place to ensure site sta ff 
receive all appropriate information throughout the study.
•I agree to conduct this study in full conformance with the laws and regulations of the 
country in which the research is conducted and the Declaration of Helsinki.
Investigator Name:
[CONTACT_1216]:
Investigator Signature:
[CONTACT_1217]/Agreement:
DD-Mmm -YYYY300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI[COMPANY_003][COMPANY_003][COMPANY_003]
[COMPANY_003]
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 5of 113
Table of Contents
Sponsor Information ................................ ................................ ................................ ............ 2
Document History ................................ ................................ ................................ ............... 3
Investigator Protocol Agreement Page ................................ ................................ ................ 4
Table of Contents ................................ ................................ ................................ ................ 5
1PROTOCOL SUMMARY ................................ ................................ ................................ 10
1.1 Synopsis ................................ ................................ ................................ ................. 10
1.2 Schedule of Activities ................................ ................................ ............................ 14
2INTRODUCTION ................................ ................................ ................................ ............. 18
2.1 Background and Rationale for Study ................................ ................................ .....19
2.2 Benefit/Risk Assessment ................................ ................................ ....................... 19
2.3 Mechanism of Action/Indication ................................ ................................ ........... 20
3STUDY OBJECTIVES AND ENDPOINTS ................................ ................................ ....21
4STUDY DESIGN ................................ ................................ ................................ .............. 23
4.1 Overall Design ................................ ................................ ................................ .......23
4.2 Scientific Rationale for Study Design ................................ ................................ ...24
4.3 Justification for Dose ................................ ................................ ............................. 28
4.4 End of Study Definition ................................ ................................ ......................... 29
5STUDY POPULATION ................................ ................................ ................................ ....29
5.1 Type and Planned Number of Subjects ................................ ................................ .29
5.2 Inclusion Criteria ................................ ................................ ................................ ...29
5.3 Exclusion Criteria ................................ ................................ ................................ ..30
5.4 Randomization Criteria ................................ ................................ .......................... 32
5.5 Lifestyle Considerations ................................ ................................ ........................ 32
5.5.1 Oral Hygiene Restrictions ................................ ................................ .....33
5.5.2 Dietary and Alcohol Restrictions ................................ .......................... 33
5.5.3 Contraception ................................ ................................ ........................ 33
5.6 Screen Failures ................................ ................................ ................................ .......33
5.7 Sponsor’s Qualified Medical Personnel ................................ ................................ 33
5.8 Rater/Clinical Assessor Qualifications ................................ ................................ ..34
6INVESTIGATIONAL/STU DY PRODUCTS ................................ ................................ ...[ADDRESS_798494] Dispensin g................................ ................................ ............... 36
6.2 Administration ................................ ................................ ................................ .......37
6.2.1 Medication/Dosing Errors ................................ ................................ .....[ADDRESS_798495] Storage ................................ ................................ ........................... 38300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798496] Supplies ................................ ................. 39
6.5 Blinding and Allocation/Randomization ................................ ............................... 39
6.6 Breaking the Blind ................................ ................................ ................................ .40
6.7 Compliance ................................ ................................ ................................ ............ 41
6.8 Concomitant Medication/Treatment ................................ ................................ ......[ADDRESS_798497] 
DISCONTINUATION/WITHDRAWAL ................................ ................................ ......... [ADDRESS_798498] Dis continuation/Withdrawal ................................ ................................ .....[ADDRESS_798499] to Follow Up ................................ ................................ ................................ ..43
8STUDY PROCEDURE S................................ ................................ ................................ ...43
8.1 Visit 1 / Screening ................................ ................................ ................................ .43
8.1.2 Demographics ................................ ................................ ....................... 44
8.1.3 Review of Oral Care Products ................................ ............................... 44
8.1.4 Medical History and Prior Medications/Treatments ............................. 44
8.1.5 Clinical Examinations and Assessments ................................ ............... 44
8.1.6 Inclusion/Exclusion Criteria ................................ ................................ .[ADDRESS_798500] Eligibility ................................ ................................ ................. 45
8.2 Study Period ................................ ................................ ................................ .......... 46
8.2.1 Visit 2 / Baseline (Day 0) ................................ ................................ ......46
8.2.2 Visit 3 / Day 28 (± 2 days) ................................ ................................ ....49
8.2.3 Visit 4 / Day 56 (± 3 d ays)................................ ................................ ....[ADDRESS_798501] ................................ ................................ ................................ 52
9STUDY ASSESSMENTS ................................ ................................ ................................ .53
9.1 Screening Examinations/DH Assessments ................................ ............................ 53
9.1.1 Erosion , Abrasion and Recession (EAR) ................................ .............. 53
9.1.2 Modified Gingiv al Index (MGI) ................................ ........................... 53
9.1.3 Clinical Mobility ................................ ................................ ................... 54
9.1.4 Screening Tactile Sensitivity Assessment ................................ ............. 54
9.1.5 Screening Evaporative (Air) Sensitivity Assessment ........................... 56
9.2 DH Efficacy Assessments ................................ ................................ ...................... 56
9.2.1 Dentine Hypersensitivity Experience Questionnaire (DHEQ -48)........ 56
9.2.2 Tactile Sensitivity Assessments ................................ ............................ 57
9.2.3 Evaporative (Air) Sensitivity Assessments ................................ ........... 58
9.2.4 Labelled Magnitude Scales (LMSs) ................................ ...................... 58
9.3 Safety Assessments ................................ ................................ ................................ 59
9.3.1 Oral Soft Tissue (OST) Examination ................................ .................... [ADDRESS_798502] Tissue (OHT) Examination ................................ .................. 59300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 7of 113
9.3.3 Pregnancy ................................ ................................ .............................. 59
9.3.4 Satisfaction with Treatment ................................ ................................ ..60
10ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS ................................ ......... 60
10.1 Definition of an Adverse Event (AE) ................................ ................................ ....60
10.2 Definition of a Serious Adverse Event (SAE) ................................ ....................... [ADDRESS_798503] Reported Outcomes ................................ ................................ 71
12STATISTICAL CONSIDERATIONS AND DATA ANALYSES ................................ ..71
12.1 Sample Siz e Determination ................................ ................................ ................... 71
12.2 Populations for Analysis ................................ ................................ ........................ 71
12.2.1 Definition s of Analysis Populations ................................ ..................... 71
12.2.2 Exclusions of Data from Analysis ................................ ......................... 72
12.3 Statistical Analyses ................................ ................................ ................................ 72
12.3.1 Primary Endpoint Analysis ................................ ................................ ...73
12.3.2 Secondary Endpoint Analyses ................................ ............................... 73
12.3.3 Exploratory Analyses ................................ ................................ ............ 75
12.3.4 Safety Analyses ................................ ................................ ..................... 76
12.3.5 Demographic and Baseline Characteristics ................................ ........... 77300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798504] (IRB) ................................ ......................... [ADDRESS_798505] Recruitment ................................ ................................ .............. 80
13.3.5 Reporting of Safety Issues and Serious Breaches of the Protocol or 
ICH GCP ................................ ................................ ............................... 80
13.4 Posting of Information on Publicly Available Clinical Trial Registers ................. 80
13.5 Provision of S tudy Results to Investigators ................................ ........................... 80
13.6 Records Retention ................................ ................................ ................................ ..81
13.7 Cond itions for Terminating the Study ................................ ................................ ...81
14REFERENCES ................................ ................................ ................................ .................. 82
15APPENDICIES ................................ ................................ ................................ .................. 89
15.1 Abbreviations ................................ ................................ ................................ ......... 89
15.2 Dentine Hypersensitivity E xperience Questionnaire (Example DHEQ -48)......... 91
15.3 Labelled Magnitude Scales: Intensity, Duration, Tolerability & Description 
(Example LMSs) ................................ ................................ ................................ ....98
15.4 LMS Training Exercise (Example) ................................ ................................ ......100300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798506] of In-Text Tables
Table 1 -1 Schedule of Activities ................................ ................................ ........... 15
Table 6 -1 Acclimatization/Investigational Toothpastes ................................ ........ 34
Table 6 -2 Sundry Items ................................ ................................ ......................... 35
Table 15 -1 Abbreviations ................................ ................................ ........................ 89300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 10of 113
1 PROTOCOL SUMMARY 
1.1 Synopsis
Summary Title:
Clinical study to evaluate the anti-sensitivity efficacy of a stannous fluoride toothpaste in a 
population of dentin hypersensitivity sufferers .
Background and Rationale for the Study :
Stannous fluoride (SnF 2) has been incorporated into oral hygiene products indicated for the 
relief of dentin hypersensitivity ( DH)since the 19 90s; it provides relief from DH by [CONTACT_603000][INVESTIGATOR_602960]. 
Randomized controlled clinical trials (many of8weeks treatment duration) support the long er-
term anti-sensitivity efficacy of 0.454% SnF 2-containing toothpastes with twice daily use. The 
aim of the current 8-week study is to confirm the clinical DH efficacy of a 0.454% SnF [ADDRESS_798507] theocclusion mode of action (MoA) of SnF 2orthe anti -sensitivity efficacy of a0.454% 
SnF 2toothpaste .In addition to demonstrat ingthe efficacy of theTest Toothpaste , this study 
will monitor the impact of daily use of a 0.454% SnF 2toothpaste on the number of ‘Sensitive 
Teeth’ , and subject perception of product benefits .
DH will be assessed at Baseline, and after [ADDRESS_798508]-Baseline time 
point, the efficacy of the 0.454% SnF 2toothpaste will be compared with that of a regular 
fluoride toothpaste with no known anti -sensitivity efficacy (negative control).
Objectives and Endpoints :
Objectives Endpoints
Efficacy
Primary
To demonstrate the clinical efficacy of a 
0.454% w/w SnF 2toothpaste in reducing DH 
to an evaporative ( air) stimulus (as measured 
by [CONTACT_603001]), compared to a 
negative control toothpaste, after 8 weeks
twice daily use.Change from Baseline in Schiff sensitivity score at Day 56 (Week 8).
Secondary
To demonstrate the clinical efficacy of a 
0.454% w/w SnF 2toothpaste in reducing DH
to a tactile stimulus (as measured by [CONTACT_603002] [g]), compared to a 
negative control toothpaste, after 8 weekstwice daily use.Change from Baseline in tactile threshold 
(g) at Day 56 (Week 8).300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 11of 113
To demonstrate the clinical efficacy of a 
0.454% w/w SnF 2toothpaste in reducing DH 
to evaporative ( air) and tactile stimuli ( as 
measured by [CONTACT_603003] (g), respectively), compared 
to a negative control toothpaste, after 4 weeks
twice daily use.Change from Baseline in Schiff sensitivity 
score at Day 28 (Week 4).
Change from Baseline in tactile threshold (g) at Day 28 (Week 4).
To describe subject-perceived changes in oral health -related quality of life (OHrQoL), as 
measured by [CONTACT_603004] (DHEQ-48), after 4- and 8- weeks twice daily use of their 
assigned investigational toothpaste.At Day 28(Week 4) & Day 56 (Week 8) :
Change from Baseline in DHEQ-48 
endpoints.
Section 1 
•Impact on Everyday Life (Q7-9) 
Section 2 
•Total Score (Q1-34) 
•Individual Domain S cores
-Restrictions (Q1-4) 
-Adaptation (Q5-16)  
-Social Impact (Q17-21)  
-Emotional Impact (Q22-29)  
-Identity (Q30-34)  
•Global Oral Health Score (Q35) 
•Effect on Life Overall Score (Q36-39)
Exploratory
To determine the number of ‘Sensitive Teeth’
(evaporative (air) sensitivity only ) in the pool 
of ‘Eligible Teeth’ identified at Screening, at 
Screening, Baseline, and after 4 and8 weeks 
twice daily use of assigned investigational
toothpaste.At Screening, Baseline, Day 28 (Week 4) & 
Day 56 (Week 8):
Number of ‘Sensitive Teeth’ 
Defined as the number of ‘Eligible Teeth’ 
(identified at Screening) with a Schiff Sensitivity 
Score ≥ 2.
To investigate subject-perceived changes in 
DH toan evaporative (air) stimulus, as 
measured by [CONTACT_603005] (LMSs), after 4 and 8 weeks twice daily useof their assigned investigational toothpaste.At Day 28(Week 4) & Day 56 (Week 8) :
Change from Baseline in LMS endpoints.
•Intensity
•Duration
•Tolerability
•Description
To investigate the relationship between subject responses to the DHEQ-48 and the 
LMSs at Baseline, and after 4 and 8 weekstwice daily use of assigned investigationaltoothpaste.At Baseline, Day 28(Week 4) & Day 56 
(Week 8):
•DHEQ-48 endpoints, as listed above.
•LMS endpoints, as listed above.
To investigate the relationship between the Schiff sensitivity scale and the LMSs at Baseline, and after 4 and 8 weeks twice daily use of assigned investigational toothpaste.At Baseline, Day 28(Week 4) & Day 56 
(Week 8):
•Mean Schiff sensitivity score of the two 
‘Test Teeth’.
•LMS endpoints, as listed above.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798509] satisfaction with their 
assigned investigational toothpaste for the 
overall management of DH, as measured by a Numeric Rating Scale (NRS), after 8 weeks treatment.At Day 56 (Week 8) :
Satisfaction NRS score  
Safety
To monitor the safety and oral tolerability of the investigational toothpastes over 8 weekstwice daily use.Treatment emergent adverse events (TEAEs).
Study Design :
This will be a single center , 8-week, randomi zed, controlled, examiner -blind, 2-treatment arm, 
parallel design, stratified (by [CONTACT_603006] 
‘Test Teeth ’) clinical study toevaluat ethe anti-sensitivity efficacy of a 0.454% SnF 2toothpaste
in a DHpopulation. The clinical efficacy of the 0.454% SnF 2toothpaste (Test Toothpaste ) will 
be compared with that of a Reference Toothpaste, a commercially available, regular fluoride 
toothpaste with no known anti -sensitivity properties (negative control) .
At Screening (Visit 1), f ollowing provision of written informed consent , suitability to 
participate will be reviewed against the protocol inclusion/exclusion criteria . Eligible subjects 
will enter an acclimatization period ( 14-28 days )prior to Baseline assessments during which 
they will brush twice daily (morning and evening) with theacclimatization toothpaste ( a 
different commercially available, regular fluoride toothpaste from the Reference Toothpaste ).
At Baseline (Visit 2), eligib ility to continue will be assessed. Subjects who demonstrate the 
required qualifying levels of DH at Screening (Visit 1) and Baseline (Visit 2) will be
randomized to study treatment and instructed to brush with their assigned investigational 
toothpaste twice daily (morning and evening) for the duration of the 8-week treatment period. 
DH will be assessed at Screening (Visit 1) and Baseline (Visit 2) , and after 28-and56-days 
treatment (Visits 3 and4, respectively ) using two independent clinical measure s:(i) tactile 
threshold (g)following a tactile stimulus and (ii) Schiff sensitivity score following an 
evaporative (air) stimulus .
Oral health -related quality of life (OHRQoL) will be monitored over the treatment period using 
theDentin Hypersensitivity Experience Questionnaire (DHEQ -48), completed by [CONTACT_603007] (Visit 2) , and after 28 -and 56-days treatmen t (Visits 3 and 4, respectively) . 
Subject -perceived DHwill also be investigated across the 8 -week treatment p eriod using four 
Labelled Magnitude Scales (LMS s)to capture the Intensity , Duration , Tolerability and 
Description of their response to theevaporative (air) stimulus .At the final visit (Day 56) , 
subjects will rate their level of satisfaction with the irassigned investigational toothp aste for the 
overall management of their DH,using a Numeric Rating Scale (NRS) .
Safety and oral tolerability of the investigational toothpastes will be monitored over the 8-week 
usage period by [CONTACT_603008] (TEAEs) .300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 13of 113
Investigational Products :
DescriptionTest 
ToothpasteReference Toothpaste 
(Negative Control)
Name 0.454% w/w SnF 2toothpasteRegular fluoride toothpaste
(Crest Cavity Protection*)
Master 
Formulation Code N/A
Fluoride Level 1100 parts per million ( ppm) fluoride†1100 ppm fluoride¥
Route of 
AdministrationTopi[INVESTIGATOR_602961] a ribbon of toothpaste, across the full brush head.
Brush the entire dentition thoroughly 
for at least 1-timed minute, twice daily 
(morning & evening), making sure to 
brush the sensitive areas of the two 
'Test teeth' carefully first.Brush the entire dentition 
thoroughly for at least 1-timed 
minute, twice daily (morning & 
evening).
Subjects who wish to rinse a fter brushing will be instructed to rinse with 10 
milliliter (ml ) water using graduated rinsing cup provided.
*Commercially available daily use toothpaste , USmarket .  
†As SnF 2
¥As sodium fluoride (NaF)
Type and Planned Number of Subjects :
Male and female subjects aged 18 -65years (inclusive), in good general and oral health ,with a 
minimum of [ADDRESS_798510] two teeth with clinical lyconfirmed DH , 
(tactile threshold ≤ 20g and Schiff sensitivity score ≥ 2 at both Screening andBaseline visits )
will be randomized to treatment .
Sufficient subjects will be screened and entered into the acclimatization period to randomi ze 
approximately 110subjects to investigational product (approx imately 55per treatment group )
and s o ensure approximately 100evaluable subjects complete the entire study (approx imately 
50per treatment group ), allowing for approximately 10% dropouts.
Statistical Analysis Summary:
A modified Intent -To-Treat (mITT) population ( all randomized subjects who receive at least 
one dose of investigational product and complete at le ast one -post Baseline DH efficacy 
assessment )will be used for the efficacy analyses .Significance testing will be conducted at the 
two-sided 5% significance level .
Schiff sensitivity score andtactile threshold (g) will be derived as the mean score /value ofthe 
two ‘Test Teeth’ (selected at Baseline). Change from Baseline will be derived for each
individual t ooth first before calculating mean change forthe two‘Test Teeth’ .
The primary endpoin t, change from Baseline in Schiff sensitivity score at Day 56 ,will be 
analyzed using a Mixed Model with Repeated Measures (MMRM) with investigational product, 
visit and [investigational product x visit] interaction as fixed effects, and Baseline Schiff 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCICCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798511] Toothpaste 
compared to Reference Toothpaste (negative control) at Day 56 from the MMRM will be 
presented ,along with the two-sided p -value and 95% con fidence interval s (CIs) .
The k ey secondary endpoint, change from Baseline in tactile threshold (g) at Day 56, will be 
analysed using the same MMRM as the primary endpoint but with Baseline tactile threshold (g) 
as covariate . In addition, the maximum Baseline Schiff sensitivity score of the two ‘Test Teeth’
(2 or 3) will be fitted as a fixed effect. The difference between the least square mean changes 
from Baseline for the Test Toothpaste compared to Reference Toothpaste (negative control) at 
Day 56 from the MMRM will be presented ,along with the two -sided p -value and 95% CIs. 
Summary statistics (mean, median, standard error ( SE), standard deviation (SD), minimum, 
maximum) will be presented for each Schiff sensitivity score and tactile threshold (g) outcome 
variable at each assessment time point. Raw means (± SE) of Schiff sensitivity score andtactile 
threshold (g) at each assessment timepoint will be plotted by [CONTACT_3148] g roup.
1.2 Schedule of Activities
The Schedule of Activities (Table 1 -1) provides an overview of the subject visits ,study 
procedures and assessments . The investigator may schedule additional (unplanned )visits to 
conduct additional evaluations or assessments required to protect the well -being of the subject.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 15of 113
Table 1-1 Schedule of Activities
Procedure/AssessmentStudy Visits
Visit 1
ScreeningVisit 2
Day 0
BaselineVisit 3
Day 28
(± 2 days ) Visit 4
Day 56
(± 3 days)  
Informed Consent XAcclimatization Period (14-28 days)Demographics X
Review Subject’s Oral Care Products X
Review Medical History & Current/Prior Concomitant Medication/Treatment1X
Review Changes in Health & Medications/Treatments1X X X
Return Acclimatization Toothpaste, Toothbrush & Diary2X
Return Investigational Toothpaste, Toothbrush & Diary2X
Compliance Checks 2X X X
Subject-Completed DHEQ 3X X X
Subject-Completed LMS Training Exercise X
Oral Soft Tissue (OST) Examination X X X X
Oral Hard Tissue (OHT) Examination X X
Eligible Teeth Assessments (Dentition Exclusions, Erosion/Abrasion/ Recession [EAR], 
Modified Gingival Index [MGI], Tooth Mobility)X
Qualifying Clinical Assessment of Tactile Sensitivity 4X X
Qualifying Clinical Assessment of Evaporative (Air) Sensitivity (Schiff sensitivity score)5X X
Subject-Perceived Evaporative (Air) Sensitivity (LMSs)6X
Clinical Assessment of Evaporative (Air) Sensitivity of the Remaining ‘ Eligible Teeth’
Identified at Screening5 X300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 16of 113
Procedure/AssessmentStudy Visits
Visit 1
ScreeningVisit 2
Day 0
BaselineVisit 3
Day 28
(± 2 days ) Visit 4
Day 56
(± 3 days)  
Clinical Examiner Selects Two ‘Test Teeth’ (Qualifying Subjects Only)7X
Review Inclusion/Exclusion Criteria X X
Confirm Subject Eligibility/Qualification X X
Dispense Acclimatization Toothpaste, Toothbrush, Timer, Rinsing Cups & Diary X
Supervised Brushing with Acclimatization Toothpaste X
Stratification/Randomization X
Dispense Investigational Toothpaste, Toothbrush, Rinsing Cups & Diary X X8
Supervised Brushing with Investigational Toothpaste X
Clinical Assessment of Tactile Sensitivity: Two ‘Test Teeth’ Only4X X
Clinical Assessment of Evaporative (Air) Sensitivity (Schiff sensitivity score) : Assess the 
Two ‘Test Teeth’ First, then the Remaining ‘ Eligible Teeth’ Identified at Screening5 X X
Subject-Perceived Evaporative (Air) Sensitivity (LMSs): Two ‘Test Teeth’ Only 6X X
Supervised Brushing with Investigational Toothpaste X
Satisfaction with Treatment: Subject-Completed NRS X
Study Conclusion X
Monitor Adverse Events (AEs) and Medical Device Incidents 9X X X X
FOOTNOTES : 
1.Female subjects of child -bearing potential should be asked to confirm pregnancy status at each visit .300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 17of 113
2.Subjects will be required to bring their study supplies (minus timer & rinsing cups) to every visit. 
Perform visual check of returned study supplies, review diary & evaluate compliance .
Visit 2: Check compliance with use of acclimatization toothpaste .
Visit 3 & Visit 4: Check compliance with use of investigational toothpaste .
Visits 2 -4:Check compliance with Lifestyle Guidelines/Medication requirements. 
3.DHEQ -48must be completed prior to the OST examination and clinical assessments .
Visit 2: Complete all questions .
Visits 3& 4:Complete Section 1 ,Questions 7-9& Section 2 ,all questions .
4.Tactile Threshold Assessment s:Visits 1 -2:Maximum force 20g (Screening and Baseline); Visits 3 -7:Maximum force 80g.
5.Evaporative (air) sensitivity (Schiff sensitivity score) should be assessed after tactile sensitivity , ensure minimum [ADDRESS_798512] evaporative (air) assessment for tooth recovery. 
Visit 1 (Screening) : Assess evaporative (air) sensitivity forall teeth with a Screening tactile threshold ≤ 20g .
Visit 2 (Baseline) :First assess evaporative (air) sensitivity forall ‘Eligible Teeth ’identified at Screening with a Baseline tactile threshold of ≤ 20g,then
assess theremaining ‘Eligible Teeth ’(i.e.,the remaining teeth from the pool of ‘Eligible Teeth ’identified at Screening ,with a Baseline tactile 
threshold >20g ).
Visit 3 (Day 28) & Visit 4 (Day 56) :First assess evaporative (air) sensitivity forthetwo‘Test Teeth ’first, then assess theremaining ‘Eligible Teeth ’ 
identified at Screening (excluding the two ‘Test Teeth’ ).
‘Eligible Teeth’ = Teeth with no dentition exclusions which met EAR, MGI & mobility criteria, with Screening tactile threshold ≤ 20g &Screening Schiff sensitivity score ≥ 2.
6.Visit 2 (Baseline) :Complete 4 LMSs (Intensity, Duration, Tolerability & Description )for each tooth with a Baseline Schiff sensitivity score ≥ 2 only, 
immediately after theBaseline Schiff sensitivity score has been recorded for thattooth .
Visit 3 (Day 28) & Visit 4 (Day 56) :Complete 4 LMSs for each ‘Test T ooth’,immediately after its Schiff sensitivity score has been recorded .
7.Selected ‘Test Teeth’ should be in different quadrants ,with the requisite qualifying levels of DH at both Screening (Visit 1) andBaseline (Visit 2) , i.e., tactile 
threshold ≤ 20 g andSchiff sensitivity score ≥ 2.
8.Visit 3: Supply new diary only.
9.AEs, and therefore all serious adverse events (SAEs) will be recorded from immediately after signing the informed consent form (ICF) until [ADDRESS_798513] use of the medical device (the manual toothbrush used to app ly the 
acclimatization and investigational toothpastes).300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 18of 113
2 INTRODUCTION
Dentin hypersensitivity (DH) is a common dental condition ; prevalence is reported to range 
from 3% to 57% in the general population ( Addy, 2002 ). It is typi[INVESTIGATOR_602962]/or gingival recession experienced in adulthood ( both of which lead to 
expos ure of the underlying dentin) (West, 2022 )and has been described as a ‘short, sharp pain 
arising from exposed dentine in response to stimuli typi[INVESTIGATOR_602963], evaporative, tactile, 
osmotic or chemical and which cannot be ascribed to any other form of dental defect or disease ’
(Addy, 1985 ; Canadian Advisory Board on Dentin Hypersensitivity, 2003 ).Clinically, the
primary diagnosis of tooth hypersensitivity is made when a patient complain sof brief, well -
localized pain resulting from thermal (typi[INVESTIGATOR_602964]), tactile, or osmotic stimulation of exposed 
dentin in the absence of any other dental pathology ( Addy, 2002 ).  
The most widely accepted theory to explain DHis the hydrodynamic theory, first described in 
the literature by [CONTACT_603009] ( Gysi, 1900 ) and expanded on later by [INVESTIGATOR_341008]ännström ( Brännström, 1963 ). 
The hydrodynamic theory proposes that an external s timulus , such as a temperature (cold or
hot)or osmotic differential ,or tactile pressure ,applied to exposed dentin disrupts the movement 
of fluid within dentin tubules. This disruption is thought to stimulate mechanoreceptors 
associated with odontoblast processes and nerve fibers located near the cervical pulp -dentin 
complex, triggering the s hort, sharp pain characteristic of DH(Absi, 1987; Pashley, 1994 ). 
Other mechanisms for DH have been proposed, however only the hydrodynamic theory 
explains the paradoxical finding that the dentin -enamel junction is sensitive to external stimuli, 
even though the dentin itself appears not to be highly innervated ( Dababneh, 1999 ). The theory 
is also consistent with the observation that treatment of hypersensitive dentin with agents that 
either occl ude the exposed dentin tubules or reduce mechanoreceptor/nerve activity ,results in 
areduction in the discomfort orpain observed clinically ( West, 2014 ). 
Twice daily use of an anti -hypersensitivity toothpaste is generally recommended as the first line 
treatment for DH; treatm ent modalities are based on either dentin tubule occlusion or intra-
dental nerve desensitization ( Addy, 2002 ; Pereira, 2015 ). SnF 2is on eof the most commonly 
employed tubule occluding agents used in Over-the-Counter (OTC) toothpastes and has been 
widely marketed as a tooth desensitizer in OTC daily use toothpastes (0.454% w/w SnF 2) in the 
US for many years . The stannous (tin [II]) ion reacts with water and phosphate minerals found 
in the saliva and dentin tubule fluid to rapi[INVESTIGATOR_602965] ( Makin, 2013 ; Miller, 1994 ).These depo sits act as barriers to external stimuli for DH , 
physically blocking or narrowing the openings of exposed tubules, thereby [CONTACT_603010]-dental nerves and 
evoke a pain respon se (Addy M, 2002; Burnett GR, 2013 ; Miller S, 1994 ; Parkinson ,2011 ).
The use of SnF [ADDRESS_798514] used as an anti-caries agent in dentifrices ( Makin, 2013 ). Numerous clinical studies 
reported in the scientific literature since then have established the safety and clinical efficacy 
of SnF 2, not only as an anti -caries active, but also as an anti-DH and anti -plaque/gingivitis agent.
Citizens Petitions were submitted by [CONTACT_226982] & Gamble in 2006 ,and GlaxoSmithKline 
Consumer Healthcare ( [COMPANY_004]CH now Haleon ) in [ADDRESS_798515] and review new efficacy data supporting 
the reclassification of SnF 2(0.454% w/w) as a Category I safe and effective tooth sensitizer ,in 
addition to its recognized anti -caries GRASE status. The outcome of the FDA review of these 
citizens petitions and the finalization of the Oral Health Care Drug Product monograph is 
pending.    300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 19of 113
2.1 Background and Rationale for Study
Stannous fluoride (Sn F2) has been incorporated into oral hygiene products indicated for the 
relief of DH since the 19 90s (Schiff, 2006 ); it provides relief from DH by [CONTACT_603011][INVESTIGATOR_602966] (Makin, 2013 ; Miller, 1994 ). Haleon (the sponsor of this study) has marketed 0.454% 
SnF 2toothpaste sindicated for DH relief in the US since 2013.
Numerous clinical studies of 4-24weeks treatment duration (typi[INVESTIGATOR_1306] y 8 weeks ) demonstrate 
the longitudinal anti -sensitivity efficacy of SnF 2-containing formulations (e.g., Amini, 2019 ; 
Chaknis, 2011 ;Creeth, 2021 ; Day, 2010 ;Du, 2011 ;Gallob, 2017 ;Hazen, 1968 ;He, 2014 [a];
He, 2019 ;Hines, 2019 ; Kim, 2021 ; Mason, 2019 ;Ni, 201 0;Ni, 201 1;Parkinson, 2013 ;
Parkinson, 2015 [a];Schiff, 2005 ;Schiff, 2006 ;Sharma, 2010 ;Vinaya, 2010 ). Reviews and 
pooled/meta -analyses of randomized controlled trials also report SnF 2-containing toothpastes 
to be clinically effective in the treatment of DH ( Badadhe, 2023 ; Bae, 2015 ;Creeth, 2019 [a];
Creeth, 2019 [b]; Exterkate 2022 ;Gerlach, 2017 ;Kanouté, 2022 ;Konradsson, 2020 ;Martins, 
2020 ;Martins, 2022 ; Marto, 2020 ;Pollard, 2023 ; West, 2015 ;West, 2019 ; West, 2021 ; Yang, 
2016 ).Thelonger -term clinical efficacy of the sponsor’s marketed 0.454% SnF 2toothpaste sis 
supported by [CONTACT_1192] 8 -week DH studies (Parkinson, 2013; Parkinson, 2015 [a]). 
Theaim of this8-week clinical study is to confirm the longitudinal anti-sensitivity efficacy of 
a 0.454% SnF 2toothpaste. Changes to the formulation, compared to those previously 
investigated, include removal of the opacifier, addition of a blue pi[INVESTIGATOR_2517], a new flavor for 
improved in -use experience, and modification of the dental abrasive system for improved stain 
removal and enamel polishing benefits. None of these changes areexpected to impact the MoA
of SnF 2(dentin tubule occlusion) orthe anti -sensitivity efficacy of a0.454% SnF 2toothpaste. 
Clinical DH assessments will be completed at Baseline, and after [ADDRESS_798516] -Baseline assessment time point, the efficacy of the 0.454% SnF 2toothpaste will be 
compared with that of a regular fluoride toothpaste with no known anti -sensitivity efficacy 
(negative control).
2.2 Benefit/Risk Assessment 
SnF 2 has been included as atherapeutic agent (anti-caries) in daily use toothpastes since the 
1950s(Makin, 2013 ). Numerous clinical studies reported in the scientific literature since then 
have established the safety and clinical efficacy of SnF 2, not only foranti-caries, but also for 
anti-hypersensitivity and anti -plaque/ anti-gingivitis indications . 
SnF 2is included in the investigational toothpast e at 0.454% w/w to provide relief from the pain 
and discomfort of DH. The formulation contain sonly ingredients with a history of safe use in 
oral healthcare products and is designed for daily use by [CONTACT_603012] .Complete safety 
information for this 0.454% SnF 2toothpaste canbe found in the single reference safety 
document for this product ,which for this study is the Investigator ’sBrochure (IB).
Numerous c linical studies support the longer -term clinical efficacy and safety of 0.454% SnF 2
toothpaste sin reducing the pain and discomfort associated with DH following exposure to a 
range of accepted stimuli (thermal and tactile (Holland, 1997 )), see Section 2.1. In these studies , 
0.454% SnF 2toothpaste swereapplied twice daily by [CONTACT_603013] 4 to 24 weeks (typi[INVESTIGATOR_897] 
8 weeks) and were well tolerated .
Review of the sponsor’s interventional clinical studies involving 0.454% SnF 2 toothpastes has 
not identified any significant safety issues. As per the sponsor's Global Data Sheet (GDS) for 
0.454% SnF [ADDRESS_798517] -marketing 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 20of 113
surveillance activities, the frequency of adverse reactions israre or very rare. The sponsor 
considers the overall benefit -risk profile of 0.454% SnF 2 toothpaste to be favorable wh en used 
as directed in its intended target treatment population.
The Acclimatization and Reference Toothpastes will be daily use, regular fluoride toothpastes
(two different products) ; each will be commercially available in the US. The ingredients listed 
on both commercial packs have a history of safe use in oral healthcare products. The usage 
instructions given to study subjects will be consistent with the instructions on the commerci al 
packs. No specific clinical benefits, risks or adverse effects are anticipated from their use in this 
study .
The manual toothbrush (Oral B Sensi -Soft toothbrush) to be used to apply the study toothpastes
by [CONTACT_603014] a medical device in the US . Device u sage instructions will be consistent 
with its commercial pack instructions. No specific clinical benefits , risks or adverse device 
effects are anticipated from its use in this clinical study.
Based on currently available data, the investigational andacclimatization toothpaste s, and the 
manual toothbrush ( medical device ) to be used to apply them, are considered safe for use under 
the conditions of the proposed clinical study.
2.3 Mechanism of Action/Indication
Dentin tubule occluding agents, such as stannous salts, are understood to act by [CONTACT_603015], thereby [CONTACT_603016]
(Makin, 2013 ). 
•In the presence of water (saliva) and saliva -derived ions , stannous ( Sn[II]) ions rapi[INVESTIGATOR_602967] ( Sn[IV]) ions and hydrolyze to form insoluble tin compounds 
(hydroxides, oxides, ph osphates and fluorophosphates) ( Makin, 2013 ). 
•The chemical precipi[INVESTIGATOR_602968] ( Burnett , 2013 ;
Earl, 2013 ),thereby [CONTACT_603017] . 
•Sn[II] ions have been shown in vitro to form insoluble precipi[INVESTIGATOR_602969] (Ellingsen, 1987 ;Miller, 1994 ;Parkinson, 2011 ;Shi,
2012 ;White, 2007 ;Zsiska, 2012 ).
The smear layer is an amorphous deposit of organic (hydroxyapatite) and inorganic (e.g., from
toothpastes/ toothbrushing or dental treatments such as prophylaxis) matter which covers the 
surface of exposed dentin and provides a degree of natural occlusion ofpatent dentin tubules. 
The smear layer is vulnerable to acid challenge ( e.g., from dietary acids). Stann ous ions are 
known to protect the smear layer from acid dissolution by [CONTACT_603018][INVESTIGATOR_602970] -resistant layers of stannous oxide, hydroxide, phosphate or fluorophosphate 
(Burnett, 2013 ). 
To maximise delivery of bioavailable stannous (tin [II])ions tothe oral cavity, SnF 2toothpastes
are often ‘stabilized’ by [CONTACT_603019] , by [CONTACT_603020] ,and/or by [CONTACT_603021]/anhydrous formulations. The investigational 
0.454% SnF 2toothpaste is an anhydrous formulation.
The longitudinal exposure of radicular or coronal primary dentin (due to enamel erosion, enamel 
abrasion and/or gum recession )results in the synthesis of tertiary or reparative dentin ; the 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798518] the pulp tissue where the tooth’s normal 
protective tissues (enamel and gum) have been irreversibly lost ( Linde, 1993 ). Thereparative 
process can be initiated in response to the effect of external stimuli at the dentin surface , as 
experienced by [CONTACT_603012] (Cox, 1992; D’Souza, 1995; Magloire, 1992; Mjor, 2002 ).The 
occluding layer formed over the dentin surface ,andwithin dentin tubules ,with daily use of a 
0.454% SnF [ADDRESS_798519] the dentin and the underlying pulp tissue from external 
pain-inducing stimuli where enamel and/or gingival tissue has been lost .
3 STUDY OBJECTIVES AND ENDPOINTS
Objectives Endpoints
Efficacy
Primary
To demonstrate the clinical efficacy of a 
0.454% w/w SnF 2toothpaste in reducing DH 
to an evaporative ( air) stimulus (as measured 
by [CONTACT_603001]), compared to a 
negative control toothpaste, after 8 weekstwice daily use.Change from Baseline in Schiff sensitivity score at Day 56 (Week 8).
Secondary
To demonstrate the clinical efficacy of a 
0.454% w/w SnF 2toothpaste in reducing DH
to a tactile stimulus (as measured by [CONTACT_603002] [g]), compared to a 
negative control toothpaste, after 8 weekstwice daily use.Change from Baseline in tactile threshold 
(g) at Day 56 (Week 8).
To demonstrate the clinical efficacy of a 
0.454% w/w SnF 2toothpaste in reducing DH 
to evaporative ( air) and tactile stimuli ( as 
measured by [CONTACT_603003] (g), respectively), compared 
to a negative control toothpaste, after 4 weekstwice daily use.Change from Baseline in Schiff sensitivity score at Day 28 (Week 4).
Change from Baseline in tactile threshold 
(g) at Day 28 (Week 4).
To describe subject-perceived changes in oral 
health -related quality of life (OHrQoL), as 
measured by [CONTACT_603022] (DHEQ-48), after 4- and 8- weeks twice daily use of their 
assigned investigational toothpaste.At Day 28(Week 4) & Day 56 (Week 8) :
Change from Baseline in DHEQ-48 
endpoints.
Section 1 
•Impact on Everyday Life (Q7-9) 
Section 2 
•Total Score (Q1-34) 
•Individual Domain S cores
-Restrictions (Q1-4) 
-Adaptation (Q5-16)  
-Social Impact (Q17 -21)  300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798520] (Q22 -29)  
-Identity (Q30-34)  
•Global Oral Health Score (Q35) 
•Effect on Life Overall Score (Q36-39)
Exploratory
To determine the number of ‘Sensitive Teeth’ 
(evaporative (air) sensitivity only) in the pool 
of ‘Eligible Teeth’ identified at Screening, at Screening, Baseline, and after 4 and 8 weeks twice daily use of assigned investigationaltoothpaste.At Screening, Baseline, Day 28 (Week 4) & 
Day 56 (Week 8):
Number of ‘Sensitive Teeth’ 
Defined as the number of ‘Eligible Teeth’ 
(identified at Screening) with a Schiff Sensitivity 
Score ≥ 2.
To investigate subject-perceived changes in 
DH toan evaporative (air) stimulus, as 
measured by [CONTACT_603005] (LMSs), after 4 and 8 weeks twice daily useof their assigned investigational toothpaste.At Day 28(Week 4) & Day 56 (Week 8) :
Change from Baseline in LMS endpoints.
•Intensity
•Duration
•Tolerability
•Description
To investigate the relationship between 
subject responses to the DHEQ-48 and the LMSs at Baseline and after 4 and 8 weekstwice daily use of assigned investigationaltoothpaste.At Baseline, Day 28(Week 4) & Day 56 
(Week 8):
•DHEQ-48 endpoints, as listed above.
•LMS endpoints, as listed above.
To investigate the relationship between the Schiff sensitivity scale and the LMSs at Baseline, and after 4 and 8 weeks twice daily use of assigned investigational toothpaste.At Baseline, Day 28(Week 4) & Day 56 
(Week 8):
•Mean Schiff sensitivity score of the two 
‘Test Teeth’.
•LMS endpoints, as listed above.
To investigate subject satisfaction with their assigned investigational toothpaste for the overall management of DH, as measured by a Numeric Rating Scale (NRS), after 8 weeks treatment.At Day 56 (Week 8) :
Satisfaction NRS score  
Safety
To monitor the safety and oral tolerability of the investigational toothpastes over 8 weekstwice daily use.Treatment emergent adverse events (TEAEs).
This study will be considered successful if the 0.454% SnF 2toothpaste demonstrates 
statistically significant, superior anti -hypersensitivity efficacy, compared to the negative control
toothpaste , as measured by [CONTACT_603023] 56 ( Week 8).300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 23of 113
4 STUDY DESIGN 
4.1 Overall Design
This will be a single center, 8 -week, ran domized, controlled, examiner -blind, 2-treatment arm, 
parallel group, stratified study in healthy subjects with DH. Subjects who meet the required 
study criteria at Screening and Baseline will be randomized to one of twostudy treatments : 
0.454% SnF 2toothpaste (Test Toothpaste )or a regular fluoride toothpaste (Reference
Toothpaste )
Two independent stimulus -based clinical measures will be employed to assess the efficacy of 
the investigational toothpastes . 
•A tactile stimulus will be administered using a constant pressure probe -Yeaple Probe 
(Polson, 1980 ); subject response to the stimulus determines the tactile threshold in 
grams (g). 
•An evaporative (air) stimulus (i.e., a thermal stimulus) will be administered using a 
dental air syringe; subject response to the stimulus will be examiner -evaluated using the 
Schiff sensitivity scale ( Schiff, 1994 ).
DHwill be assessed at Screening, Day 0 (Baseline), Day 28 (Week 4) and Day 56 (Week 8) .
On completion of the Baseline assessments , the clinical examiner will select two ‘ Test Teeth ’ 
for assessment of tactile and evaporative (air) sensitivity at all subsequent visits . To qualify for 
selection as a ‘Test Tooth’ , the tooth must meet the protoc ol-specif icinclusion/exclusion 
criteria (Section 5.2Inclusion Criteria 6 & 7 ;Section 5.3Exclusion Criterion 26) , specifically 
tactile threshold ≤ 20g and Schiff sensitivity score ≥ 2 at both Screening and Baseline visits.
In addition, t he number of ‘Sensitive Teeth’ will be determined at each study visit (Schiff 
sensitivity score ≥2)as described in Sections 8.1.5 , [IP_ADDRESS] , [IP_ADDRESS] and [IP_ADDRESS] .
Approximately 110qualifying subjects will be stratified according to the maximum Baseline 
Schiff sensitivity score of their two ‘Test Teeth’ and randomized to treatment (approximately 
55subjects per treatment group) . Randomized subjects will be instructed to brush twice da ily 
(morning and evening) with their assigned investigational toothpaste for the next 56 days 
(8weeks )and record each brushing in the diary provided . First usewill be performed under 
supervision at the investigator site; to facilitate compliance an additional supervised on-site 
brushing will be completed at the end of Visit 3 .
Changes in OHRQoL will be monitored over the treatment period using the validated Dentin 
Hypersensitivity Experience Questionnaire (DHEQ -48). The DHEQ -[ADDRESS_798521] -perceived DH will also 
be investigated for the two selected ‘Test Teeth’ using Labelled Magnitude Scales ( LMSs ).
Subjects will complete four LMSs to captu re the Intensity , Duration , Tolerability and 
Description of their response to the evaporative (air) stimulus administered at Baseline, Day 28 
and Day 56 .At the final visit (Day 56), after all clinical procedures have been completed, 
subjects will rate their level of satisfaction with their assigned investigational toothpaste for the 
overall management of DH using a NRS. 
To standardize oral hygiene practic e in the study population prior to treatment and to help 
minimize the potential impact of ‘placebo’/‘no treatment’ effects , eligible subjects will 
complete an acclimatization period ( 14-28 days duration) between the Screening and Baseline 
visits during whi ch they will brush twice daily (morning and evening) with aregular fluoride 
toothpaste (a different commercially available product from the Reference Toothpaste ).First 
use of acclimatization toothpaste will be performed under supervision at the investigator site .300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798522] s(Holland, 1997 ). In line with these same recommendations, 
two independent , controllable DH stimul i (tactile and thermal ) will be employed to assess the 
performance of the 0.454% SnF 2toothpaste , with the least severe stimulus (tactile) applied first
(Holland, 1997 ). Toavoid inter -examiner variability, the same clinical examiner willadminist er
a given stimulus (tactile and/or evaporative (air)) and assess itsassociated DHmeasure (tactile 
threshold (g) or Schiff sensiti vity score) throughout the study . 
DH will be clinically assessed at Screening andBaseline (pre -treatment) to determine suitability
to participate and confirm subject qualification ,and again after [ADDRESS_798523] Toothpaste will be compared with that of a
Reference Toothpaste -a conventional , daily use fluoride toothpaste with no known anti -
sensitivity efficacy ( i.e., a non -desensitising toothpaste will act asthe negative control ).
Qualifying subjects will be randomi zed to one of the two investigational treatment susing a 1:1 
allocation ratio. 
•Day 56 has been selected as the primary time point t o confirm the anti-sensitivity
efficacy of the investigational 0.454% SnF 2toothpaste ; 56-day ( 8-week) study duration 
is accepted as appropriate to evaluate the long -term efficacy of most anti -sensitivity 
products (Holland, 1997 ).
•Evaporative (air) is a thermal stimulus representative of the impact of chilled food sand 
drinks ,oran intake of cold air ,on sensitive teeth .‘Cold’ is reported to be the most 
common stimuli for DHpain ( Fischer, 1992 ; Flynn, 1985 ;Gillam, 2002 ).Thus, change 
from Baseline in Schiff sensitivity score at Day 56 has been selected as the primary 
endpoint , with study success defined as statistically significant, superior anti -
hypersensitivity efficacy for the 0.454% SnF 2toothpaste , vs.negative control, as 
measured by [CONTACT_603023] 56 ( Week 8 ).
On completion of the Baseline assessments, the clinical examiner will select two ‘Test Teeth’
from those that qualif yat both Screening (Visit 1) and Baseline (Visit 2) for ass essment of 
tactile and evaporative (air) sensitivity at all subsequent visits. Qualifying subjects will be 
stratified according to the maximum Schiff sensitivity score of their two selected ‘Test Teeth ’
to ensure treatment groups are balanced for DH severi ty.Repeated stimulation of multiple 
sensitive teeth may alter the pain response as testing continues around the mouth ; the 
anticipation of pain or discomfort with protracted testing, along with the discomfort of having 
to keep the mouth open for an extended period of time, may also affect subject perception of 
pain (Holland, 1997 ).Thus, the selection of two representative ‘Test Teeth’ to evaluate changes 
in DH with treatment is common practice in DH efficacy studies. To be representative of 
different areas of the mouth ,with independent innervation, the ‘Test Teeth’ should be non-
adjacent and in different quadrants .
The number of teeth sensitive to an evaporative (air) stimulus in the pool of ‘Eligible Teeth’ 
identified at Screening will be monitored across the study period . The evaporative (air) 
sensitivity of all ‘Eligible Teeth ’identified at Screening ( i.e., teeth with no dentition exclusions 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798524] a Screening tactile 
threshold ≤ 20g and a Screening Schiff sensiti vity score ≥ 2 ) will be assessed at Baseline, and 
after 28-and 56 -days treatment . For this purpose, a‘Sensitive Tooth’ will be defined as having 
a marked response to the evaporative (air) stimulus (Schiff sensitivity score ≥2). 
To help minimize exposure to environmental triggers for sensitivity prior to clinical DH
assessment , subjects will be instructed to refrain from oral hygiene, chewing gum , eating and 
drinking for a period of time prior to their arrival at the investigator site.
Clinical trials evaluating pain-related endpoints can be prone to ‘placebo effects’ (Addy, 1985 ; 
West, 1997 ); such effects are frequently observed in DH studies. A study conducted to evaluate 
the natural history of the DHcondition also highlighted the existence of a ‘no treatment’ effect ,
characteri zed by [CONTACT_603024] a result of study participation (Leight, 
2008 ).To help minimi ze the potential impact of such effects , an acclimati zation period (14-28 
days duration) will precede the Baseline visit . During this period , study subjects will brush 
twice daily with the regular fl uoride toothpaste and toothbrush provided ( in place of their own
oral hygiene products ) and record each brushing occasion in a diary. The acclimati zation period 
will also serve to s tandardi zeoral hygiene practice across the study population and familiarize
participants with several important study procedures (e.g., toothpaste dosage, timed brushing s,
diary completion) prior to treatment . 
DH is an epi[INVESTIGATOR_174343]; symptoms are known to vary spontaneously (West, 2008, West, 
2013) . Baseline clinical values that would support enrolment may represent random highs that 
could be followed by [CONTACT_603025], lea ving the subject or selected test tooth without 
the condition under investigation (i.e., DH) during the treatment period. To help minimize the 
potential for this to occur in the current study, randomized subjects will be required to 
demonstrate consistency in response to both DH stimuli at both the Screening andBaseline 
visits. Qualifying subjects will have a minimum of two qualifying teeth with a tactile threshold 
≤ 20g andaSchiff sensitivity score ≥ [ADDRESS_798525] s, inconsistent responders will be excluded (Holland, 1997 ).
The etiology of DHrequires tooth wear (loss of enamel) and/or gingival recession (with loss of 
cementum) to expose the underlying dentin (Addy, 19 87).In the absence of an underlying 
condition or pathology, t hese processes are slow and progressive ,leading to dentin exposure in 
early adulthoo d; thus, DHisrarely seen in children (West, 2022 ).While t heage range over
which an individual can experience DH is wide (early teens to 70s), peak incidence is known 
to occur between the ages of 20 -40 years and decline thereafter (Bartold, 2006 ;Dababneh, 1999; 
Fischer, 1992 ;Flynn, 1985 ;West, 2014 ).The fall in prevalence observed in later decades 
reflects age -related changes in the dentin and pulp of the tooth which act to reduce both dentin 
permeability and the tooth’s response to external triggers of DH (Seltzer, 1975 ; Splieth, 2013 ). 
Dental pain experienced by [CONTACT_603026] (Rees, 2000 ), thus an age range of [ADDRESS_798526] e.The study population will comprise male and female subjects and the protocol 
inclusion/exclusion criteria will not unnecessarily preclude any subject from participation .To 
further increase the diversity of enrolled subjects : (i) the investigator site will be encouraged to 
employ a range of advertising methods (e.g., posters in local community centers, retail outlets 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 26of 113
and healthcare facilities, local radio, social media) to maximize their ability to reach a diverse 
population within their geographic location; (ii) wherever possible, the investigator site will 
ensure accessibility to clinical areas forsubjects with mobility issues; (iii) flexibility will be 
added to Visit3 and Visit [ADDRESS_798527] attendance at site ( Day 28 ± 2 days; 
Day 56 ± 3days);(iv) study payment will appropriately compensate potential subjects for the 
anticipa ted costs of participation (e.g., travel to the investigator site for scheduled visits) to 
ensure financial considerations do not impede participation .
Female subjects who are pregnant (or intending to become pregnant during the study )or breast -
feeding will be excluded from participation in the study . The study toothpastes are not contra -
indicated for pregnancy orbreastfeeding (their use would not be expected to cause harm to the 
mother, the foetus or a baby), however, pregnant and la ctating females will be excluded due to 
the increased prevalence /severity of gingivitis and periodontal disease reported during 
pregnancy and breastfeeding which, together with the increased amounts of calculus and plaque 
observed on the teeth during pregn ancy, could affect DH assessment (Aghazadeh, 2019 ; 
Samant, 1976 ).
Potential study s ubjects willbeasked to bring their current oral hygiene products to Screening 
(Visit1)where they will be checked for presence of known anti -sensitivity ingredients . 
Individuals already using anti -sensitivity product (s)as part of their normal oral hygiene routine 
will be excluded . If they are using such products and continuing to experience DH, they would
beunlikely to respond to further use of anti -sensitivity toothpaste in this study and will be 
advised to seek help from their dental healthcare provider.
‘Patient -reported outcome s’(PRO s) can provide valuable information about the effect of a 
condition ,and its treatment ,on day -to-day life from the perspective of the person suffering with 
the condition . The inclusion of well-defined , reliable ‘PRO s’inclinical studies is increasingly 
encouraged to ensure the impact of treatment on quality of life and subject -reported symptoms
is assessed alongside conventional clinical outcomes .Indeed, published guid elines for the 
design and conduct of studies investigating the clinical efficacy of anti-sensitivity product s
(Holland, 1997 ), recommend that treatment evaluation sinclude subject -assessment of overall 
change to every day triggers for DH . Three‘PRO ’measures will be included in this study : 
(i)the Dentine Hypersensitivity Experience Questionnaire (DHEQ) ; (ii) a series of Labelled 
Magnitude Scales (LMS s); (iii)a Treatment Satisfaction NRS .Given study participants will not 
be patients, for the purposes of this study, these measures will be described as ‘subject -reported 
outcomes’ .
The DHEQ and the LMSs were developed with DH sufferers and can be used to assess the 
impact of DH on daily life , to measure DH pain and/orassess subject respons eto DHtreatment .
Study subjects will complete a DHEQ -48 (Appendix 15.2 ) at Baseline (Visit 1), and after 28 -
and 56 -days treatment (Visits 6 and 7), prior to any clinical examinations or assessments. 
•The DHEQ is a validated, condition -specific measure of OHRQoL used to investigate 
the impacts of tooth sensitivity on everyday life .It was developed by [CONTACT_603027] a robust theoretical framework, ( Baker, 
2014 ;Boiko, 2010 ; Robinson, 2014 )and has shown reliability and validity in both a 
general population ( Porritt, 2016 ) and in clinical studies ( Boiko 2010 ;Gibson, 2015 ).
It has been validated asboth long -and short -form versions (DHEQ -48 and DHEQ -15),
comprising 48 ( Baker, 2014; Boiko, 2010 ) and 15 ( Machuca, 2014 ) questions , 
respectively ,and has been translated into multiple languages (e.g., Chinese, Turkish, 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 27of 113
Portuguese), confirming its global relevance ( Başaran, 2018 ;Douglas -De-Oliveira ;
2018 ; He, 2015 [a];He, 2015 [b]). 
Study subjects will complete four LMSs (Appendix 1 5.3) relating to condition -specific 
characteristics of the DH pain response ( intensity ,duration ,tolerability anddescription )at 
Baseline ( for each tooth which qualifies for evaporative (air) assessment ),and after 28 -and 56 -
days treatment (for the twoselected ‘Test Teeth’ only).LMSs will be completed shortly after 
the evaporative (air) stimulus has been administered , and after the clinical ex aminer has 
recorded their Schiff sensitivity score . To avoid bias , the examiner andthe subject will have no 
visibility oftheir respective ‘scores’ . 
•Visual Analogue Scales (VASs) with two anchor points at 0 millimeters (mm) and 100 
mm(typi[INVESTIGATOR_602971] ‘no pain’ and‘worst imaginable pain’)are frequently employed 
in the clinical stud yofpain. While are effective for measuring change in high intensity 
pain (e.g., post -operative pain Gagliese, 2005 ), they can be less useful for low -level , 
epi[INVESTIGATOR_602972], such as that associated with DH.TheLMSs to be used in this study were 
developed by [CONTACT_603028] (Seattle , 
US),specifically to discriminate between different levels of DH pain, and have been 
pi[INVESTIGATOR_31219], validated, and utilized in observational and interventional clinical DH studies 
(Cunha -Cruz, 2013; Heaton, 2013; Mason, 2017; Mason, 2019 ).Recurring , consistent
descriptors of DH pai n(from themildest to the most severe )were identified during
focus groups with clinically confirmed DH sufferers .Psychophysical procedures 
(magnitude estimation and cross -modality magnitude matching) were then applied to 
align these condition -specific descriptors along VAS sat distances reflect ingthe 
psychological distances between the descriptive terms . 
To investigate satisfaction with their assigned investigational toothpaste for the overall 
management of DH, subjects will be asked to complete a NRS (an 11 -point ordinal scale) at the 
end of the treatment period .They will record the numeric value (from 0 to 10) t hat best describes 
their level of satisfaction and describe why they gave the product that rating (free text) .
Per International Conference on Harmonization (ICH)GCP guidance (ICH E6 (R2) Good 
Clinical Practice ),for a study to be class ified as double blind , the subjects, investigator(s) and 
staff involved in the treatment or clinical evaluation of subjects should be unaware of treatment 
received; this includes staff involved in the determin ation of subject eligibility, evaluati onof
endpoints (clinical examiner s), or assess ments of protocol compliance (e.g., moni tors, data 
analyst s). In summary, neither the subject nor the researcher sshould know ifthe subject has 
been assigned to Test or Reference treatment .In addition, the products under test should have 
the same appearance ,smell and taste (i.e., study arms should not be distinguishable from each 
other ). Given this will not be possible for the investigational products evaluated in this study 
(an experiment al toothpaste and commercially available regular fluoride toothpaste ), the study 
is described as ‘examiner blind’. However , given design of the study and the procedures in 
place at the investigator site to maintain the blind during study conduct , it is highly unlikely 
that the subject s, investigator, clinical examiner(s) or any member of the site staff involved in 
efficacy and safety assessments will be aware of treatment allocation.
•In this parallel -design study , study subjects will see and use only one of the two 
investigational toothpastes for the duration of the treatment period . They will be 
instructed not to discuss the appearance , usage or perceived performance of their 
assigned investi gational toothpaste with the clinical examiner (s), with staff involved in 
clinical assessments or with other study subjects . 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 28of 113
•Both investigational products are blue toothpastes . They will be provided to the 
investigator site overwrapped in white vinyl to mask their identity ,and to obscure any 
branding on the Reference Toothpaste ,with a study label affixed.
•The investigational toothpastes will be supplied in c arton s, each carton will contain 4
over-wrapped tubes of tooth paste. The c arton and its 4 tubes will be labelled with the 
same unique randomization number . Subjects will be centrally randomi zed to treatment
in order of qualification using an Interactive Response Technology (IRT) ; product codes 
will not be used .
•The clinical examiner(s) and sitestaff involved in efficacy and safety assessments will 
not be permitted in any area where the investigational toothpastes or diaries arestored , 
dispensed or in use .
•Sitestaff involved in the dispensing of investigational toothpastes , providing brushing 
and diary completion instruction , supervision of on -site brushings ,treatment 
compliance checks and product accountability will not beinvolved in clinical efficacy 
and safety assessments and will work in a separate area from the clinical examiner(s) 
and sitestaff involved in efficacy and safety assessments.
•Subjects will be instructed not to remove their assigned investigational toothpaste or 
diaryfrom the opaque carrier bag provided outside of the dispensing/supervi sed 
brushing room ,while at the investigator site.
•Where certain staff will be unblinded to carry out their responsibilities ( e.g.,staff
involved in SAE reporting , monitors ), the investigator and sponsor arerequired to put
adequate procedures in place to prevent inappropriate dissemination of treatment 
identification .
4.3 Justification for Dose
The investigational products are toothpastes ; they are intended for topi[INVESTIGATOR_602973] a manu al toothbrush.
In line with widely recommended oral hygiene practice and typi[INVESTIGATOR_602974], qualifying 
subjects will be instructed to brush twice daily (morning and evening) with their assigned 
investigational toothpaste, covering the toothbrush head with full ribbon of toothpaste 
(approximately 1.5g) on each brushing occasion. 
•Subjects randomized to Test Toothpaste will b e instructed to brush their entire dentition 
thoroughly for at least 1 -timed minute, making sure to brush the sensitive areas of their 
two 'Test teeth' carefully first.
•Subjects randomized to Reference Toothpaste will be instructed to brush their entire 
dentition thoroughly for at least [ADDRESS_798528] 1-minute brushing is in 
linewith thebrushing times specified insimilar DH efficacy studie s (Docimo, 2009 ; Hall, 2017 ; 
He, 2014[b]); Parkinson, 201 3; Parkinson, 2015 [a]). 
After 8 weeks ( i.e., 56 ± 3days) twice daily usage, each subject should complete between 10 6-
118brushings.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798529] scheduled procedure shown in the Schedule of 
Activities (Table 1 -1).The end of this study is defined as the date of the last scheduled 
procedure for the last subject , as described in the Schedule of Activities (Table 1 -1).
5 STUDY POPULATION
5.1 Type and Planned Number of Subjects
The study will be conducted in male and female subjects in good general /oralhealth , with pre -
existing self -reported tooth sensitivity ,and at least two sensitive teeth ( with clinically confirmed 
DH)that meet study eligibility criteria at both Screening (Visit 1) and Baseline (Visit 2). 
Sufficient subjects will be screened and entered into the acclimatization phase to ensure 
approximately [ADDRESS_798530] (approximately 55
subjects per treatment group ) and approximately 100 subjects complete the study 
(approximately 50subjects per treatment group ), allowing for 10% dropouts . Subjects will be 
recruited primarily from the investigator site database.
For this study, a n enrolled subject is defined as a subject who has agreed to participate in the 
study following completion of the informed consent process and suc cessfully met the study 
eligibility criteria to proceed beyond the screening visit .
The investigator site will make every effort to enroll subjects representative of the adult 
population who would benefit from use of an anti -sensitivity toothpaste ; the r ationale for study 
population selection is provided in the Scientific Rationale for Study Design (Section 4.2).
A clinical study can only fulfill its objectives if appropriate subjects are enrolled . The following 
eligibility criteria have been designed to select subjects for whom participation in the study is 
considered appropriate while not u nnecessarily preclud ing any subject from study participation . 
All relevant medical and non -medical conditions should be taken into consideration when 
deciding whether or not a subject is suitable. Eligibility to participate will be reviewed and 
documented by [CONTACT_093] (or medically qualified designe e) before each subject is 
included in the study.
5.[ADDRESS_798531] the irsafety or300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798532] 
theirability to understand and follow study requirements .
6.SCREENING (Visit 1)
Subject must have :
a)History of tooth sensitivity lasting more than six months but not more than 10 years
(self-reported ).
b)Good general oral health , with a m inimum of 20 natural teeth.
c)Minimum of 2 accessible, non -adjacent teeth (incisors, canines, premolars), in different 
quadrants, which meet allof the following criteria:
•Exposed dentin due to facial/cervical erosion, abrasion or gingival recession (EAR).
•MGI = 0 directly adjacent to the exposed dentin (i.e., the test area only)(Lobene, 
1986 ).
•Clinical mobility = 0 (Laster, 1975 ).  
•Clinically confirmed DH to both tactile andevaporative (air) stimuli:
-Qualifying tactile threshold ≤ 20g
-Qualifying Schiff sensitivity score ≥ 2.
7.BASELINE (Visit 2, Pre -Treatment )
Subject must have a minimum of two, non -adjacent accessible teeth (incisors, canines, 
premolars ), in different quadra nts, with clinically confirmed DH to both tactile and 
evaporative (air) stimuli at both Screening (Visit 1) andBaseline (Visit 2) .
•Qualifying tactile threshold ≤ 20g at Screening &Baseline
•Qualifying Schiff sensitivity score ≥ 2 at Screening &Baseline
The clinical examiner will select two ‘Test Teeth ’from those which meet the tactile 
threshold and Schiff sensitivity score inclusion criteria at both Screening and Baseline.
Note s: All teeth with clinically confirmed , qualifying levels of DH at Screening ( i.e., a 
Screening tactile threshold ≤ 20 g and a Screening Schiff sensitivity score ≥ 2 ) will be 
assessed for tactile sensitivity at Baseline . Teeth with a Baseline tactile threshold ≤ 20g will 
then be assessed for Baseline evaporative (air) sensitivity.
5.[ADDRESS_798533] who is pregnant or intending to become pregnant during the study (self-
reported ).
4.Female s ubject who is breastfeeding (self-reported ).300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798534] with known or suspected intolerance or hypersensitivity to the study products , any 
of their stated ingredients or closely related compounds (self-reported ). 
6.Subject with a recent history (within the last year) of alcohol or other substance abuse (self-
reported ).
7.Subject is participating in or has participated in other studies (including non -medicinal 
studies) involving investigational product (s)within 30 days of Screening (Visit 1) or plans 
to participate in other studies (including non -medicinal s tudies) during this study.
8.Subject has participated in atooth sensitivity study within 8 weeks of Screening (Visit 1) .
9.Subject is currently using an oral care product indicated for DHrelief or care of sensitive 
teeth or has used an anti -sensitivity produ ctwithin 8 weeks of Screening (Visit 1)
Subject swill be required to bring their current oral care products to Screening ( Visit 1 )for 
staff to verify the absence of known anti -sensitivity ingredients and sensitivity -related claims
onthe product packaging/ label text.
10.Subject takes daily doses of medication s/treatments which, in the opi[INVESTIGATOR_602975], could interfere with their perception of tooth sensitivity 
(e.g., analgesics, anticonvulsants, antihistamines that cause marked or moderate sedation, 
sedatives, tranquili zers, antidepressants, mood -altering and anti -inflammatory drugs).
11.SCREENING ( Visit 1)
Subject has taken antibiotics in the 2 weeks prior to Screening (Visit 1) .
12.BASELINE (Visit 2 , Pre -Treatment )
Subject has taken antibiotics in the 2 weeks prior to Baseline (Visit 2), i.e., during the 
acclimati zation period.
13.Subject takesdaily doses of a medication which, in the opi[INVESTIGATOR_1066], is causing xerostomia.
14.Subject requires antibiotic prophylaxis for dental procedures.
15.Subject hashad professional tooth de-sensitising treatment within 8 weeks of Screening 
(Visit 1) .
16.Subject has had a tooth bleaching procedure within 8 weeks of Screening (Visit 1) .
17.Subject has had dental prophylaxis within 4 weeks of Screening (Visit 1) .
18.Subject has had treatment for periodon tal disease (including surgery) within 12 months of 
Screening (Visit 1) .
19.Subject has had scaling or root planning within 3 months of Screening (Visit 1) .
20.Subject with gross periodontal disease .
21.Subject with a tongue or lip pi[INVESTIGATOR_77219] .
22.Subject with evidence of gross intra -oral neglect or the need for extensive dental therapy.
23.Subject with a fixed or removable partial prosthesis which, in the opi[INVESTIGATOR_602976] , could impact study outcomes .
24.Subject with multiple dental implants which, in the opi[INVESTIGATOR_602977] , could impact study outcomes.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798535] with fixed or removable orthodontic braces/bands or a fixed orthodontic retainer.
26.SPECIFIC DENTITION EXCLUSIONS FOR ‘TEST TEETH’:
a)Tooth with evidence of current /recent caries
b)Tooth with (self-reported )treatment fordecay within 12 months of Screening (Visit 1) .
c)Tooth with exposed dentin anddeep, defective or facial restorations.
d)Tooth with a full crown or veneer.
e)Tooth adjacent to a bridge abutment or crown which, in the opi[INVESTIGATOR_602976] , could impact study outcomes.
f)Sensitive tooth with contributing etiologies other than EAR to exposed dentin.
g)Sensitive tooth not expected to benefit from use of a n anti -sensitivity toothpaste ,in the 
opi[INVESTIGATOR_602978] .
27.Subject who, i n the opi[INVESTIGATOR_66678] , is unable to provide appropriate
responses to the LMS training q uestions (Appendix 15.4). 
28.Subject has previously been enrolled in this study.
29.Subject who, i n the opi[INVESTIGATOR_1071] , should not 
participate in the study.
5.[ADDRESS_798536] will be stratified by [CONTACT_603029] ‘Test Teeth’ . The stratification factor will give rise to two strata.
•Stratum 1: Maximum Schiff sensitivity score = 2.
•Stratum 2: Maximum Schiff sensitivity score = 3.
5.[ADDRESS_798537] has not complied 
with a lifestyle restriction (oral hygiene, dietary or alcohol -related) prior to a study visit, every 
effort will be made to re -appoint them within the permitted visit tolerances ,as defined in the 
Schedule of Activities (Table 1 -1)). The reason for re -appointment will be docu mented in the 
electronic case report form (eCRF).
If re-appointment is not possible, the following visit specific actions should be taken.
•Baseline (Visit 2): the subject will be withdrawn from the study ( Section 7.1 ). No 
clinical assessments will be performed. The subject may be replaced.
•Day 28 (Visit 3):the subject will continue in the study. No clinical assessments will be 
performed.
•Day 56 (Visit 4): if the subject cannot be reappointed, they will be withdrawn f rom the 
study ( Section 7.1 ). No clinical assessments will be performed. The subject will not be 
replaced.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 33of 113
5.5.1 Oral Hygiene Restrictions
For the Duration of the Study: From Screening (Visit 1) to the Subject’s Last Visit
•Subjects should not use any other oral care products (e.g., toothpastes, toothbrushes, 
oral rinses, tongue cleaners, whitening/bleaching products, inter -dental cleaning 
products) than those provided during the study.
Note: Use of d ental floss is permitted to remove impacted food only. 
•Subjects should not use any other products intended for treating or caring for sensitive 
teeth (including herbal remedies) than those provided during the study.
•Subjects should not chew gum. 
Before a Clinical Assessment Vis it:From Baseline (Visit 2) to the Subject’s Last Visit
•Subjects will refrain from all oral hygiene procedures for at least 8 hours before a study 
visit.
5.5.2 Dietary and Alcohol Restrictions
Before a Clinical Assessment Visit : Baseline (Visit 2) to the Subject’s Last Visit
•Subjects must not eat or drink for at least 2 hours before a clinical assessment visit.
Note: Small sips of room -temperature water are permitted to take medications or to 
relieve a dry mouth up to 1 hour before their appointment time
•Subjects should refrain from excessive alcohol consumption for 24 hours before a 
clinical assessment visit .
5.5.3 Contraception
The study toothpastes are not contra -indicated for pregnancy orbreastfeeding (their use would 
not be expected to cause harm to the mo ther, the foetus or a baby) and there will be no pregnancy 
warning son the labelling of any of the study products .Thus, study -specific contraceptive 
requirements are not deemed necessary for study subjects (female or male) . 
5.6 Screen Failures
Screen failures are defined as subjects who consent to participate in the clinical study but are 
not subsequently randomized . To ensure transparent reporting of screen failure subjects, a 
minimal set o f screen failure information will include demography, screen failure reason (e.g.,
withdrawal of consent), eligibility criteria, any protocol deviations and any AEs,as applicable. 
Individuals who do not meet the criteria for participation in this study ( screen failure) will not 
be re -screened.
5.7 Sponsor’s Qualified Medical Personnel
Contact [CONTACT_1133]'s appropriately qualified and experienced medical/dental 
personnel or Clinical Research Scientist (CRS) for th isstudy is documented in the Study 
Contact [CONTACT_603030].
The c ontact number is only to be used by [CONTACT_603031]/dental 
questions or problems in the event that the established communication pathways between the 
investigat orsite and the sponsor’s study team are not available. 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798538] use by [CONTACT_34450] y subjects. To facilitate access to 
appropriately qualified and experienced investigator site or sponsor personnel on study -related 
medical/dental questions or problems, subjects will be provided with a contact [CONTACT_1137]. The 
contact [CONTACT_1138], as a mi nimum, protocol identifiers, the subject’s study identification 
number, contact [CONTACT_31039], and contact [CONTACT_603032] a medical question or problem 
identifi ed by a healthcare professional other than the investigator.
5.8 Rater/Clinical Assessor Qualifications 
The examiner responsible for the clinical efficacy measures will be a qualified dental hygienist
trained in the clinical assessment of DH (tactile and /orevaporative (air) sensitivity). 
The oral (OST and OHT )examinations will be completed by a qualified dentist , ora dental 
hygienist , as needed .  
6 INVESTIGATIONAL/STUDY PRODUCTS
For the purposes of this study, per ICH guidelines and sponsor policy, study intervention is 
defined as a ny investigational intervention(s), marketed product(s), placebo, or medical 
device(s) intended to be administered to a study subject according to the study protocol. This 
includes a product with a marketing authorization when used or assembled (formulated or 
packaged) in a way different from the approved form, or when used for an unapproved 
indication, or when used to gain further information about an a pproved use. 
6.[ADDRESS_798539] will receive sufficient tubes of the acclimatization toothpaste and their assigned 
investigational toothpaste to cover usage during the acclimatization and treatment periods, 
respectively .The following stu dy products (acclimatization and investigational toothpastes) 
will be supplied by [CONTACT_456]’s Clinical Supplies department (Table 6-1).
The toothpaste u sage instructions areconsistent with the proposed labelling for the Test 
Toothpaste , when marketed, and with the commercial pack instructions forthe Reference and 
Acclimatization T oothpaste s.
Table 6-1 Acclimatization/ Investigational Toothpastes
DescriptionAcclimatization
ToothpasteTest 
ToothpasteReference Toothpaste 
(Negative Control)
Product NameRegular fluoride 
toothpaste
(Colgate Cavity 
Protection *)0.454 % w/w SnF 2
toothpasteRegular fluoride 
toothpaste
(Crest Cavity Protection *)
Fluoride Level 1000 ppm fluoride†1100 ppm fluoride¥1100 ppm fluoride≠
Master 
Formulation Code N/A N/A
Dispensing DetailsOne carton containing 
2 tubes of toothpaste at 
Screening (Visit 1)One carton containing 4 over-wrapped tubes of 
toothpaste at Baseline (Visit 2)300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCICCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 35of 113
Route of 
AdministrationTopi[INVESTIGATOR_602961] a ribbon of toothpaste, across the full brush head.
Start the timer (pre- set for 1 -minute). 
Brush the entire 
dentition thoroughly 
for at least 1- timed 
minute, twice daily 
(morning & evening).Brush the entire 
dentition thoroughly for 
at least 1-timed minute, 
twice daily (morning & 
evening), making sure to 
brush the sensitive areas 
of the two 'Test teeth' 
carefully first.Brush the entire 
dentition thoroughly 
for at least 1- timed 
minute, twice daily 
(morning & evening).
Subjects who wish to rinse after brushing will be instructed to rinse with 
10 ml water using graduated rinsing cup provided.
Duration of 
TreatmentApproximately 8 weeks (56 ± 3 days)
Return 
RequirementsAll used/unused tubes to be returned to the sponsor
*Commercially available daily use , regular fluoride toothpaste, USmarket .  
†As sodium monofluorophosphate    ¥As SnF 2    ≠As NaF  
Sufficient suppl iesof the following sundry items (Table 6-2) will be supplied to complete the 
study by [CONTACT_456]’s Clinical Supplies department (tobe dispens edby [CONTACT_92860],as required ).
Table 6-2 Sundry Items
Item Pack Design Dispensing DetailsReturn/Disposal Details
Used SamplesUnused 
Samples
Oral B Sensi-S oft
(USmarket)
Manual, flat trim, 
medium toothbrushesOne toothbrush in 
its commercial 
pack Screening (Visit 1): 
One toothbrush
Baseline (Visit 2): 
One toothbrushDestroy at site 
using site disposal 
procedures.
Return to 
sponsorCountdown TimersOne timer in its commercial pack Screening (Visit 1): One timerSubject to keep or 
destroy at site using site disposal 
procedures .
Graduated 
Rinsing CupsN/AScreening (Visit 1): 4 cups
Baseline (Visit 2): 
[ADDRESS_798540] to keep or 
destroy at site using site disposal 
procedures.
Opaque Carrier BagsN/AScreening (Visit 1): One bag
Baseline (Visit 2): 
One bag300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798541] sand sundry supplies for accountability 
checks andsubsequent destruction will be provided by [CONTACT_603033].
6.1.1 Medical Devices
The medical device provided by [CONTACT_603034] (Oral 
B Sensi -Soft toothbrush , USmarket) to be used to apply the study products by [CONTACT_603035] . The device will be supplied to study subjects in its commercial pack ;usage 
instructions will be consistent with thecommercial pack instructions.
Device deficiencies, (including malfunction, use error and inadequate labelling) will be 
documented and reported by [CONTACT_603036] (see Section 1 0.10).The device does not include any medicinal, human or animal 
or biologically active materials . 
6.1.2 Dosage Form and Packaging
The study products are toothpastes . They are intended for topi[INVESTIGATOR_602979] a manual toothbrush. 
The investigational toothpastes will be provided to the investigator site in laminate tubes , 
overwrapped in white vinyl (to mask the iridentity ,and to obscure any branding , imagesand 
texton the commercial pack of the Reference Toothpaste )with a study label affixed. The 
acclimatization toothpaste will be supplied in its commercial pack ,without overwrappi[INVESTIGATOR_007] ,with 
a study label affixed . The content of the product label swill be in accordance with all applicable 
regulatory requirements and will be the responsibility of the sponsor’s Clinical Supplies 
department. Each study label will contain (but not be limited to ) the protocol number and 
storage requirements.
Care shoul d be taken to ensure allsupplied study product ismaintained in good condition.  It is 
important that all product labels remain intact and legible for the duration of the study. Subjects 
should be instructed to not remove or deface any part of the study label.
Study product swill be received at site by [CONTACT_603037]. These individuals will not be involved in any safety orefficacy 
assessments or any other aspect of the study that could be inf luenced by [CONTACT_603038] a subject has been assigned to.
Study products supplied are for use in this clinical study only and should not be used for any 
other purpose.
6.1.[ADDRESS_798542] dispensing area (s)will be separate from th e clinical examination area (s). 
Investigational toothpastes will be dispensed to the subject, per protocol ,in blinded fashion by 
[CONTACT_7355]. These staff members will not be involved in any safety or clinical 
efficacy assessments or any other aspect of the study that could be influenced by [CONTACT_603039] a subject has been assigned to. An additional member of the dispensing staff will verify 
the dispensing procedure has been completed correctly for each subject. 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798543] will be maintained in the dispensing log; 
completion of the dispensing procedure will be recorded in the eCRF.
6.[ADDRESS_798544] be stored in a secure, 
environmentally controlled, and monitored (manual or automated) area in accordance with the 
product label storage conditions with access limited to the authorized site staff only.
Subjects will self -administer the acclimatization toothpaste (from Visit 1 to Visit 2) and their 
assigned investigational toothpaste (from Visit 2 to Visit 4) according to the usage instructions 
provided by [CONTACT_603040]. Subjects 
will be instructed to record each brushing with study product in their diary. 
To help ensure subjects fully understand the amount of toothpaste to use, the brushing 
instructions and how to complete the diary: 
•Screening (Visit 1): Staff will demonstrate dispensing a full ribbon of toothpaste along 
the length of the toothbrush head to each enrolled subject and supervise their first timed 
brushing with the acclimatizatio n toothpaste and diary completion at the end of the visit, 
after all clinical assessments have been completed. 
•Baseline (Visit 2): Staff will supervise the dispensing of a full ribbon of toothpaste by 
[CONTACT_603041]. Staff will show each subject 
randomized to Test Toothpaste the location of their ‘Test Teeth ’ and confirm the subject 
can correctly locate the two ‘Test Teeth’ themselves, prior to starting their on-sitetimed 
brushing .
•Day 28 ( Visit 3 ):Staff will supervise each subject brushing with their assigned 
investigational toothpaste and completing their diary at the end of the visit, after all 
clinical assessments have been completed. Staff will check thatsubjects randomized to 
Test Toothpaste can correctly identify their ‘Test Teeth’ prior to starting their on -site 
timed brushing. If a subject cannot correctly identify their two ‘Test Teeth’ , they will 
be re -instructed in the irlocation and a deviation will be recorded.
On-site administration of study products will be recorded in the dispensing log and the eCRF .
6.2.1 Medication/Dosing Errors
In this study, dosing errors may result from the administration or useofthe wrong study product,
by [CONTACT_1148], at the wrong time, inthe wrong way. Such dosing errors should be 
captured in the eCRF.
Dosing errors are reportable irrespective of the presence of an associated AE, including:
•Dosing errors involving subject exposure to any of the study products.
•Potential dosing errors or uses outside of what is foreseen in the p rotocol that do or do 
not involve the participating subject.
If a dosing error is accompanied by [CONTACT_1149], as determined by [CONTACT_19445] , the dosing error and any associated AEs are to be recorded in the eCRF. 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798545] at an amount higher 
than specified in the protocol. Overdose is not likely to occur in this study.
Overdose per se is not an AE. However, any clinical sequelae of an overdose should be reported 
as an AE ( orserious adverse event (SAE), asappropriate) per protocol follow ingthe AE and 
SAE reporting instructions.
6.[ADDRESS_798546] be capable of measuring and documenting ( e.g., via a log), asa 
minimum, daily minimum and maximum temperatures for all study product storage locations 
(including frozen, refrigerated, and/or room -temperature products).  This should be captur ed 
from the time of first product receipt throughout the study.  For continuous monitoring systems, 
a log or site procedure that ensures active daily evaluation for excursions should be in place .  
The operation of temperature -monitoring device sand tempera ture-controlled storage unit s
(e.g., refrigerator s) should be regularly inspected to ensure they are maintained in working 
order. 
Any excursions from the product -label storage conditions should be reported to appropriate site 
staff upon discovery and comm unicated to sponsor as soon as possible.  The investigator site 
should actively pursue options for returning the study product to the storage conditions 
described onitslabel as soon as possible.  Excursions from storage requirements, including any 
action s taken, must be documented as a protocol deviation and reported to the sponsor.  
Once an excursion is identified, the affected study product (or products) must be quarantined 
and not used until the sponsor provides documentation of permission to use. Use of any of the 
affected study product(s) prior to sponsor approval will be considered a protocol deviation.  
Site staff will instruct subjects on the proper storage requirements for all take -home study 
products , in accordance with the label requirements . 
6.[ADDRESS_798547] label. 
Study products willbe dispensed to enrolled /randomized subjects only,in accordance with the 
protocol, by [CONTACT_172049]. Subjects will return allused/unused tubesofacclimati zation 
toothpaste to the investigator site at their Baseline visit (Visit 2). Subjects will bring all300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 39of 113
used/unused tubes of their assigned investigational toothpaste to each of their scheduled visits 
to the investigator site(per Schedule of Activities , Table 1 -1)and return all used/unused study 
product to the investigator siteat study conclusion. Returned study products should not be re -
dispensed to any subject.
The investigat orsite must maintain adequate records (e.g., product acco untability form s) 
documenting the receipt, use, loss, return or other disposition of all study product and supplies . 
Accountability records must be available for inspection by [CONTACT_374791]. 
Product accountability will be monitored during investigator site visits and onthe completion 
of the study ,as required by [CONTACT_603042] . 
6.4.[ADDRESS_798548] Supplies 
At the end of the study, the investigator or an appropriate designee and thesponsor ’s
representative (study monitor) will inventory all used and unused study products and th e study 
product accountability record for returned st udy products will be completed. 
All study product (used and unused) for this clinical study will be returned to the sponsor or 
designated vendor for destruction using the return instructions provided by [CONTACT_456]’s 
Clinical Supplies Department . 
Unused sundry items will be returned to the sponsor; u sed items will bedisposed of at the 
investigator site as described in Section 6.1(Table 6.2). Documented approval for disposal of 
used sundry items must be received from the sponsor’s Clinical Supplies Department prior to 
destruction.
Detailed instructions for the return of study product s and the destruction of sundry items , will 
be provided by [CONTACT_603043].
6.5 Blinding and Allocation/Randomization
Qualifying subjects will be centrally randomi zed to one of twoinvestigational toothpastes using 
an Interactive Response Technology (IRT). Before the study is initiated, training, login 
information and directions for the IRT will be provided to the investigator site. Investigational 
toothpaste will be dispensed according to the instruction received through the IRT at the 
Baseline visit (Visit 2) .Returned study products should not be re -dispensed to any subject.
Only s ubjects who meet the study selection criteria willbe randomi zedto treatment .Qualifying 
subjects will be stratified by [CONTACT_603044] 
‘Test Teeth’ ; thisstratification factor will give rise to two strata.
•Stratum 1: Maximum Schiff sensitivity score = 2.
•Stratum 2:Maximum Schiff sensitivity score = 3.
This study is described as examiner -blind ( the clinical examiner (s)will be blinded to treatment
received). However, s tudy s ubjects, investigator site staff involved in safety or efficacy 
assessments , study statistician (s), data management staff, other employees of the Sponsor 
(including the CRS ) and vendors acting on behalf of the sponsor who may influence study 
outcomes will also be blinded to treatment allocation. Monitors and the sponsor’s Clinical Study 
Manager (CSM) cannot be fully blinded as they may observe subjects brushing with their 
allocated treatment while at the investigator site.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 40of 113
As described in Section 4.2,to maintain the blind throughout the study :
•Study subjects will see and use only one of the two investigational toothpastes for the 
duration of the treatment period . They will be instructed not to discuss the appearance , 
usage or perceived performance of their assigned investi gational toothpaste with the 
clinical examiner (s), with staff involved in clinical assessments or with other study 
subjects . 
•The investigational toothpastes will be provided to the investigator site overwrapped in 
white vinyl to mask their identity ,and to obscure any branding on the Reference 
Toothpaste ,with a study label affixed.
•The investigational toothpastes will be supplied in c arton s;each carton will contain 4 
over-wrapped tubes of tooth paste. The c arton and its 4 tubes will be labelled with the 
same unique randomization number . Subjects will be centrally randomi zed to treatment
in order of qualification using an IRT ; product codes will not be used .
•The c linical examiner(s) and site staff involved in efficacy and safety assessments will 
not be permitted in any area where the investigational toothpastes or diaries arestored , 
dispensed or in use .
•Site s taff involved in the dispensing of investigational toothpastes , providing brushing 
and diary completion instruction , supervision of on -site brushings ,treatment 
compliance checks and product accountability will not beinvolved in clinical efficacy 
and safety assessments and will work in a separate area from the clinical examiner(s) 
and investigator staff involved in efficacy and safety assessments.
•Subjects will be instructed not to remove their assigned investigational toothpaste or 
diary from the opaque carrier bag provided outside of thedispensing/ supervi sed
brushing room, while at the investigator site.
•Where certain staff will be unblinded to carry out their responsibilities ( e.g.,staff
involved in SAE reporting , monitors ), the investigator and sponsor are required to put
adequate procedures in place to prevent inappropriate dissemination of treatment 
identification .
6.6 Breaking the Blind
At study initiation, the investigator site will be instructed on the method for breaking the blind ; 
thiswill be an electronic process.
The electronic system will be programmed with blind -breaking instructions. In case of an 
emergency, the investigator has sole responsibility for determining if the unblinding of the
subject’s treatment assignment is warranted. Subject safety must always be t he first 
consideration in making such a determination. If the investigator decides that unblinding is 
warranted, the yshould make every effort to contact [CONTACT_603045]’s 
treatment assignment unless this would delay emergency treatment of the subject.
Once treatment assignment is unblinded, the sponsor must be notified within [ADDRESS_798549] be recorded and reported perprotocol. 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798550] will be provided with three diaries, one at Screening 
(Visit 1) , one at Baseline (Visit 2) and one at Day 28 (Visit 3) ,to record each brushing with the 
acclimatization and investiga tional toothpaste s. The diaries will also provide product usage 
instructions for the subject to refer to throughout their participation in the study.
•Subjects will be instructed to note any missed/additional brushings andthe reasons for 
missed/additional brushings in the diary .
•Subjects will also be instructed to record additional information in the diary such as 
changes in health, oral problems, changes inmedications/treatments , new medications/
treatments andanyissue s with the toothpaste they are using in the diar y. 
Subjects will be instructed to bring their completed diary to each scheduled study visit. 
Completed diaries will be reviewed by [CONTACT_603046] (to 
maintain the blind, staff performing diary reviews should not be involved in any safety or 
efficacy assessments) . Any m issed or additional brushings will be recorded in the eCRF as 
protocol deviations and s ubjects will be re -instructed in correct product usage requirements and 
diary completion ,as needed .
Information recorded in the diary relating to changes in health , medications and treatments will
be reviewed by [CONTACT_093] ,or medically qualified designee , with the subject and 
transcribed into the eCRF ,as appropriate (e.g., as an AE) .Information related to product use or 
issues should also transcribed into the eCRF ,as needed , taking care to maintain the blind.
Subjects will be instructed to bring all tubes of study product (used and unused) and their
toothbrush to each scheduled study visit. Study staff will perform a visual check of product 
usage and toothbrush condition . Any suspected over or under use will be documented in the 
eCRF and the subject will be re -instructed in the correct usage requirem ents. 
Toconfirm the subject understand sthe usage instructions provided at Screening (Visit 1) and 
Baseline (V isit2),their first use of study product (acclimatization toothpaste and investigational
toothpaste, respectively ) will be supervised on-site. To facilitate compliance, a further 
supervi sed brushing will be completed on-site at the end of Visit3 (Day 28) . Subjects deemed 
non-compliant with any aspect of the usage requirements or diary completion will be re-
instructed in correct procedu re. Any de viation from protocol requirements will be recorded in 
the eCRF .
6.8 Concomitant Medication/Treatment
Any medications, treatments or vaccine s(including over -the-counter or prescription medicines, 
vitamins and/or herbal supplements) taken or received during the study, from the signing of
informed consent, must be recorded in the eCRF with indication, reason for use, unit dose, daily 
dose and st art/stop dates of administration. Subjects will be questioned about changes in their 
medications/treatments at the start of each study visit.
Medication sand treatments taken or received in the 30 days prior to signing the informed 
consent will be document ed as prior medication/treatment. Medications and treatments taken 
or received after signing the informed consent will be documented as concomitant 
medication/treatments . 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 42of 113
For the Duration of the Study: Screening (Visit 1) to the Subject’s Last Study Vis it 
•Subjects should delay any non -emergency, elective dental treatment suntil after study 
completion (including dental prophylaxis). 
•Should a n enrolled/ randomi zed subject start a course of treatment which includes daily , 
regular or intermittent use of any medication , details of that treatment will be recorded 
in the eCRF . The investigator or their medically qualified designee will decide if the 
subject should continue in the study or be withdrawn. 
•Should a subject take a medicat ion which, in the opi[INVESTIGATOR_602980], could impact the subject’s perception of pain (e.g., an 
analgesic) within 8 hours of a scheduled study visit, every effort will be made to 
reappoint them within permitted visit tolerances (see Schedule of Activities , Table 1 -1). 
The reason for re -appointment will be documented in the eCRF. The medication and 
any associated AE should be recorded in the eCRF.
If re-appointm ent is not possible, the following visit specific actions should be taken :
-Screening (Visit 1): The subject will be withdrawn from the study. No tooth 
sensitivity assessments will be performed. The subject may be replaced.
-Baseline (Visit 2): The subject w ill be withdrawn from the study. No tooth 
sensitivity assessments will be performed. The subject will not be replaced. 
-Day 28 ( Visit 3 ) & Day 56 (Visit 4) :The subject will continue in the study. Tooth 
sensitivity assessments will be performed .
Subjects should not participate in any other clinical study (including cosmetic studies) or be in 
receipt of another investigational product for the duration of this study .
[ADDRESS_798551] DISCONTINUATION/WITHDRAWAL
7.[ADDRESS_798552] Discontinuation/Withdrawal 
A subject may withdraw from the study at any time at their own request or may be withdrawn 
from the study at any time at the discretion of the investigator or the sponsor for safety or
behavior al reasons, or due to the inability of the subject to comply with the protocol -required 
schedule of study visits or procedures.  
The following circumstances will require discontinuation of study product and/or premature 
subject withdrawal .
•Protocol violat ion that could impact the subject’s safety
•Withdrawal of informed consent
•Subject lost to follow -up 
•Unblinding of the subject 
•Pregnancy
If a subject is discontinued or prematurely withdraws from the study, the reason(s) for 
discontinuation or withdrawal ,and the associated date ,must be documented in the eCRF. 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798553] wishes to and/or should continue in the study.
A subject will be considered lost to follow up if they repeatedly fail to attend scheduled visits 
and cannot be contact[CONTACT_36165]. Before thesubject is deemed lost to follow up, the 
investigator or designee must make every effort to regain contact [CONTACT_7089] m(where possible
three telephone calls and, if necessary, a certified letter to the subject’s last known mailing 
address or equivalent local methods). Each contact [CONTACT_603047]. If contact [CONTACT_603048], the investigator or designee should inquire about the reason for their withdrawal, request 
that the subject return all products provided and,if appropriate ,request that the subject return 
for a final visit and follow -up any unresolved AEs. Final safety assessments may be carried out 
when the subject returns to the investigator site, at the investigator’s discretion, which may 
include an oral examination.
Should the subject continue to be unreachable, they will be considered to have withdrawn from 
the study and lost to follow up. This will be documented in the eCRF . Lack of completion of 
all or any of the early termination procedures will not be viewed as protocol deviations provided
subject safety was preserved.
If the subject withdraws from the study and withdraws consent for disclosure of future 
information, no furth er evaluations should be performed, and no additional data should be 
collected.  The sponsor may retain and continue to use any data collected before thewithdrawal 
of consent.
8 STUDY PROCEDURES
This section lists the procedures to be completed at each scheduled study visit.  The timing of 
each procedure is listed in the Schedule of Activities (Table 1 -1).Adherence to the study design 
requirements, including all procedures isessential and required for study conduct.
8.1 Visit 1 /Screening
Screening procedures will be conducted by [CONTACT_093] , the clinical examiner(s) or suitably 
qualified /experienced and trained designee s,14-28 days prior to the Baseline visit (Visit 2) .
Where practically feasible, they should be completed in the order listed below. Data collected 
will be recorded in the eCRF .
[IP_ADDRESS] Informed Consent
The investigator or designee must obtain inf ormed consent from each subject participating in 
this study after adequate explanation of the aims, methods, objectives and potential hazards of 
the study. The investigator or designee must also explain to the subjects that they are completely 
free to refu se to enter the study or to withdraw from it at any time.  Subjects will be provided 
with an ingredients list for the products to be used in the study to enable them to confirm they 
are not aware of any allergy or hypersensitivity to any of the ingredients listed.
Two copi[INVESTIGATOR_1076] (ICF) will be signed and dated by [CONTACT_423] . The 
investigator or designee will also sign and date each copy of the ICF ,after the subject has 
signed ,to confirm that the consent process was comp leted correctly. The subject will retain one 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 44of 113
copy and the other will be kept at the investigator site.The time of consent will also be captured 
on the ICF ; AEs will be captured from this point. The date and time of consent will be recorded 
inthe eCRF. Appropriate forms for documenting informed consent will be provided by [CONTACT_603049] .
If new information becomes available during the conduct of the study that might affect subject 
willingness to participate in the study, each ongoing subject should receive a verbal explanation 
and written summary of th enew information andbe re -consented into the study. Each subject 
will be provided with a copy of the irsigned /dated amended ICF. Date of re -consent will be 
recorded in the eCRF.
After signing the ICF, each subject will undergo a series of screening procedures and clinical 
assessments to confirm that they meet the protocol required inclusion criteria and none of the 
exclusion criteria. 
8.1.2 Demographics
The following demographic information will be recorded in the eCRF: year of birth, gender , 
race and ethnicity .
8.1.3 Review of Oral Care Products
Subjects will be requ ired to bring their curr ent oral care products to Screening (Visit1)for 
investigator staff to confirm the absence of known anti -sensitivity ingredients and sensitivity -
related claims on the product packaging/label text .Subjects who are currently using anti -
sensitivity oral car e product(s) will be excluded .
Subjects will also be asked about the oral care products they have been using in the last 8 weeks; 
those who report using anti -sensitivity product (s)in the 8 weeks prior to Screening will be 
excluded.
8.1.4 Medical History and Prior Medication s/Treatment s
The following will be documented in the eCRF:
•Details of relevant medical history and recent surgery(within the last year), including 
allergies and drug sensitivities.
•Female subjects: p regnancy status (sel f-reported).
•Prior medications/treatm ents, including prescription and non -prescription drugs, dietary 
supplements and herbal remedies, taken in the [ADDRESS_798554] will complete the LMS Training 
Exercise (source ),seeAppendix 15.4 (training exercise responses will notbe transcribed in to 
the eCRF ). Any s ubject who, i n the opi[INVESTIGATOR_66678] , is unable to provide 
appropriate responses to the LMS training questions, will be excluded from participation in the 
study (Section 5.3 Exclusion Criterion 2 7).
The following clinical examinations and DH assessments will be comple ted as described in 
Study Assessments (Section 9) and the findings recorded in the eCRF. To facilitate subject flow, 
source documents can be used to record clinical data for later transcri ption into the eCRF . 
Transcri ption into the eCRF must be completed within [ADDRESS_798555].300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 45of 113
•Oral soft tissue ( OST )examination
•Oral hard tissue ( OHT )examination 
•Clinical assessment of incisors, canines and pre -molars for dentition exclusions, erosion 
abrasion and attrition ( EAR ), Modified Gingival Index ( MGI ),adjacent to the test area 
only, and clinical mobility to identify appropriate teeth for DH assessment.
•Clinical assessment of tactile sensitivity (tactile threshold (g );maximum force 20g ):
Assess all teeth with no dentition exclusions ( Section 5.3 Exclusion Criterion 26 ) which
meet EAR, MGI andtooth mobility requirements (Section 5.2 Inclusion Criteria 6 (c)).
Ensure at least a 5 -minute break between completing the tactile assessments and 
starting the evaporative (air) assessments.
•Clinical assessment of evaporative (air) sensitivity (Schiff sensitivity score) :
Assess each tooth with a Screening tactile threshold of ≤ 20g.
Subjects must have a minimum of two ‘Eligible Teeth ’in different quadrants tocontinue
in the study (Section 5.2 Inclusion Criterion 6 c); ‘Eligible Teeth ’ must have a Screening 
tactile threshold ≤ 20g anda Screening Schiff sensitivity score ≥ 2
Subjects with fewer than two ‘Eligible Teeth ’will be discontinued .
8.1.6 Inclusion/Exclusion Criteria
Information relating to in clusion /exclusion criteria will be completed in the eCRF .
8.1.[ADDRESS_798556] Eligibility
The investigator or medically qualified designee will review themedical history, prior 
medications /treatments , clinical examination/assessment data and the inclusion/exclusion 
criteria for each subject to determine their eligibility to participate in the study . The e ligibility
decision will be documented in the eCRF.
If confirmed as eligible to participate ,thesubject will be considered enrolled in the study.
To prepare for study participation, enrolled subjects will be instructed inthe Lifestyle 
Guidelines (Sectio n 5.5 )and Concomitant Medications/Treatments (Section 6.8) requirements 
of the study (as already detailed in the ICF and described during the consent process). 
Adherence to the requirements of the study protocol is essential for success ful study conduct .
[IP_ADDRESS] Supervi sedBrushing with Acclimati zation Toothpaste
Enrolled subjects will be provided with the acclimatization toothpaste, a toothbrush, a timer, 
rinsing cups and a diary to use during the acclimatization period. 
Dispensing s taff will describe the toothpaste usage instructions to the subject , demonstrate 
covering the full brush head with a ribbon of toothpaste and how to use the timer . Staff will 
then supervise the subject carrying out their first timed brushing with the acclimatization 
toothpaste and recording first use in their diary. Any deviation from the product usage 
instructions will be captured as a protocol deviation in the eCRF and the subject will be re -
instructed in the correct directions for use. Dispensing of the acclimatization toothpaste and 
completion of the supervised first brushing will b e documented in the eCRF. 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798557] to respond to non -
leading question s(such as ‘ how do you feel?’ )on completion of the supervised brushing will 
be recorded in the eCRF.
Dispensing staff will remind subjects to note any changes in their health , medications or 
treatments in the diary (or report such changes to the investigator staff between visits using the 
contact [CONTACT_603050] , if preferred) and to bring their 
acclimati zation toothpaste , toothbrush and completed diary to the irnext study visit .
8.2 Study Period
8.2.1 Visit 2 /Baseline (Day 0)
The following procedures and assessments will be completed by [CONTACT_32595], the clinical 
examiner (s)or a suitably qualified/experienced and trained designee . Where practically 
feasible ,theprocedures and assessments should be completed in the order listed below .All data 
collected willbe recorded in the eCRF.
[IP_ADDRESS] Compliance Checks
Dispensing staff will c omplete visual checks of the returned acclimatization toothpaste andthe 
toothbrush and review the completed diary to assess compliance .
Suspected over or under use and the number of misse d or additional brushings will be recorded 
in the eCRF. Any deviation from the required usage instructions will be captured as a protocol 
deviation in the eCRF and subjects will be re -instructed in the correct usage.
Do not return the acclimati zation toothpaste, toothbrush orcompleted diary to the subject.
[IP_ADDRESS] Changes in Medical History and Concomitant Medications /Treatments
Investigator staff will ask subjects if there have been any changes in their health, concomitant 
medications and non -drug treatments ; female subjects of child -bearing potential will self -report 
pregnancy status. All c hanges w ill be documented in the eCRF. 
Spontaneously reported AEs and any AEs elicited during questioning about changes in health 
or by [CONTACT_603051] t o non -leading question s(such as ‘ how do you feel?’ )will 
recorded in the eCRF .AEs and/or changes in medications/treatments identified during review 
of the diary will be recorded in the eCRF.
[IP_ADDRESS] Subject Adherence and Continuance
Investigator staff will question subject s about adherence to the requirements of the protocol ; 
any deviations from study requirements will be recorded in the eCRF .Subject continuance will 
be confirmed.
[IP_ADDRESS] Subject -Reported Outcomes
Prior to commencing the OST examination and DH assessments , each subject will 
independently (without supervision) complete a hard copy of the DHEQ -48(source ), Sections 
1 and 2 (i.e., all question sin both sections ),see Appendix 15.2. Subject responses will be 
transcribed in to the eCRF.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 47of 113
[IP_ADDRESS] Clinical Examination s and Assessments
The following clinical examination and DH assessment s will be completed as described in 
Study Assessments (Section 9). To facilitate subject flow, source documents can be used to 
record clinical data for later transcription into the eCRF.
•OST examination
•Clinical assessment of tactile sensitivity (tactile threshold (g); maximum force 20g) :
Assess each ‘eligible tooth ’identified at Screening (Screening tactile threshold of ≤ 20g 
anda Screening Schiff sensitivity score ≥ 2 ).
Ensure at least a 5 -minute break between completing the tactile sensitivity assessments 
and starting the evaporative (air) sensiti vity assessments.
•Clinical assessment of evaporative (air) sensitivity (Schiff sensitivity score) :
-First assess each tooth with a Baseline tactile threshold of ≤ 20g .
-Subject will complete the four LMSs (Intensity, Duration, Tolerability &
Description )for each tooth with a Baseline Schiff sensitivity score ≥ 2immediately 
after theSchiff sensitivity score for thattooth is recorded .
-When Schiff sensitivity score shavebeen recorded ,and LMSs completed ,forall 
teeth with a Baseline tactile threshold of ≤ 20g , then assess Schiff sensitivity score 
for any remaining ‘Eligible Teeth ’identified at Screening (i.e., the ‘Eligible Teeth ’ 
with a Baseline tactile threshold >20g) .
‘Eligible Teeth’ = Teeth with no dentition exclusions which met EAR, MGI and mobility inclusion 
criteria, with a Screening tactile threshold ≤ 20g and a Screening Schiff sensitivity score ≥ 2.
Note: LMSs should notbe completed for the remaining ‘Eligible Teeth ’.
Subjects must have at least two ‘qualifying teeth ’, in different quadrants, with atactile 
threshold ≤ 20g and a Schiff sensitivity score ≥ 2 at both Screening and Baseline to
continue in the study Section 5.2 Inclusion Criterion 7 .
Subjects with fewer than two ‘qualifying teeth ’will be discontinued .
Transcri ption of data from source documents into the eCRF must be completed within [ADDRESS_798558].
[IP_ADDRESS] Selection of Test Teeth
The clinical examiner responsible for evaporative (air) assessments will select two ‘ Test Teeth’ 
for assessment of both tactile and evaporative (air) sensitivity at all subsequent study visits. 
‘Test Teeth’should only be selected from teeth which met the EAR, MGI and tooth mobility 
requirements and ha dno dentition exclusions at Screening ,with the required qualif ying levels 
of DH at both Screening (Visit 1) andBaseline (Visit 2) :
•Tactile threshold ≤ 20g at Screening andBaseline.
•Schiff sensitivity score ≥ 2 at Screening andBaseline.
To be representative of different areas of the mouth with independent innervation, ‘ Test Teeth ’ 
should be non -adjacent and in different quadrants. The identity of the two ‘Test Teeth’ will be 
recorded in the eCRF.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 48of 113
[IP_ADDRESS] Subject Eligibility
The investigator, or medically qualified designee, will review the inclusion/exc lusion criteria 
and verify the presence of twoqualifying ‘Test Teeth’ which meet all study criteria before 
confirm ing each subject ’ssuitability to continue in the study ; the eligibility decision will be 
documented in the eCRF .
[IP_ADDRESS] Stratification and Randomi zation
Each qualifying subject will be stratified to one of two strata as described in Section 6.5and 
randomized to treatment .Subject stratum will be entered directly into the eCRF. 
Each subject will be assigned a randomi zation number from their designated stratum in 
ascending numerical order, and as each subject is determined to be fully eligible. The 
random ized toothpaste code will be entered directly into the eCRF .
[IP_ADDRESS] Supervised Brushing with Investigational Toothpaste
Randomi zed subjects will be provided with their allocated investigational toothpaste, a new
toothbrush, additional rinsing cups and a new diary .
Dispensing staff will describe the toothpaste usage instructions to each subject, remind ingthem 
tocover the full brush head with a ribbon of toothpaste and use the timer each time they brush . 
•Subjects randomized to the Test Toothpaste will be shown the location of their two ‘Test 
Teeth’ within the mouth (using a tooth diagram/model and a mirror, asneeded) .
They will be then instructed to start their timer (pre -set for 1 -minute) and brush their 
entire dentition thoroughly for at least 1 -timed minute, making sure to brush the 
sensitive areas of their two selected 'Test teeth' carefully first. 
•Subjects randomi zed to the Reference Toothpaste will be instructed to start their timer 
(pre-set for 1 -minute) and brush their entire dentition thoroughly for at least [ADDRESS_798559] to respond to non -
leading questions (such as ‘ho w do you feel?’) on completion of the supervised brushing will 
be recorded in the eCRF.
Dispensing staff will remind subjects to note any changes in their health , medications or 
treatments in the diary (or report such changes to the investigator staff between visits using the 
contact [CONTACT_603050] , if preferred) and to bring their 
investigational toothpaste , toothbrush and completed dairy to the irnext study visit .
Randomized subjects will also be re-instructed in the Lifestyle Guidelines (Section 5.5 ) and 
Concomitant Medications/Treatments (Section 6.8 ) requirements of the study . 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 49of 113
8.2.2 Visit 3 /Day 28(± 2 days)
The following procedures and assessments will be completed by [CONTACT_093], the clinical 
examiner (s)or a suitably qualified/experienced and trained designee . Where practically 
feasible ,theprocedures and assessments should be completed in the order listed below .All data 
collected will be recorded in the eCRF.
[IP_ADDRESS] Compliance Checks
Dispensing staff will complete visual checks of the returned investigational toothpaste and
toothbrush and review the completed di ary to assess compliance .
Suspected over or under use and the number of missed or additional brushings will be recorded 
in the eCRF. Any deviation from the required usage instructions will be captured as protocol 
deviation sin the eCRF and subjects will b e re-instructed in the correct usage .
Return the investigational toothpaste and toothbrush to the subject . Retain the completed 
diary .
[IP_ADDRESS] Changes in Medical History and Concomitant Medications /Treatments
Investigator staff will ask subjects if there have been any changes in their health, concomitant 
medications and non -drug treatments; f emale subjects of child -bearing potential willself-report 
pregnancy status. All changes will be documented in the eCRF. 
Spontaneously reported AEs and any AEs elicited du ring questioning about changes in health 
or by [CONTACT_603052] -leading questions (such as ‘how do you feel?’) will 
recorded in the eCRF .
AEs and/or changes in medications/treatments identified during review of the diary will be 
recorded in the eCRF.
[IP_ADDRESS] Subject Adherence and Continuance
Investigator staff will question s ubject s about adherence to the requirements of the protocol; 
any deviations from study requirements will be recorded in the eCRF. Subject continuance will 
be confirmed.
[IP_ADDRESS] Subje ct-Reported Outcome s
Prior to commencing the clinical examinations and DH assessments, each subject will 
independently (without supervision) complete a hard copy of the DHEQ -48(source ), Section 1 
Questions 7 -9 only and Section 2 all questions (see Appendix 15.2). Subject responses will be 
later transcribed into the eCRF.
[IP_ADDRESS] Clinical Examination s and Assessments
The following clinical examination and DH assessments will be completed as described in 
Study Assessments (Section 9). To facilitate subject flow, source documents can be used to 
record clinical data for later transcri ption into the eCRF .
•OST examination
•Clinical assessment of tactile sensitivity (tactile threshold (g); maximum force 80g):
Assess the two ‘Test Teeth’ only.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798560] a 5 -minute break between completing the tactile sensitivity assessments 
and starting the evaporative (air) sensitivity assessments.
•Clinical assessment of evaporative (air) sensitivity (Schiff sensitivity score):
-First assess the two ‘Test Teeth’ .
-Subject will complete the four LMSs ( Intensity, Duration, Tolerability &
Description ) for each ‘Test Tooth’ immediately after the Schiff sensitivity score 
for that tooth is recorded.
-When Schiff sensitivity scores have been recorded, and LMSs completed, for both 
‘Test Teeth’ , then assess Schiff sensitivity score for any remaining ‘Eligible Teeth ’, 
as identified at Screening (do not re -assess the two ‘Test Teeth’) .
‘Eligible Teeth’ = Teeth with no dentition exclusions which met EAR, MGI and mobility inclusion 
criteria, with a Screening tactile threshold ≤ 20g and a Screening Schiff sensitivity score ≥ 2.
Note: LMSs should notbe completed for the remaining ‘Eligible Teeth ’.
Transcription of data from source documents into the eCRF must be completed within [ADDRESS_798561].
[IP_ADDRESS] Supervised Brushing with Investigational Toothpaste
Dispensing staff will visuall y check the condition of the subject’s toothb rush. If it isdamaged, 
a new tooth brush should be provided; supply of a replacement toothbrush willbe documented 
in the eCRF. Each s ubject will be provided with a new diary.
Dispensing staff will re-describe the toothpaste usage instructions to each subj ect(reminding 
them to cover the full brush head with a ribbon of toothpaste and use the timer each time they 
brush ) and then supervise each subject completing an on -site brushing with their allocated 
investigational toothpaste and recording th isusein their diary. 
Dispensing staff will ask subjects randomized to the Test Toothpaste to indicate the location of 
their two ‘Test Teeth’ in the mouth (before they start brushing) and confirm the subject brushes
these teeth first , prior to brushing their entire dentition .
Any deviation from the required product usage instructions will be captured as a protocol 
deviation in the eCRF and the subject will be re -instructed in the correct dir ections for use.
Completion of each supervised on-site brushing will be documented in the eCRF. 
Spontaneously reported AEs and any AEs elicited by [CONTACT_603053] -
leading questions (such as ‘how do you feel?’) on completion of the supervised brushing will 
be recorded in the eCRF.
Dispensing staff will remind subjects to note any changes in their health , medications or 
treatments in the diary (or report such changes to the investigator staff between visits using the 
contact [CONTACT_15750] p rovided or inform staff at their next visit , if preferred) and to bring their 
investigational toothpaste , toothbrush and completed diary to the irnext study visit .
Randomized subjects will also be re-instructed in the Lifestyle Guidelines (Section 5.5 ) and 
Concomitant Medications/Treatments (Section 6.8 ) requirements of the study . 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 51of 113
8.2.3 Visit 4/Day 56(± 3 days)
The following procedures and assessments will be completed by [CONTACT_093], the clinical 
examiner (s)or a suitably qualified/experienced and trained designee . Where practically 
feasible ,theprocedures and assessments should be completed in the order listed below .All data 
collect ed will be recorded in the eCRF.
[IP_ADDRESS] Compliance Checks
Dispensing staff will complete visual checks of the returned investigational toothpaste and 
toothbrush and review the completed diary to assess compliance .Suspected over or under use 
and the number of mis sed or additional brushings will be recorded in the eCRF. Any deviation 
from the required usage instructions will be captured as protocol deviation sin the eCRF . 
Do not return the investigational toothpaste, toothbrush orcompleted diary to the subject.
[IP_ADDRESS] Changes in Medical History and Concomitant Medications /Treatments
Investigator staff will ask subjects if there have been any changes in their health, concomitant 
medications and non -drug treatments; f emale subjects of chil d-bearing potential willself-report 
pregnancy status. All changes will be documented in the eCRF. 
Spontaneously reported AEs and any AEs elicited during questioning about changes in health 
or by [CONTACT_603052] -leading questions (such a s ‘how do you feel?’) will 
recorded in the eCRF .
AEs and/or changes in medications/treatments identified during review of the diary will be 
recorded in the eCRF.
[IP_ADDRESS] Subject Adherence and Continuance
Investigator staff will question s ubject s about adherence to the requirements of the protocol; 
any deviations from study requirements will be recorded in the eCRF.
[IP_ADDRESS] Subject -Reported Outcomes
Prior to commencing the OST/OHT examinations and DH assessments, each subject will 
independently (without supervision) compl etea hard copy of the DHEQ -48(source ), Section 1 
Questions 7 -9 only, and Section 2 all questions (see Appendix 15.2). Subject responses will be 
later transcribed into the eCRF.
[IP_ADDRESS] Clinical Examination s and Assessments
The following clinical examination sand DH assessments will be completed as described in 
Study Assessments (Section 9). To facilitate subject flow, source documents can be used to 
record cl inical data for later transcri ption into the eCRF .
•OST examination
•OHT examination
•Clinical assessment of tactile sensitivity (tactile threshold (g); maximum force 80g):
Assess the two ‘Test Teeth’ only.
Ensure at least a 5 -minute break between completing the tactile sensitivity assessments 
and starting the evaporative (air) sensitivity assessments.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 52of 113
•Clinical assessment of evaporative (air) sensitivity (Schiff sensitivity score):
-First assess the two ‘Test Teeth’.
-Subject will complete the four LMSs ( Intensity, Duration, Tolerability &
Description ) for each ‘Test Tooth’ immediately after the Schiff sensitivity score 
for that tooth is recorded.
-When Schiff sensitivity scores have been re corded, and LMSs completed, for both 
‘Test Teeth’, then assess Schiff sensitivity score for any remaining ‘Eligible Teeth’ , 
as identified at Screening (do not re -assess the two ‘Test Teeth’).
‘Eligible Teeth’ = Teeth with no dentition exclusions which met EAR, MGI and mobility inclusion 
criteria, with a Screening tactile threshold ≤ 20g and a Screening Schiff sensitivity score ≥ 2.
Note: LMSs should notbe completed for the remaining ‘Eligible Teeth’ .
After the clinical examinations/assessments have been complete d, subjects will complete a 
Satisfaction with Treatment NRS and describe (free text) why they gave their rating (Section 
9.3.4).
Transcri ption of data from source documents into the eCRF must be completed within [ADDRESS_798562].
8.3 Study Conclusion
The Study Conclusion page of the eCRF will be completed for all subjects whether or not they 
complete all study procedures (i.e., even i f they arediscontinued early at any po int during the 
study ). If the subject is discontinued early, the primary reason for withdrawal should be 
recorded on the Study Conclusion page. For subjects who attend all scheduled study visits, the 
Study Conclusion page of the e CRF will be completed at V isit 4.
Investigator s taff will instruct each subject to inform the site if they experience any change in 
health ,medications or treatments in the [ADDRESS_798563] has any clinically significant, study -related abnormalities or AEs at the end of the 
study, the sponsor’s medical monitor (or designated representative) should be notified . The 
subject may be asked to return to the investigator site for a follow -up visit to ensure any issue 
is resolved or deemed not clinically significant. 
8.[ADDRESS_798564] they return to the site for additional follow -
up visits (final safety assessments). At the discretion of the investigator or medically qualified 
designee , additional oral examinations may be carried out at such visits .300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798565] taken to ensure therequired procedure s are adhered to as soon as possible. 
The sponsor should be informed of anymissed examinations or assessments in a timely manner.
9.1 Screening Examinations/ DH Assessments
Screening examinations and assessments will be performed by [CONTACT_603054] /staff at the times and in the order defined in the Study 
Procedures section of this protocol (Section 9).
The eligibility of eac h tooth will be assessed against the protocol inclusion/exclusion criteria 
(Sections 5.2and 5.3) and recorded in the eCRF. If,in the opi[INVESTIGATOR_1067] ,the
value/ score for a particular tooth/ area of gingiva lies between two values /descriptions , a 
conservative approach should be adopted, and t he more conservative value/ score recorded . The 
same approach should be applied throughout the study to ensure consistency of assessment at 
all timepoints. 
9.1.1 Erosion , Abrasion and Recession (EAR) 
The facial surfaces of all incisor, canine and pre -molar teeth (Figure 9-1) that do not present 
any of the general dentition exclusion criteria, or specific dentition exclusion criteria ,for 
‘Eligible Teeth’ will be examined for signs of facial/ cervical EAR (Addy, 2000 ).
Figure 9-1Dental Nomenclature (Dempsey, 2001 )
9.1.2 Modified Gingival Index (MGI) 
The MGI is a non -invasive visual assessment of gingival health (Lobene, 1986 ). MGI will be 
assessed for incisor, canine and pre -molar teeth (Figure 9-1) exhibiting none of the dentition 
exclusions and presenting with facial/cervical EAR. MGI should be scored for the facial gingiva 
directly adjacent to the area of exposed dentin (i.e., the test area only). 
300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 54of 113
‘Eligible Teeth’will have a MGI of zero (0) directly adjacent to the area of exposed dentin .
Score Description
0 Absence of inflammation
1Mild inflammation; slight change in colour, little change in colour; little change in 
texture of any portion of the marginal or papi[INVESTIGATOR_282701].
2Mild inflammation; criteria as above but involving the entire marginal or papi[INVESTIGATOR_602981].
3Moderate inflammation; glazing, redness, oedema, and/or hypertrophy of the marginal 
or papi[INVESTIGATOR_282701].
4Severe inflammation; marked redness, oedema and/or hypertrophy of the marginal or 
papi[INVESTIGATOR_282701], spontaneous bleeding, congestion, or ulceration.
9.1.3 Clinical Mobility 
Clinical mobility will be assessed for incisor, canine and pre -molar teeth (Figure 9-1) exhibiting 
none of the dentition exclusions, with facial/cervical EAR and a MGI = [ADDRESS_798566] 
area only, using a modification of the Miller Index (Laster, 1975 ).
‘Eligible Teeth’will have clinical mobility = 0.
Score Description
0 No movement or mobility of the crown of the tooth < 0.2mm in a horizontal direction
1 Mobility of the crown of the tooth 0.2 - 1mm in a horizontal direction
2 Mobility of the crown of the tooth exceeding 1mm in a horizontal direction
3 Mobility of the crown of the tooth in a vertical direction as well.
9.1.4 Screening Tactile Sensitivity Assessment
The tactile sensitivity of incisor, canine and pre -molar teeth (Figure 9-1) exhibiting none of the 
dentition exclusions, and meeting the EAR, MGI and clinical mobility criteria, will be assessed 
using a constant pressure probe ( Yeaple probe (Polson, 1980 )). The probe tip will be placed 
perpendicular to the facial surface of the tooth and drawn slowly across the exposed dentin to 
ensure application of the stimulus across the potentially ‘sensitive’ area . 
After each application of the tactile stimulus , the subject will be asked to indicate whether the y 
experienced any pain or discomfort. The examiner will tell th e subject to only respond ‘ yes’if 
they fe elPAIN or DISCOMFORT when the probe isapplied to their tooth. ‘Yes’and‘no’are 
the only acceptable answers. The subject may respond ‘yes’if they feel pressure . The examiner 
will remind them, ifneeded, that they will feel pressure each time the probe is in contact [CONTACT_603055] ‘yes’if they feel pain or discomfort. 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 55of 113
The gram setting which elicits two consecutive ‘yes’ responses will be recorded as the tactile 
threshold (g) for that tooth . At Screening, the upper force setting will be 20g. 
•To be deemed ‘eligible ’for Baseline DH assessment , atooth must have a Screeni ng 
tactile threshold ≤ 20g. 
•If no sensitivity is observed at the upper force setting, Screening tactile threshold 
will be recorded as > 20g and the tooth will be disqualified from further testing.
If asubject fails to give a definite answer, the examiner will re-prompt them to provide a 
response ( ‘yes’or ‘no’). If theiruncertainty continues, this should be recorded in the source 
document .If the subject continues to be unsure, or the examiner is unsure of the reliability of 
their response, the examiner may opt to re -probe at the same force setting (indicated to the 
scribe by a non -verbal signal, e.g., a hand gesture) or move to the next for ce setting (10g 
increase). If the examiner considers the subject ’s ‘yes’ response may be between gram settings , 
a conservative approach should always be adopted, and the lower (more ‘severe’) tactile 
threshold (g) recorded.
The examiner will generally make the force setting adjustments ( this can also be done by [CONTACT_603056]) ; the scribe will record the micro -amperage setting and subject’s 
responses in the source document .
Calibration of the Yeaple Probe: 
The Yeaple probe will be calibrated by [CONTACT_603057] 
(typi[INVESTIGATOR_602982] , their assistant or scribe) before use on each day subjects are 
assessed. The microamp settings may vary from day to day (partly due to battery power 
consumption), but the difference should not be significant. Thus, previous probe settings can 
be used as a guide. Calibration should start at the lowest microamp setting and then increase.
Either calibration method described below is acceptable.
•Method 1 (‘Water Cup’): The Yeaple probe is fixed to a clamp attached to a ring stand 
so that the probe tip is vertical. A small paper cup attached with cotton thread is balanced 
over the end of the Yeaple probe, without the probe trippi[INVESTIGATOR_007]. The probe dial is set to the 
microamp setting and wat er is fed into the paper cup using a dropper until the probe 
trips. The gram setting is recorded, and the Yeaple probe reset to the next microamp 
value. The procedure is repeated until data has been collected to more than 80 g. 
•Method 2: The Yeaple probe is fixed to a clamp attached to a ring stand so that the top 
is perpendi cular to the pan of an ohaus dial -o-gram®balance or equivalent. The probe 
tip is positioned to just touch the pan when the balance is set at zero grams. The probe 
dial is set to the microamp setting and the gram setting is increased on the balance until 
the probe trips. The gram setting is recorded, and the Yeaple probe reset to the next 
microamp value.
The data are plotted, and the points connected with line segments in order to interpolate the 
micro -amp values equivalent to 10, 20, 30, 40, 50, 60, 70 and 80 g. This calibration should be 
repeated three times and the mean of the three used for th atday’s settings. The settings will be 
recorded on the Yeaple probe calibration record (along with the probe’s serial number) which 
will serve as the force setting guide for that day’s examinations.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 56of 113
9.1.5 Screening Evaporative (Air)Sensitivity Assessment
Evaporative (air)sensitivity will be assessed on the facial surfaces of incisor, canine and pre -
molar teeth (Figure 9-1)which exhibit none of the dentition exclusions, meet the EAR, MGI, 
clinical mobility criteria and have a Screening tactile threshold ≤20g. Evaporative (air) 
assessment swill start a minimum of [ADDRESS_798567] completed
(tooth recovery time) . 
The assessment will be made by [CONTACT_603058] a 1-second application of air from a standard dental 
syringe held perpendicular to the tooth surface, approximately [ADDRESS_798568] response to the stimulus will be evaluated using the Schiff sensitivity scale (Schiff, 
1994 ). This is an examiner -based index, scored immediately following administration of the 
evaporative (air) stimulus. The scale focuses on a combination of specific, observable, physical, 
behavioral and verbal responses from the subject, whi ch may facilitate discrimination. 
Score Description
[ADDRESS_798569] responds to stimulus, considers stimulus to be painful, and requests 
discontinuation of the stimulus
•To be deemed ‘eligible’ for Baseline DH assessment s, a tooth must have a Screening 
tactile threshold ≤ 20g and a Screening Schiff sensitivity score ≥ 2 . 
•Teeth with a Screening Schiff sensitivity score < 2 will be disqualified from further 
testing.
9.2 DH Efficacy Assessments
The following DH efficacy assessments will be performed by [CONTACT_603054] /staff ,at the times and in the order defined in the Study 
Procedures section of this protocol (Section 8).
If,in the opi[INVESTIGATOR_602983] ,the value/ score for a particular tooth is between two 
values/descriptions , a conservative approach should be adopted, and the more conservative 
value/ score recorded . The same approach should be applied throughout the study to ensure 
consistency of assessment at all timepoints. 
9.2.1 Dentine Hypersensitivity Experience Questionnaire (DHEQ -48)
The DHEQ -48is a condition -specific measure of OHrQoL i n relation to DH ( Boiko, 2010 )that 
has been previously validated in longitudinal studies and shown to be responsive to treatment 
(Baker, 2014 ).TheDHEQ total score can be broken down into 5 separa te ‘domain ’scores to 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 57of 113
provide a more granular understanding of thespecific areas of improvement subjects experience 
in their OHrQOL.
•Restrictions :Derived from participant responses to Section 2, Q1 -4(‘the ways in which 
any sensations in your teeth affect you in your daily life ’).
•Adaptation : Derived from participant responses to Section 2, Q 5-16 (‘the ways in 
which the sensations in your teeth have forced you to change things in your daily life ’; 
‘things you do in your daily life to avoid experienc ing the sensations in your teeth ’).
•Social Impact :Derived from participant responses to Section 2, Q1 7-21(‘the way the 
sensations affect you when you are with other people or in certain situations ’). 
•Emotional Impact :Derived from participant responses to Section 2, Q 22-29(‘the way 
the sensations in your teeth make you feel ’). 
•Identity :Derived from participant responses to Section 2, Q 30-34(‘what the sensations 
in your teeth mean for you ’). 
TheDHEQ also provides specific information on how much the sensations in the participant ’s 
teeth affect their life overall: 
•Global Oral Health :Derived from participant response to Section 2, Q 35(‘rate the 
health of your mouth, teeth and gums ’). 
•Effect on Life Overall :Derived from participant responses to Section 2, Q 36-39
(impact of DH on overall QoL).
Subjects will independently (unsupervised) complete a hard copy of the DHEQ -48(Appendix 
15.2) at Baseline ( Visit 2), Day 28 (Visit 3)and Day 56 (Visit 4),prior to any clinical 
examinations and assessments .
•Baseline :Complete Section 1 and Section 2 (i.e., all questions in both sections) .
•Day 28 & Day 56:Complete Section 1 Questions 7-9only, andSection 2 all questions. 
9.2.2 Tactile Sensitivity Assessment s
Tactile sensitivity will be assessed at Baseline (Visit 2), Day 28 (Visit 3) and Day 56 (Visit 4) . 
The tactile stimulus will be administered, and subject response recorded, as described in Section 
9.1.4. The gram setting which elici ts two consecutive ‘yes’ responses will be recorded as the 
tactile threshold (g).
•Baseline : Assess the tactile sensitivity of all teeth which exhibit none of the dentition 
exclusions and meet the EAR, MGI and clinical mobility criteria , with a Screening 
tactile threshold of ≤ 20g and a Screening Schiff sensitivity score ≥ 2 (i.e., the ‘eligible 
teeth’ identified at Screening) . 
The upper force setting will be 20g; if no sensitivity is found at the upper setting, record 
tactile threshold as > 20g.
•Day 28 & Day 56:Assess the tactile sensitivity of the two ‘ Test Teeth’ only (i.e., the 
two teeth selected by [CONTACT_603059], as described in Section [IP_ADDRESS] ).
The upper force setting will be 80g; if no sensitivity is found at the upper setting, record 
tactile threshold as > 80g.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 58of 113
9.2.3 Evaporative (Air) Sensitivity Assessment s
Evaporative (air) sensitivity will be assessed at Baseline (Visit 2), Day 28 (Visit 3) and Day 56 
(Visit 4) . The evaporative (air) stimulus will be administer ed, and subject response recorded
(Schiff Sensitivity Score) , asdescribed in Section 9.1.5. Evaporative (air) assessment swill start
a minimum of [ADDRESS_798570] completed (tooth recovery time).
•Baseline :
-First assess evaporative (air) sensitivity for all ‘Eligible Teeth ’ identified at 
Screening with a Baseline tactile threshold of ≤ 20g .
-Then assess evaporative (air) sensitivity for theremaining ‘Eligible Teeth ’
identified at Screening with a Baseline tactile threshold of > 20g.
•Days 28 & 56 :
-First assess evaporative (air) sensitivity for the two ‘Test Teeth’ (i.e., the two teeth 
selected by [CONTACT_603059], as described in Section [IP_ADDRESS] ).
-Then assess evaporative (air) sensitivity for all remaining ‘Eligible Teeth ’
identified at Screening . Do not re-assess the two ‘Test Teeth’ .
‘Eligible Teeth’ = Teeth with no dentition exclusions which me etEAR, MGI and mobility inclusion criteria, 
and ha vea Screening tactile threshold ≤ 20g and a Screening Schiff sensitivity score ≥ 2.
Score Description
[ADDRESS_798571] responds to stimulus, considers stimulus to be painful, and requests 
discontinuation of the stimulus
9.2.4 Labelled Magnitude Scales (LMSs)
Subjects will rate the (i) intensity , (ii) duration and (iii) tolerability of their response to the
evaporative (air) stimulus and (iv) descri betheir response ,using four 100-millimetre (mm) 
LMSs ( Appendix 1 5.3),at Baseline (Visit 2), Day 28 (Visit 3) and Day 56 (Visit 4) . 
LMSs should be completed immediately after the clinical examiner has recorded the Schiff 
sensitivity score for a given tooth .To avoid bias, the subject should be unaware of the 
examiner’s score and the clinical examiner should not have visibility of the subject’s LMS 
responses.
•Baseline :Complete four LMSs for each tooth with a Baseline tactile threshold of ≤ 20g
and a Baseline Schiff sensitivity score ≥ 2 .
•Days 28 & 56 :Complete four LMSs for each ‘Test T ooth’ (i.e., the two teeth selected 
by [CONTACT_603059] , as described in Section [IP_ADDRESS] ).
Study staff will measure the distance to the subject’s mark (‘X’) from left to right along the [ADDRESS_798572] this value (in mm) in the eCRF for each LMS completed .300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 59of 113
Note: Subjects willcomplete the LMS training exercise (Appendix 1 5.4) at Screening (Visit 1),
before theirclinical examinations/ DH assessments. Any s ubject who, i n the opi[INVESTIGATOR_82948] , is unable to provide appropriate responses to the LMS training 
questions, will be excluded from participation in the study (Section 5.3 Exclusion Criter ion 2 7). 
9.3 Safety Assessments
The following safety assessments will be performed by [CONTACT_1141] s, 
at the times and in the order defined in the Study Procedures section of this protocol (Section 8).  
9.3.1 Oral Soft Tissue (OST) Examination
TheOST examination will be accomplished by [CONTACT_603060] , using 
retraction aids as appropriate , and will include examination of the labial mucosa (includ ing 
lips), buccal mucosa, mucogingival folds, gingival mucosa, hard palate, soft palate, tonsillar 
area, pharyngeal area, tongue, sublingual area, submandibular area and salivary glands. 
The results of the examination will be recorded in the eCRF as eithe r ‘normal ’or ‘abnormal ’; 
details of any abnormalities will be documented in the eCRF . Any observation that changes 
from ‘normal ’to‘abnormal ’, or worsens, from the OST examination completed at S creening
willbe recorded as an AE.
9.3.[ADDRESS_798573] Tissue (OHT) E xamination
The OHT examination will be accomplished by [CONTACT_603061] , using retraction aids 
as appropriate , and will identify enamel irregularities, tooth fractures, grossly carious 
lesions/gross decay, defective/faulty restorations ( both direc t and indirect restorations ,
including fixed/ remova bleprostheses), non -carious tooth surface loss (abrasion, attrition, 
abfraction and erosion), any other hard tissue irregularities (e.g. ,hypo -and hyper -
minerali zation , decalcification) and significant tooth staining . 
Observations will be listed as ‘absent ’or ‘present ’; conditions noted as ‘present ’will be 
described in the eCRF . Any observation that changes from ‘absent ’to‘present ’ or worsens from 
the OHT examination completed at S creeni ngwillbe recorded as an AE.
The presence of any implants, fixed or removable dentures, fixed or removable orthodontic 
braces/bands, fixed orthodontic retainers, full crowns or veneers will be recorded, along with 
evidence of gross intra -oral neglect or t he need for extensive dental therapy.
The OHT examination will also be used to assess the subject’s dentition against the general and 
specific d entition exclusions described in Section 5.3 (Exclusion Criteria 22, 23, 24, 25, 26a -g).
9.3.3 Pregnancy 
This clinica l study will utilize toothpastes classified as OTC monograph drugs in the US. 
However, none of the study toothpastes are contra -indicated for pregnancy or breastfeeding 
(their use would not be expected to cause harm to the mother, the foetus or a baby) ; the US 
commercial products (the Acclimatization and Reference Toothpastes) do not carry pregnancy 
warning son the labelling (e.g., instructions to speak to a doctor before use if pregnant) ; the Test 
Toothpaste will not carry a preg nancy warning when markete d in the US . Thus,pregnancy 
testingoffemale subjects is not required prior to their enrolment .300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 60of 113
Female subjects will provide verbal confirmation of pregnancy status at Screening (Visit 1) and 
at each subsequent study visit ; this will be recorded in the eCRF. They will be instructed to 
inform the investigator staff immediately should they find out they are pregnant at any point 
during the study.
Female subjects who are pregnant or intending to become pregnant during the study (self-
reported) will be excluded (therationale for exclusion is provided in Section 4.2).
9.3.4 Satisfaction with Treatment
At the end of the study (Visit 4), subjects will be asked to rate their level of satisfaction with 
their allocated investigational toothp aste using a Numeric Rating Scale (NRS). 
The NRS is an [ADDRESS_798574]’s satisfaction with the product’s 
overall management of their DH. The scale ranges from 0 (completely dissatisfied) to 10 
(completely satisfied), with higher scores indicative of greater satisfaction ( van Berckel, 2017 ): 
see example below . 
Subjects will be asked to record the numeric value on the segmented scale that best describes 
their level of satisfaction after 8 weeks twice daily use and indicate why they selected a 
particular score in answer to the question ‘Please give more details on why you are satisfied or 
dissatisfied with the product’ (free text response).
Example NRS -Not to Scale
[ADDRESS_798575] 
orstudy participation.
10.1 Definition of an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study su bject, temporally associated 
with the use of a study product including an acclimatization product (or medical device), 
whether or not considered related to the study product, including an acclimatization product (or 
medical device).
300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 61of 113
Note:An AE can therefo re be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the 
use of a study product including an acclimatization product (or medical device).
Events Meeting the AE Definition:  
•Any abnormal laboratory test results (hematology, clinical chemistry or urinalysis) or 
other safety assessments (e.g. ,electrocardiogram ,radiological scans, vital sign 
measurements), including those that worsen from Baseline, considered clinically 
significant in the medical and scientific judgment of the investigator (i.e., not related to 
progression of underlying disease).
Note: Any OST observation that changes from ‘normal’ to ‘abnormal’, or worsens, from the OST 
examination completed at Screening should be recorded as an AE’ irrespective of clinical significance.
•Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.
•New conditions detected or diagnosed after study product administration even though it 
may have been present before the start of the study.
•Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
•Signs, symptoms, or the clinical sequelae of a suspected ov erdose of either study product 
or a concomitant medication. Overdose per se will not be reported as an AE/SAE unless 
it is an intentional overdose taken with possible suicidal/self -harming intent. Such 
overdoses should be reported regardless of sequelae.
•‘Lack of efficacy ’or ‘failure of expected pharmacological action ’per se will not be 
reported as an AE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms and/or clinical sequelae resulting from lack of efficacy 
will be reported as an AE if they fulfill the definition of an AE. 
Events NOT meeting the AE definition: 
•Any clinically significant abnormal laboratory findings (if applicable) or other abnormal 
safety assessments which are associated with the underlying dise ase, unless judged by 
[CONTACT_1173]’s condition. 
•The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the subject’s 
condition. 
•Amedical or surgical procedure (e.g. ,endoscopy, appendectomy) is not anAE. The 
condition that leads to the procedure is an AE ( e.g., appendicitis).
•Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
•Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen. 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 62of 113
10.2 Definition of a Serious Adverse Event (SAE)
Aserious adverse event (SAE) is a particular category of AEwhere the adverse outcome is 
serious. If an event is not an AE per definition above, then it cannot be an SAE ,even if serious 
conditions are met (e.g. ,hospi[INVESTIGATOR_1080]/symptoms of the disease under study , death 
due to progression of disease).
A serious adverse event is any untoward medical occurrence at any dose that:
•Results in death
•Is life -threatening
-The term 'life -threatening' in the definition of 'serious' refers to an event in which 
the subject wa s at risk of death at the time of the event. It does not refer to an event, 
which hypothetically might have caused death, if it were more severe .
•Requires inpatient hospi[INVESTIGATOR_1081]
-In general, hospi[INVESTIGATOR_602984] (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_1083]/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Complications that occur during 
hospi[INVESTIGATOR_1084]. If a complication prolongs hospi[INVESTIGATOR_1085], the event is serious. When in doubt as to whether 
‘hospi[INVESTIGATOR_059] ’occurred, or was necessary, the AE should be considered serio us.
-Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen 
from Baseline is not considered an AE.
•Results in persistent or significant disability/incapacity
-The term disability means a substantial disruption of a person’s ab ility to conduct 
normal life functions.
-This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (e.g. ,sprained ankle) whic h may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption .
•Results in congenital anomaly/birth defect
•Other situations:
-Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is app ropriate in other situations such as important medical events that 
may not be immediately life -threatening or result in death or hospi[INVESTIGATOR_602985]. These events 
should usually be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convul sions that do not result in hospi[INVESTIGATOR_059], or development of drug 
dependency or drug abuse.
Note: Classification of an AE as ‘serious’ is based on the outcome of the event and is a factor 
in determining reporting requirements.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798576] provides 
consent to participate in the study by [CONTACT_1174] (signature) of the ICF until [ADDRESS_798577] (or the last study procedure). 
Medical occurrences that began before obtaining informed consent will be recorded in the 
Medical History/Current Medical Conditions section of the eCRF ,not the AE section .
Details recorded by [CONTACT_2181] a diary or similar document that meet the definition of an AE 
must be discussed with the subjects and transcribed intothe AE section of the eCRF. 
All SAEs will be recorded and reported to the sponsor or designee immedia tely,and under no 
circumstance should this exceed [ADDRESS_798578] about any changes in their health. Open -ended and non -leading verbal 
questioning should be used.
AEs s pontaneous lyreport edby [CONTACT_603062] -leading questions ( such as ‘how do you fee l?’)will be assessed , recorded in the eCRF
and reported ,as appropriate .
Each AE is to be assessed to determine if it meets the criteria for a SAE. If an SA E occurs, 
expedited reporting will follow local and international regulations, as appropriate.
When an AE occurs, it is the responsibility of the investigator or their medically qualified 
designee to review all documentation (e.g. ,hospi[INVESTIGATOR_1088], laboratory and diagnostics 
reports) related to the event. The investigator or study staff will then record all relevant 
information relating to the event in the AE section of the eCRF . In addition, all details relating 
to an SAE will be recorded o nthe pa per SAE form provided.
It is notacceptable for the investigator or their medically qualified designee to send photocopi[INVESTIGATOR_602986]’s medical records to the sponsor in lieu of completion of the AE section of the 
eCRF /paper SAE form. There may be instan ces when copi[INVESTIGATOR_394073] 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798579] 
number, will be redacted on the copi[INVESTIGATOR_1091] .
The investigator or their medically qualified designee will attempt to establish a diagnosis based 
on signs, symptoms and/or other clinical infor mation related to the event . The diagnosis will be 
the documented as the AE/SAE ,where known ,and not the individual signs/symptoms (e.g. ,
upper respi[INVESTIGATOR_602987] ,not‘runny nose ’).
10.4.1 Reporting an AE
AEs will be reported by [CONTACT_093] , their medically qualified designee or site staff in the 
AE section of the eCRF .  The paper form used for collection of SAE information is not the same 
as the AE section of the eCRF . AEs/SAEs should be reported using concise medical 
terminolo gy.Where the same data are collected, the AE section of the eCRF and the SAE form 
must be completed in a consistent manner (e.g., the same AE term should be used forboth).  
10.4.[ADDRESS_798580] copi[INVESTIGATOR_1093] ‘paper’ SAE form will be provided 
in the investigator sitefile. Original , completed SAE forms will be retained in the investigator 
sitefile.
It is essential to record the following information for each SAE : 
•Protocol and subject identifiers
•Subject demography
•Description of event with diagnosis ,if available
•Investigator opi[INVESTIGATOR_65348] (or study procedure)
•Criterion for seriousness.
The following are desirable and are of particular relevance for investigator and sponsor
assessment of the SAE report:
•Date of onset of SAE 
•Date SAE stopped, if relevant
•Study product start date
•Study product end date ,if relevant
•Action taken in relation to study product
•Outcome ,if known
The SAE form, completed as fully as possible, must be scanned and e -mailed to the sponsor’s 
Case Management Group mailbox ,with the appropriate 
sponsor Study Manager in copy ,with the study number and subject number in the subject line 
of the email immediately after site staff learn of the event , and under no circumstance s
should this exceed 24 hours . The investigator will submit any updated SAE data to the sponsor, 
immediately it becomes available, andunder no circumstance should this exceed 24 hours 
of it being available . 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI[COMPANY_003]
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 65of 113
The initial report will be followed up with more information as relevant, or as requested by [CONTACT_130376]’s Study Manager .The sponsor’s Study Manager will be responsible for forwarding the 
SAE form to other sponsor personnel as appropriate.
10.5 Evaluating AEs 
10.5.1 Assessment of Intensity
The investigator or their medically qualified designee will make an assessment of intensity for 
each AE reported during the study and will assign it to one of the following categories:
•Mild:   An event that is easily tolerated by [CONTACT_423], causing minimal discomfort and 
not in terfering with everyday activities.
•Moderate:   An event that is sufficiently discomforting to interfere with normal 
everyday activities
•Severe:   An event that prevents normal everyday activities. 
Note:An AE assessed as ‘severe ’should not be confused with an SAE. ‘Severe ’is a category 
utilized for rating the intensity of an event . Both non -serious AEs and SAEs can be assessed as 
severe , e.g., a headache may be severe ( significantly interferes with the subject's usual function) 
but would not be classified as serious unless it met one of the criteria for SAEs listed in Section 
10.2. An event is defined as ‘serious’ when it meets at least oneof the pre -defined outcomes
described in the definition of an SAE (Section 1 0.2), notwhen it is rated as ‘severe ’.
10.5.2 Assessment of Causality
For each AE (non -serious and serious ), the investigator or their medically qualified designee
must provide an assessment of causality in the AE section of the eCRF and on the SAE form 
(as appropriate, subject to classification of the AE). Causality is one of the criteria used to
determin eregulatory reporting requirements. 
A ‘reasonable possibility ’of a relationship conveys there are facts (evidence )and/or arguments 
to suggest a causa l relationship, rather than a relationship cannot be ruled out. Generally, the 
facts (evidence) or arguments to suggest a causal relationship should be provided in the AE /SAE
report .
The investigator or their medically qualified designee will use clinical judgment to determine 
causality and will also consult the Investigator Brochure (IB), Safety Statement and/or Product 
Information, as appropriate , when making their assessment. Alternative causes, such as 
underlying disease(s), concomitant therapy ,other r isk factors and the temporal relationship of 
the event to study product use will be considered and investigated.
Where applicable, the investigator or their medically qualified designee must document in the 
medical notes th ey have reviewed the AE/SAE and p rovided an assessment of causality.
There may be situations ,when an SAE has occurred, where the investigator or their medically 
qualified designee has minimal information to include in the initial SAE report. However, it is 
very important that the investigator or their medically qualified designee always make s
an assessment of causality for every event prior to initial transmission of the SAE data to
the sponsor . The investigator may change their opi[INVESTIGATOR_602988] ,in light of follow -up 
information ,and send an SAE follow -up report with anupdated causality assessment. 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 66of 113
10.6 Follow -up of AEs and SAEs
After the initial AE/SAE report, the investigator or their medically qualified designee is required 
to proactively follow up with each subject and provide further information on the subject’s 
condition , as available.
All AEs (non -serious and serious ) should be followed until resolution, until the condition 
stabilizes, until the event is otherwise explained or until th e subject is lost to follow -up.  
The investigator or their medically qualified designee is obligated to perform or arrange for the 
conduct of supplemental measurements and/or evaluations as may be indicated (or as requested 
by [CONTACT_456] )to elucidate as fully as possible the nature and/or causality of the AE /SAE .
Thesemay include additional laboratory tests or investigations, histopathological examinations, 
or consultation with other healthcare professionals.
New or updated information will be recorded in the AE section of the eCRF and on the SAE 
form ( as appropriate, subject to classification of the AE) .The investigator or their medically 
qualified designee will submit any updated SAE data to the sponsor within [ADDRESS_798581] promptly notify the sponsor by [CONTACT_603063]’s Case Management Group mailbox 
, with the appropriate sponsor Study Manager in copy .
The investigator or their medically qualified designee will submit any updated SAE data to the 
sponsor within the designated reporting time frames.
10.7 Withdrawal Due to an Adverse Event 
Withdrawal due to AEs should be distinguished from withdrawal due to other causes, according 
to the definition of an AE provided (Section 1 0.1)and recorded in the AE section of the eCRF . 
When a subject withdraws due to an SAE, the SAE must be reported in accordance with the 
reporting requirements defined in this protocol .
10.[ADDRESS_798582] be prepared for suspected unexpected serious adverse reactions 
(S[LOCATION_003]R) according to local regulatory requirements and sponsor policy ,and forwarded to the 
investigator ,as appropriate .300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI[COMPANY_003]
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 67of 113
If the investigator receives an investigator safety report describing a SA E or other specific safety 
information (e.g., asummary or listing of SAE s)from the sponsor , they will review it, file it
with other safety information (e.g., the IB) in the investigator sitefile and notify the IRB, if 
appropriate ,according to local req uirements.
10.[ADDRESS_798583] is 
participating in the study from the date/time of signing theinformed consent until [ADDRESS_798584] will be followed to determine the outcome of the pregnancy. Information 
on the status of the mother and infant/neonate (including concomitant medications taken by [CONTACT_603064]) will be forwarded by [CONTACT_603065]’s Case Management Group mailbox 
, with the appropriate sponsor Study Manager in copy . 
Generally, follow -up will be for no longer than 6 to 8 weeks following the estimated delivery 
date. Termination of pregnancy will be reported.
While pregnancy itself is not considered to be an AE, abnormal pregnancy outcomes (e.g. ,
spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are, and 
should be recorded as an SAE.
Any female subject who becomes pregnant while participating wi ll be withdrawn.   
10.10 Medical Device Incidents
A medical device is being provided by [CONTACT_603066]; the medical device in 
this study is the manual toothbrush (Oral B Sensi -Soft,USmarket) used to apply the study 
toothpastes .
The investi gator and the sponsor will comply with local medical device reporting requirements.
10.10.1 Definition of an Incident
A medical device incident is any malfunction or deterioration in the characteristics and/or 
performance of a device as well as any inadequacy in t he labeling or the instructions for use 
which, directly or indirectly, might lead to or might have led to the death of a subject/user/other 
person or to a serious deterioration in their state of health.
Not all incidents lead to death or serious deteriorat ion in health. The non -occurrence of such a 
result might have been due to other fortunate circumstances or to the intervention of healthcare 
personnel.
It is sufficient that an incident associated with a device happened and the incident was such 
that, if it occurred again, might lead to death or a serious deterioration in health.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI[COMPANY_003]
[COMPANY_003]
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 68of 113
A serious deterioration in state of health can include any of the following:
•Life-threatening illness
•Permanent impairment of body function or permanent damage to body structure
•Condition necessitating medical or surgical intervention to prevent one of the above 
•Fetal distress, fetal death, or any congenital abnormality or birth defects
Examples of incidents:
•A subject, user, caregiver, or healt hcare professional is injured as a result of a medical 
device failure or its misuse.
•A subject’s study treatment is interrupted or compromised by a medical device failure.
•A misdiagnosis due to medical device failure leads to inappropriate treatment.
•A sub ject’s health deteriorates due to medical device failure.
10.10.[ADDRESS_798585]'s 
medical records, if in accordance with the investigator's n ormal clinical practice, and on the 
appropriate Incident Report Form.  In addition, for incidents fulfilling the definition of an AE 
(non-serious and serious ), the AE section of the eCRF /SAE form will be completed and reported 
as per the AE /SAE reporting s ections above .
The Incident Report Form will be completed as thoroughly as possible and signed by [CONTACT_1185] .  It is very important that the investigator describes 
any corrective or remedial actions taken to prevent recurrence of the incident.
The completed Incident Report Form should be scanned and emailed to the sponsor’s Case 
Management Group mailbox ),with the appropriate sponsor
Study Manager in copy ,with the study number and subject number in the subject line of the 
email immediately after site staff learn of the event and under no circumstance sshould this 
exceed [ADDRESS_798586] the procedure forreport ingan SAE.  The original 
completed Incident Report Form will be retained in the investigator sitefile. 
The initial medical device incident report will be followed up with more information as relevant, 
or as requested by [CONTACT_456]’s study manager.
The investigator will follow the following directions regarding the reporting of a device failure 
(malfunction):
•Notify the sponsor immediately ( asdescribed above).
•Schedule the subject to return to site promptly to return the failed device.
•Record any incidents in the eCRF and on the Incident Report Form (as described above ).
•For any incident/malfunction occurring with a medical device (including those that are 
part of combination products) supplied by [CONTACT_456] , return the failed device to the 
sponsor as soon as possible, including documentation of the details of the failure .300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI[COMPANY_003]
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 69of 113
•For any incident /malfunction occurring with a medical device (including those that are 
part of combination products) supplied by [CONTACT_382815], report the incident to the 
device manufacturer and follow the manufacturer instruction sfor the return of the failed 
device (whilst keepi[INVESTIGATOR_602989]).
10.10.[ADDRESS_798587] or are 
withdrawn from the study.
The investigator is responsible for ensuring that follow -up includes any supplemental 
investigations as indicated to elucidate the nature and/or causality of the incident.
New or updated information w ill be recorded on the originally completed Incident Report form ,
with all changes signed and dated by [CONTACT_093].
10.10.[ADDRESS_798588] data will be entered 
into an electronic CRF (eCRF), using a validated system. Data relating to SAEs, pregnancy an d 
incidents will also be collected on paper forms .
Subjects will complete paper cop iesof the DHEQ -48(source) ,the LMSs (source) andthe 
Treatment Satisfaction NRS (source) ;to facilitate subject flow, paper forms (source) may also 
be used to record clini caldata for later transcri ption into the eCRF . Transcri ption of 
DHEQ /LMS /NRS responses and clinical data into the eCRF must be completed within [ADDRESS_798589] Number.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798590] be completed and signed by [CONTACT_298956] (or authorized designee) to certify that the data are complete and correct.  The 
investigator must maintain accurate documentation (source data) tosupport the information 
entered in the CRF.
Management of clinical data will be performed in accordanc e with Third Party BDM Vendor 
applicable standards and data cleaning procedures ,with oversight by [CONTACT_603067] (e.g., to remove errors and inconsistencies in the data ). 
To protect the privacy of study subjects, no Personal Informa tion (PI) , including subject name , 
initials andbirth date , is to be recorded in the CRF or as part of query text.
All CRF pages should be completed during a subject assessment when the CRF isthedesignated 
source.  Data recorded elsewhere should be transcribed from the source document into the CRF 
within 5 days of the data being recorded .  
The sponsor will obtain an d retain all CRFs and associated study data ,as applicable ,on
completion of the study. 
11.2 Data Handling
Documentation of all data management activities should allow step -by-step retrospective 
assessment of data quality and study performance. 
Changes andcorrections to data will be performed in the Electronic Data Capture (EDC) System
which will include arationale for the change or correction . The EDC system has an audit trail 
toprovide a complete record of the changes and corrections endorsed by [CONTACT_093].
AEs will be coded using Medical Dictionary for Regulatory Activities (MedDRA) , and 
concomitant medication terms (if applicable) using an internal validated medication dictionary
(WHO Drug) .  
11.2.1 Data Queries
Programmed edit checks will be generated a utomatically as the data are being entered into the 
system. Reports and listings on the CRF data will also be run, in addition to the queries already 
programmed and generated by [CONTACT_1190], to raise manual queries as needed for investigator 
site clarificat ion or correction. The Clinical Dictionary Development and Management Group 
will raise queries as needed on safety data to code the terms (AEs and Drugs or concomitant 
medication) appropriately. 
The study monitor will perform ongoing review of the CRFs ,in accordance with the monitoring 
plan, to confirm that data entered into the CRF by [CONTACT_603068], complete, and verifiable from source documents; that the safety and rights of 
participants are being protected; and tha t the study is being conducted in accordance with the 
currently approved protocol and any other study agreements, ICH GCP and all applicable 
regulatory requirements.
Queries generated in the EDC System will automatically be sent to the investigator site, 
enabling errors to be addressed in parallel with Data Management review. The study monitor 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798591] reported outcomes will be recorded in p aper-based diariesand in questionnaire s 
(DHEQ -48, LMSs and NRS )for later transcription in to the eCRF .
Source documents recording s ubject -reported outcome swill be reviewed by [CONTACT_603069] m onitor toensure the data, and any potential AEs or concomitant medications 
reported in these documents ,are accurately transcribed into the eCRF.
Subject reported outcomes classed as source data will be retained by [CONTACT_093] ; 
true/certified copi[INVESTIGATOR_602990] -party vendor ,as required. To protect 
subject privacy , no PI (including subject name , initials or birth date )is to be recorded in any 
subject reported outcome source document that willbe forwarded to the sponsor or athird -party 
vendor .
[ADDRESS_798592] (approximately 55subjects per treatment 
group ) to ensure approximately 100 complete the study (approximately 50subjects per 
treatment group ), allowing for approximately 10% dropout s.
The study will be sufficiently powered to demonstrate statistical superiority of the Test 
Toothpaste compared to the Reference Toothpaste (negative control) for the change from 
Baseline in the Schiff sensitivity score (primary objective) and tactile thresh old (key secondary 
objective) after 56 days ( 8weeks )treatment .A sample size of 50evaluable subjects per 
treatment group will provide at least 90% power to detect a mean difference of 0.4units (SD = 
0.6) in change from Baseline in Schiff sensitivity sc ore after 56days treatment, using a [ADDRESS_798593] with a 5% significance level. The sample size calculation was performed using 
PASS software version 23.0.1.
The dropout rate and SD estimates are based on the results of DH efficacy studies of similar 
design and duration evaluating 0.454% SnF 2toothpastes (Clinical Studies 205794 , 208153 and
216954 : sponsor data held on file, available on request ). 
12.[ADDRESS_798594] receive d.
The primary population for the assessment of efficacy will be a modified intention -to-treat 
(mITT) population. The mITT population will comprise all randomized subjects who receive at 
least one dose of investigational product and complete at least one -post Baseline DH efficacy 
assessment . This population will be based on the investigational product the subject was 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798595] swho re ceive a randomization number will be considered
randomized.
The P er-Protocol (PP) population will comprise allsubjects in the mITT population who have 
at least one DH efficacy assessment considered to be unaffected by p rotocol deviations .
12.2.2 Exclusions of Da ta from Analysis
Exclusion of data from anyof the planned analyses will be agreed during Blinded Data Review 
(BDR) ,prior to database lock. The reason (s)for exclusion of a subject from an analysis 
population or specific data from an analysis will be documented and, if applicable, listed in the 
Clinical Study Report (CSR) .
A PP analysis will be performed forthe primary endpoint if ≥ 10% subjects in the mI TT 
population are excluded from the PP population. Efficacy data determined to have been 
potentially impacted by a protocol deviation will be excluded from the PP analysis. The 
decision s as to whether or not a protocol deviation impacts efficacy data and w hether to perform 
a PP analysis will be made during BDR ,prior to database lock.
12.3 Statistical Analyses
This is a summary of the planned statistical analyses; the detail of the proposed statistical 
analyses will be documented in theStatistical Analysis Plan (SAP), to be written following 
finali zation of the protocol and prior to study unblinding.
The mITT population will be used for allefficacy analyses.
All p -values presented will be two-sided and assessed at the 5% significance l evel.A sequential 
testing strategy will be used to adjust for the comparisons between the Test and Reference 
Toothpastes in change from Baseline in Schiff sensitivity score and tactile threshold (g) at each 
assessment time point .
At each time point, chang e from Baseline in tactile threshold (g) will only be assessed for 
confirmatory evidence if the change from Baseline in Schiff sensitivity score achieves a 
statistically significant greater reduction for the Test Toothpaste compared to the Reference 
Toothp aste (negative control) . This strategy will begin at Day 56, then move to Day [ADDRESS_798596] Toothpaste compare d to the Reference 
Toothpaste (negative control) for both Schiff sensitivity score and tactile threshold (g) .There 
will be no further adjustments for multiplicity for the other secondary endpoint s(DHEQ -48).
Summary statistics (mean, median, SE, SD, minimum, maximum) will be presented for each
Schiff sensitivity score and tactile threshold (g) outcome variable at each assessment time point. 
Raw means (± SE) of Schiff sensitivity score andtactile threshold (g) at each assessment 
timepoint will be plotted by [CONTACT_1570].
The results from each Mixed Model with Repeated Measures (MMRM) will be tabulated, 
presenting the following information, in addition to the results specified for the primary and 
secondary analyses below: least square mean change fro m Baseline for each investigational 
product at Days 28 and 56 (based on the observed stratification margins for those MMRM with 
a term for randomized strata) and used to test for any change from Baseline, with two -sided p -
values and 95% CIs.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 73of 113
12.3.1 Primary Endpoi ntAnalysis
The primary endpoint of this study is the change from Baseline in Schiff sensitivity score at 
Day 56 (Week 8); the primary hypothesis test will be the comparison between the Test 
Toothpaste and the Reference Toothpaste ( negative control )in the mITT population.
Schiff sensitivity score will be derived as the mean score forthe two‘Test Teeth’ (selected at 
Baseline). Change from Baseline will be derived for each individual tooth first before 
calculating mean change for the two ‘Test Teeth’ where change from Baseline in Schiff 
sensitivity score at Day X is defined as [(Schiff sensitivity score at Day X) minus (Baseline 
Schiff sensitivity score)] .
Change from Basel ine in Schiff sensitivity score at Day 56 will be analysed using a Mixed 
Model with Repeated Measures (MMRM) with investigational product, visit and 
[investigational product x visit] interaction as fixed effects, and Baseline Schiff sensitivity score 
as a covariate. Subject will be included as a repeated measure with unstructured covariance 
matrix. Kenward Rogers degrees of freedom approach will be applied (Kenward, 1997 ). The 
difference between the least square mean change sfrom Baseline for the Test Toothpaste 
compared to Reference Toothpaste (negative control) at Day 56 from the MMRM will be 
presented ,along with the two-sided p -value and 95% CIs.
The assumption sof normality and homogeneity of variance in theMMRM will be investigated. 
In case of violation of these assumptions, a suitable non -parametric test (adjusted for the 
randomization stratification) will be performed to assess the change from Baseline comparison 
(Test T oothpaste vs.Reference Toothpaste at Day 56 ); the results will be provided to support 
the MMRM results .
12.3.2 Secondary Endpoint Analyses
Tactile Threshold at Day 56 :
Tactile threshold (g) will be derived as the mean value forthe two‘Test Teeth’ (selected at 
Baseline). Change from Baseline will be derived for each individual tooth first before 
calculating mean change for the two ‘Test Teeth’ where change from Baseline in tactile 
threshold (g) at Day X is defined as [(tactile threshold at Day X) m inus (Baseline tactile 
threshold)] .
This k ey secondary endpoint, change from Baseline in tactile threshold (g) at Day 56 ,will be 
analysed using the same MMRM as the primary endpoint but with Baseline tactile threshold (g)
as a covariate (rather than Baseline Schiff sensitivity score ). In addition, the maximum Baseline 
Schiff sensitivity score of the two ‘Test Teeth’ (2 or 3) will be fitted as a fixed effect. The 
difference between the least square mean change sfrom Baseline for the Test Toothpaste 
compared to Reference Toothpaste (negative control) at Day 56 from the MMRM will be 
presented, along with the two -sided p -value and 95% CIs. 
Tactile Threshold /Schiff Sensitivity Score at Day 28 :
The other secondary endpoints :
•Change from Baseline in Schiff sensitivity score at Day 28
•Change from Baseline in tactile threshold (g) at Day 28
will beanaly sed using the same MMRM models described above for Schiff sensitivity score 
and tactile threshold (g), respectively. Differences betwe en the least square mean change sfrom 
Baseline in Schiff sensitivity score and tactile threshold (g) will be presented for the Test 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 74of 113
Toothpaste compared to Reference Toothpaste (negative control) at Day 28fromtheir 
respective MMRMs, along with two -sided p -values and 95% CIs.
The assumption sof normality and homogeneity of variance in each MMRM will be 
investigated. In case of violation of these assumptions, a suitable non -parametric test (adjusted 
for the ran domi zation stratification value ) will be performed to assess change from Baseline
comparisons ( Test Toothpaste vs.Reference Toothpaste at Day 56andDay 28, as app ropriate ); 
the results will be provided to support the MMRM results . 
DHEQ -48:
Change from Baseline will be calculated at Day 28 and Day 56 for allDHEQ endpoints .
•Section [ADDRESS_798597] on Everyday Life: Q 7, Q8&Q9(separate scores)
•Section 2
-DHEQ Total Score (sum of Q1 -34)
-DHEQ Restrictions Domain score (sum of Q1 -4)
-DHEQ Adaptation Domain score (sum of Q5 -16) 
-DHEQ Social Impact Domain score (sum of Q17 -21)
-DHEQ Emotional Impact Domain score (sum of Q22 -29)
-DHEQ Identity Domain score (sum of Q30 -34)
-DHEQ Global Oral Health (Q35)
-DHEQ Effect onLife Overall (sum of Q36-Q39)
Change from Baseline will be calculated at the subject -level first then mean change from 
Baseline will be calculated for each DHEQ endpoint across all subjects. 
Change from Baseline foreach DHEQ endpoint listed above will be analyzed using a MMR M 
with time point and maximum Baseline Schiff sensitivity score of the two ‘Test Teeth’ (2 or 3) 
as fixed effect s, and the respective Baseline DHEQ score as covariate . Subject will be included 
as a repeated measure with unstructured covariance matrix. Kenw ard-Rogers degrees of 
freedom will be applied. The estimate sof the adjusted mean (SE) change from Baseline will be 
presented along with 95% C Isfor each treatment group .
For each DHEQ endpoint listed above ,and each individual DHEQ question, the value at each 
timepoint (Baseline , Day 28 and Day 56 ) and the corresponding change from Baseline will be 
summarized descriptively for each treatment group . Raw means (± SE) for each DHEQ 
endpoint, and the individual DHEQ questions, at each assessment timepoint will be plotted by 
[CONTACT_1570].300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 75of 113
12.3.3 Exploratory Analyses
Number of ‘Sensitive Teeth ’:
The number of teeth sensitive to an evaporative (air) stimulus in the pool of ‘Eligible Teeth’ 
identified at Screening will be monitored across the study peri od. For this purpose, a ‘Sensitive 
Tooth’ will be defined as having a Schiff sensitivity score ≥2. 
‘Eligible Teeth’ = Teeth with no dentition exclusions which meet EAR, MGI and mobility inclusion criteria, and 
have a Screening tactile threshold ≤ 20g and a Screening Schiff sensitivity score ≥ 2.
The number of ‘Sensitive Teeth’ (i.e., the number of ‘Eligible Teeth’ with Schiff sensitivity 
score ≥ 2) will be calculated at Screening, Baseline, Day 28 and Day 56 .
•At Screening, the number of ‘Sensitive Teeth’ will be equal to the number of ‘Eligible 
Teeth ’ (as described in Section 8.1.5 ).
‘Eligible Teeth’ = Teeth with Screening tactile threshold ≤ 20g and Screening Schiff sensitivity 
score ≥2.
•At Baseline, Day 28 and Day 56, all‘Eligible Teeth ’ will be tested for evaporative (air) 
sensitivity . The number of ‘Sensitive Teeth’ will be the number of ‘Eligible Teeth ’ with 
a Schiff sensitivity score ≥ 2 at that visit .
Summary statistics (m ean, median, SE, SD, minimum, maximum ) will be presented at each 
assessment timepoint for each treatment group .For each subject, the Schiff sensitivity score of 
each ‘eligible tooth’ at each timepoint will be listed by[CONTACT_1570]. Mean ( ±SE) number 
of ‘Sensitive Teeth’ will be plotted by [CONTACT_603070] (LMSs) :
Change from Baseline will be calculated at Day 28 and Day 56 for each LMS endpoint.
•Intensity
•Duration
•Tolerability
•Description
LMS data will be a nalysed for the two ‘Test Teeth’ only . Change from Baseline will be derived 
for each ‘Test T ooth’first before calculating mean change for the two ‘Test Teeth’ for each 
subject.
Change from Baseline for each LMS endpoint listed above will be analyzed using a MMRM 
with time point and maximum Baseline Schiff sensitivity score of the two test teeth (2 or 3) as 
fixed effect s, the respective Baseline LMS value as a covariate and subjec t as a repeated 
measure with unstructured covariance matrix. Kenward -Rogers degrees of freedom will be 
applied. The estimate sof the adjusted mean (SE) change from Baseline will be presented along 
with 95% C Isfor each treatment group .
For each LMS endpoin tlisted above, the value (in mm) at each timepoint (Baseline, Day 28 
and Day 56) and the corresponding change from Baseline (in mm) will be summarized 
descriptively for each treatment group . Raw means (± SE) for each LMS endpoint, at each 
assessment timepoint ,will be plotted by [CONTACT_1570].300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 76of 113
DHEQ -48 and Labelled Magnitude Scales (LMSs) Relationship :
The relationship between subject responses to the DHEQ -48and the four LMS swill be 
investigated . For each DHEQ domain (Restrictions, Ada ptation, Social Impact, Emotional 
Impact, Identity) , each LMS endpoint (Intensity, Duration, Tolerability, Description) will be 
plotted against domain score at each assessment timepoint (Baseline, 28 and 56 days). A matrix 
of correlation plots will be presented for each domain. Spearman’s correlation coefficient will 
be calculated along with the associated p -value and presented with its respective correlation 
plot.
Schiff Sensitivity Score and Labelled Magnitude Scales (LMSs) Relationship :
The relationship between Schiff sensitivity score and the four LMSs will be investigated. Schiff 
sensitivity score ( mean score ofthe two ‘Test Teeth’) and the four LMS endpoints ( Intensity, 
Duration, Tolerability, Description ) will be plotted at each assessment timepoint (Baseline, 28 
and 56 days) in a matrix of correlation plots. Spearman’s correlation coefficient will be 
calculated along with the asso ciated p -value and presented with its respective correlation plot.
Satisfaction with Treatment NRS
A summary of the number of subjects reporting at each level of the NRS and the cumulative 
number of subjects reporting at each level or higher at Day 56 (Wee k 8) will be presented , and 
theNRS score at Day 56 (Week 8) will be summarized descriptively , by [CONTACT_1570] .
Subject free text comments will be listed by [CONTACT_1570] .
12.3.[ADDRESS_798598] 
received. AEs will be regarded as ‘treatment emergent’ if they occur on or after the first use of 
investigational product at Baseline (Visit 2).In the event o f a missing start date, anAE will be 
assumed to be ‘treatment emergent’ unless the end date is prior to starting treatment . Incase of 
misallocation, compared to the randomization schedule, TEAEs will be associated with the 
most recent study investigation al received.
Each AE will be categorized as oral or non -oral by [CONTACT_603071]. All will be reviewed by [CONTACT_603072] . 
A listing of all AEs will be presented for all subjects in the Safety population with the following 
AE summaries (number of distinct AEs and frequency/proportion of subjects affected) 
presented by [CONTACT_6654] : 
•TEAEs
•TEAEs by [CONTACT_1196] (SOC) and Preferred Term (PT) 
•TEAEs by [CONTACT_1197]/Non -Oral and PT 
•Treatment emergent treatment related AEs by [CONTACT_1197]/Non -Oral and PT
•Treatment emergent treatment related serious AEs by [CONTACT_603073]:
•Deaths, SAEs and any AEs leading to product or study discontinuation.
•OST findings (with a summary of abnormalities by [CONTACT_765])300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 77of 113
•OHT findings (with a summary of changes by [CONTACT_765])
•Exposure to study product (Section 1 [IP_ADDRESS].)
Medical device incidents will be listed; if there are no incidents, a null listing will be produced.
While n o specific risks or anticipated adverse device effects are expected from use of the 
medical device (manual toothbrush) provided , anymedical device incidents reported during the 
conduct of this study will be assessed to evaluate the safety of the device .
12.3.5 Demographic and Baseline Characteristics
Demographic and Baseline characteristics will be summari zed by [CONTACT_603074] (and for the PP population ,if a PP analysis is performed )using 
descriptive statistics .
Categorical variables (such as sex, race , ethnicity and Baseline Schiff sensitivity score 
stratification value ) will be summari zed by [CONTACT_603075]. Continuous variables such as (age) will be 
summari zed by [CONTACT_8477], SD, median, minimum and maximum values in each treatment group .
12.3.[ADDRESS_798599] Compliance a nd Use of Other Therapi[INVESTIGATOR_014]
[IP_ADDRESS] Study Product Compliance
Compliance with investigational product use (number of brushings) will be listed and 
summarized for the mITT population at each visit, and cumulatively for the entire treatment 
period (for most subjects th is will be approximately 8weeks) by [CONTACT_1570]. 
Number of expected brushings = 2 × Number of days between Visit 2and Visit X
Number of actual brushings      = (Number of expected brushings )–(Number of miss ed
brushings )+ (Number of additional b rushings )
% Compliance at ‘Visit X’ = (Number of actual brushings prior to Visit X)     x 100
(Number of expected brushings prior to Visit X )
[IP_ADDRESS] Prior and Concomitant Medications
Prior medications /non-drug therapi[INVESTIGATOR_602991] /significant non -drug 
therapi[INVESTIGATOR_602992] .
12.3.7 Handling of Dropouts and Missing Data 
MMRM analyses account for missing data using ‘a missing at random ’assumption, i.e., there 
is a systematic relationship between the propensity formissing values and the observed data, 
but not the missing data. 
Under such assumptions, MMRM is shown to provide unbiased estimates of the treatment effect 
whilst analysis of only complete cases using analysis of covariance (ANCOVA) isbiased 
(Ashbeck, 2016 ; Baron, 2008 ). 
Such complete case analysis requires a ‘missing completely at random’ assumption to remain 
unbiased and this is unlikely to hold, i.e., the fact that the data are missing is independent of the 
observed and unobserved data .300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798600] with similar non -missing results at other 
timepoints ( Baseline and the other post-Baseline assessment visits). 
12.3.8 Interim Analysis 
No interim analysis is planned for this study .
13 STUDY GOVERNANCE CONSIDERATIONS
13.1 Quality Control 
In accordance with applicable regulations (including GCP )and sponsor procedures, the sponsor
or designee (i.e. ,third -party vendor) monitors will contact [CONTACT_603076], study requirements and siteresponsibilities to satisfy 
regulatory, ethical and sponsor requirements with the study staff.
When review ing data collection procedures, the discussion will include identification, 
agreement and documentation of data items for which the eCRF will serve as the source 
document.
The sponsor or designee will monitor the study and site activity to verify that:
•Data are authentic, accurate, and complete.
•The s afety and rights of subjects are being protected.
•The s tudy is conducted in accordance with the currently approved protocol , any other 
study agreements, GCP and all applicable regulatory requirements.
The exten t and nature of monitoring will be described in a written monitoring plan held on file 
by [CONTACT_456] . The investigator (or designee) agrees to allow the monitor direct access to all 
relevant documents and agrees to co -operate with the monitor to ensure th at any problems 
detected during these monitoring visits are resolved.
13.[ADDRESS_798601] a quality assurance assessment and/or audit of the investigator site r ecords ; regulatory 
agencies may conduct a regulatory inspection at any time during or after completion of the 
study.
In the event of an assessment, audit or inspection, the investigator must agree to grant advisors, 
auditors and inspectors direct access to all relevant documents and to allocate their time and the 
time of their staff to discuss the conduct of the study, any findings/relevant issues and to 
implement any corrective and/or preventative actions to address any findings/issues identified.
The inve stigator will notify the sponsor or its agents immediately of any regulatory inspection 
notification in relation to the study. Furthermore, the investigator will cooperate with the 
sponsor or its agents to prepare the investigator site for the inspection and will allow the sponsor
or its agent, whenever feasible, to be present during the inspection. The investigator will 
promptly supply copi[INVESTIGATOR_602993]. Before response 
submission to the regulatory authority, the investigator will provide the sponsor or its agents 
with opportunity to review and comment on responses to any such findings. 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798602] (IRB)
It is the responsibility of the investigator to have prospective approval of the study protocol, 
protocol amendments, the ICF, the IBand/or safety statement (including any updates) ,and other 
relevant doc uments (e.g.,recruitment advertisements , diaries) , asapplicable, from the IRB.  All 
correspondence with the IRB should be retained in the investigator site file. Copi[INVESTIGATOR_602994], and 
subsequently for any protocol amendment s.
The only circumstance in which an amendment may be initiated prior to IRB approval is where 
the change is necessary to eliminate apparent immediate hazards to the subjects.  In that event, 
the investigator must notify the IRB and the sponsor in writing immediately after 
implementation.
13.3.[ADDRESS_798603] of the Study
The study will be conducted in accordance with the protocol and applicable local regulatory 
requirements and laws , as well as the general princip les set forth in the International Ethical 
Guidelines for Biomedical Research Involving Human Subjects (Council for International 
Organizations of Medical Sciences 2002), International Ethical Guidelines for Health -Related 
Research Involving Humans (Counci l for International Organizations of Medical Sciences, 
2016) , Guidelines for GCP ( ICH Topic E6 (R2) Guideline for Good Clinical Practice, Nov 
2016 ), and the Declaration of Helsinki ( World Medical Association, 64th General Assembly, 
Fortaleza 2013 ). In addi tion, the study will be conducted in accordance with applicable medical 
device regulation s.
13.3.[ADDRESS_798604]’s numerical code to their actual identity. In case of data transfer, the 
sponsor will maintain high standards of confidentiality and protection of subjects’ personal data 
consistent with applicable privacy laws.
Informed consent documents must be in complian ce with ICH GCP , local regulatory 
requirements (including applicable local medical device regulations) and legal requirements
(including applicable privacy laws ).Alldocuments used during the informed consent process 
must be reviewed and approved by [CONTACT_941] s ponsor, approved by [CONTACT_112392], and available 
for inspection.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798605]'s informed consent signed document (s).
13.3.[ADDRESS_798606] Recrui tment 
Advertis ing materials approved by [CONTACT_603077] ’sdatabase may be used to 
recruit study subject s.  Use of an IRB approved pre-screening questionnaire to assess general 
suitability (basic subject characteristics ) for th estudy ispermi tted.This generic questionnaire 
may be used as a phone script and/or to review internal databases to identify potential subjects.  
The sponsor will have an opportunity to review and approve the content of any recruitment 
materials before such materials are submitted for IRB review and used to identify potential 
study subjects . 
13.3.[ADDRESS_798607] research studies. 
In the event of any prohibition or restriction imposed (i.e., clinical hold) by [CONTACT_603078] i n any area of the world, or if the investigator is aware of any new 
information that might influence the evaluation of the benefits and risks of the investigational 
product (s), the sponsor should be informed immediately. 
In addition, the investigator will inform the sponsor immediately of any urgent safety measures 
taken by [CONTACT_1205], and of any 
serious breaches of this protocol or of ICH GCP that the investigator becomes aware of.
13.[ADDRESS_798608] the opportunity to review the 
complete study results at a sponsor site or other mutually agreeable location.
The sponsor will also provide the investigator with afull summary of the study results. The 
investigator is encouraged to share the summary results with the study subjects, as appropriate.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798609] maintain all site study records (except for 
those required by [CONTACT_1206]) in a safe and secure location.  
Records ( investigator site file) must be maintained in such a way to allow easy and timely 
retrieval when needed (e.g. ,for sponsor audit or regulatory inspection) and must be available 
for review in conjunction with assessment of the facility, supporting systems and relevant 
investigator site staff.
Where permitted by [CONTACT_1207]/regulations or institutional policy, some or all of thes e records 
can be maintained in a format other than hard copy (e.g. ,microfiche, scanned, electronic); 
however, caution needs to be exercised before such action is taken. The investigator must ensure 
that all reproductions are legible ,are a true and accura te copy of the original and meet 
accessibility and retrieval standards, including re -generati onofa hard copy, if required.  
Furthermore, the investigator must ensure there is an acceptable back -up of these reproductions 
and that an acceptable quality con trol process exists for making these reproductions.
The investigator must assure the subject’s anonymity will be maintained. In CRFs or other 
documents submitted to the sponsor , subjects should not be identified by [CONTACT_1208], 
but by [CONTACT_603079]. The investigator should keep a separate log of subjects’ codes, 
names and addresses.  Documents not for submission to the sponsor ( e.g.,subject signed consent 
forms )should be maintained by [CONTACT_1210].
Records and documents, including signed ICF s, pertaining to the conduct of this study must be 
retained by [CONTACT_1211], from the issue of the final 
CSR or equivalent summary, unless local regulations or institutional polici es require a longer 
retention period. The minimum retention time will meet the strictest standard applicable to that 
investigator site for th isstudy, as dictated by [CONTACT_380150], sponsor standards/procedures, and/or institutional requirements.  
No study document should be destroyed without a prior written agreement between the sponsor
and the investigator. The investigator must notify the sponsor of any changes in the archival 
arrangements including, but not limited to, archival at an off -site facility or transfer of 
ownership of the records in the event the investigator is no longer associated with the 
investigator site.
13.[ADDRESS_798610] all participating subjects and should assure 
appropriate therapy/follow -up for the subjects.  As directed by [CONTACT_456] , all study materials 
must be collected and all CRFs completed to the greatest extent possible. Where required by 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 82of 113
the applicable regulatory requirements, the spon sorshould inform the regulatory authority(ies) 
and the investigator should promptly inform the IRB and provide the IRB a detailed written 
explanation forthe termination or suspension. 
If the IRB terminates or suspends its approval/favorable opi[INVESTIGATOR_23748] , the investigator 
should promptly notify the sponsor and provide the sponsor with a detailed written explanation 
forthe termination or suspension.
Upon completion or premature discontinuation of the study, the sponsor’s monitor will conduct 
site closure activities with the investigator andsite staff, as appropriate, in accordance with 
applicable regulations ,including GCP and sponsor Standard Operating Procedures.
14 REFERENCES
[Absi EG, Addy M, Adams D (1987)] Dentine hypersensitivity: A study of the patency of 
dentinal tubules in sensitive and non -sensitive cervical dentine. J Clin Periodontol 1987; 14(5): 
280-284.
[Addy M, Mostafa P, Absi E , et al., editors (1985)] Cervical dentin hypersensitivity: Etiology 
and management with particular reference to dentifrices. Proceedings of Symposium on 
Hypersensitive Dentin: Origin and Management 1985: University of Michigan.
[Addy M, Mostafa P, Newcombe RG (1987)] Dentine hypersensitivity: the distribution of 
recession, sensitivity and plaque. J Dent 1987; 15(6): 242 -248.
[Addy M. (2000)] Dentine hypersensitivity: definition, prevalence, distribution and 
aetiology. Tooth wear and sensitivity: Clinical advances in restorative dentistry. London: 
Martin Dunitz 2000: 239 -248.
[Addy , M (2002)] Dentine hypersensitivity : New perspectives on an old problem. Int Dent J 
2002; 52: 367 -375.
[Aghazadeh Z, Behroozian A, Najafi H , et al. (2019 )]Comparison of gingival and dental 
indices in lactating a nd non -lactating mothers during first 6 month after delivery. Pesqui Bras 
Odontopediatria Clín Integr 2019; 19: e4586 .
[Amini P, Klukowska M, Eusebio R, et al. (2019)] Anti -Sensitivity Efficacy of Bioavailable 
Stannous Fluoride Dentifrice vs. Negative Cont rol (Abstract # 2322). IADR. Vancouver, 
Canada.
[Ashbeck EL, Bell ML. (2016)] Single time point comparisons in longitudinal randomized 
controlled trials: power and bias in the presence of missing data. BMC Med Res Methodol 2016; 
16: 43.
[Badadhe S, Gangarde G, et al. (2023)] Impact of anti -sensitivity toothpaste on oral health. 
World J Pharm Res 2023; 12(7): 1043 -1060.
[Bae JH, Kim YK, Myung SK (2015)] Desensitizing toothpaste versus placebo for dentin 
hypersensitivity: A systematic review and m eta-analysis. J Clin Periodontol 2015; 42(2): 131 -
141.
[Baker SR, Gibson BJ, Sufi F, et al. (2014)] The dentin hypersensitivity experience 
questionnaire (DHEQ): A longitudinal validation study. J Clin Periodontol 2014; 41: 52 -59. 
doi: 10.1016/B9780 -12-8016 31-2.[ZIP_CODE] -9. 
[Baron G, Ravaud P, Samson A, et al. (2008)] Missing data in randomized controlled trials of 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 83of 113
rheumatoid arthritis with radiographic outcomes: A simulation study. Arthritis Rheum -Arthritis 
Care Res 2008; 59: 25 -31.
[Bartold PM. (2006)] Dentin al hypersensitivity: a review. Aust Dent J 2006; 51(3): 212 -218.
[Başaran S, Celik C. (2018)] Turkish adaptation of dentin hypersensitivity experience 
questionnaire (DHEQ). Community Dent Health 2018; 35(1): 47 -51. 
[Boiko OV, Baker SR, Gibson BJ, et al. (2010)] Construction and validation of the quality of 
life measure for dentin hypersensitivity (DHEQ). Journal of clinical periodontology. 2010; 
37(11): 973 -980. 
[Brännström M (1963)] A hydrodynamic mechanism in the transm ission of pain producing 
stimuli through the dentin. In: Anderson DJ: Sensory mechanism in dentin. Oxford, Pergammon 
Press, 1963; 73 -79.
[Burnett GR, Willson RJ, Lucas RA .(2013) ]In vitro studies investigating the dentin tubule
occlusion properties of an experimental anhydrous stannous fluoride dentifrice. Am J Dent; 26
(SpI[INVESTIGATOR_602995]): 10A -14A. 
[Canadian Advisory Board on Dentin Hypersensitivity (2003)] Canadian Advisory Board 
on Dentin Hypersensitivity, Consensus -based recommendations for the diagnosis and 
management of dentin hypersensitivity. J Can Dent Assoc 2003; 69: 221 -226.
[Chaknis P, Panagakos FS, DeVizio W, et al. (2011)] Assessment of hypersensitivity reduction 
of a dentifrice containing 0.3% triclosan, 2.0% PVM/MA copolymer, 0.243% NaF and 
specially -designed silica as compared to a dentifrice containing 0.454% stannous fluoride, 
sodium hexametaphosphate and zinc lactate and to a dentifrice containing 0.243% NaF on 
dentin hypersensitivity reduction: An 8 -week study. Am J Dent; 24(A): 14 -20.
[Cox CF, White KC, Ramus DL, et al. (1992)] Reparative dentin: factors affecting its 
deposition. Quintessence Int 1992; 23: 257 -270.
[Creeth J, Gallob J, Sufi F, et al. (2019 [a])] Randomised clinical studies investigating 
immediate and short -term efficacy of an occluding toothpaste in providing dentine 
hypersensitivity relief. BMC Oral Health 2019; 19: 98.
[Creeth J, Maclure R, Seong J, et al. (2019 [b])] Three randomized studies of dentine 
hypersensitivity reduction after short‐term SnF 2toothpaste use J Cl in Periodontol 2019; 46: 
1105 -1115.
[Creeth JE, Burnett GR. (2021)] Efficacy of an Experimental Occlusion Technology 
Toothpaste in the Relief of Dentinal Hypersensitivity: An 8 -week Randomised Controlled Trial. 
Oral Health & Preventive Dentistry 2021; 19(1 ): 195 -202.
[Cunha -Cruz J, Wataha JC, Heaton LJ, et al. (2013)] The prevalence of dentin hypersensitivity 
in general dental practices in the northwest [LOCATION_002]. J Am Dent Assoc 2013; 144(3): 288 -
296.
[Dababneh RH, Khouri AT, Addy M . (1999)] Dentine hypersensitivity -an enigma? A review 
of terminology, mechanisms, aetiology and management. Br Dent J 1999; 187(11): 606-11. 
Discussion 603. DOI: 10.1038/sj.bdj.4800345. PMID: 16163281.
[Day T, Einwag J, Hermann J, et al. (2010)] A clinical asse ssment of the efficacy of a stannous 
containing sodium fluoride dentifrice on dentinal hypersensitivity. J Contemp Dent Pract 2010; 
11(1): E001 -E8.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 84of 113
[Dempsey PJ, Townsend G C. (2001)] Genetic and environmental contributions to variation in 
human tooth size. Heredity 2001; 86(6): 685.
[Docimo R, Montesani L, Maturo P, et al. (2009)] Comparing the Efficacy in Reducing Dentin 
Hypersensitivity of a New Toothpaste Containing 8.0% Arginine, Calcium Carbonate, and 1450 
ppm Fluoride to a Commercial Sensitive Toothpas te Containing 2% Potassium Ion: An Eight -
Week Clinical Study in Rome, Italy . J Clin Dent 2009; 20(1) (Spec Iss): 17 -22. 
[Douglas -de-Oliveira DW, Vitor GP , Silveira JO, et al. (2018)] Effect of dentin 
hypersensitivity treatment on oral health related quality of life –A systematic review and meta -
analysis. J Dent 2018; 71: 1 -8. 
[D’Souza RN, Bachman T, Baumgardner KR, et al. (1995) ] Characterization of cellular 
responses involve d in reparative dentinogenesis in rat molars. J Dent Res 1995; 74: 702 -709.
[DuM, Jiang H, Tai B, et al. (2011)] De -sensitizing effect of a stannous containing sodium 
fluoride novel dentifrice (Abstract #2826). IADR 2011 ,San Diego, [LOCATION_004].
[Earl JS, Langford RM (2013)] Physical and chemical characterization of the surface layers 
formed on dentin following treatment with an experimental anhydrous stannous fluoride 
dentifrice. Am J Dent 2013; 26 (SpI[INVESTIGATOR_602995]): 19A -24A.
[Ellingsen JE, Rolla G. (1987)] Treatme nt of dentin with stannous fluoride –SEM and electron 
microprobe study. European J Oral Sci 1987; 95(4): 281 -286.
[Exterkate RAM. (2022)] What is the functioning of tin in stannous fluoride? Nederlands 
tijdschrift voor tandheelkunde 2022; 129(5): 219 -222.
[Fischer C, Fischer RG, Wennberg A. (1 992)] Prevalence and distribution of cervical dentine 
hypersensitivity in a population in Rio de Janeiro, Brazil J Dent 1992 ;20:272-276.
[Flynn J, Galloway R, Orchardson R. (1985)] The incidence of “hypersensitive” teeth in the 
West of Scotland. J Dent 1985 ;13:230-236.
[Gagliese L, Weizblit N, Ellis W, et al.(2005)] The measurement of postoperative pain: a 
comparison of intensity scales in younger and older surgical patients. Pai n 2005; 117(3): 412 -
420. 
[Gallob J, Sufi F, Amini P, et al. (2017)] A randomised exploratory clinical evaluation of 
dentifrices used as controls in dentinal hypersensitivity studies. Journal of dentistry; 64: 80 -87.
[Gerlach RW, Sagel P (2017)] Concurrent Sensitivity and Gingivitis Effects of SnF 2/H2O2 
Hygiene: Inclusive Meta -Analysis (Abstract # 3042). IADR 2017 San Francisco, [LOCATION_004].
[Gibson BJ, Boiko OV, Baker SR, et al. (2015) ]The everyday impact of dentin sensitivity: 
Personal and functional aspects.  Dentin Hypersensitivity: Elsevier; 2015. p. 89 -107. 
[Gillam DG, Aris A, Bulman JS, et al. (2002 )]Dentine hypersensitivity in subjects recruited 
for clinical trials: clinical evaluation, prevalence and intra -oral distribution .JOral Rehab 2002 ;
29:226-231.
[Gysi A(1900)] An attempt to explain the sensitiveness of dentine. Br Dent J 1900; 43:865-
868. 
[Hall C, Mason S, Cooke J. (2017)] Exploratory randomised controlled clinical study to 
evaluate the comparative efficacy of two occluding toothpastes –a 5% calcium sodium 
phosphosilicate toothpaste and an 8% arginine/calcium carbonate toothpaste –for the longer -
term relief of dentine hypersensitivity. J Dent 2017 ;60:36-42.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 85of 113
[Hazen S, Volpe A, King W ( 1968)] Comparative desensitizing effect of dentifrices containing 
sodium monofluorophosphate, stannous fluoride, and formalin. Periodontics 1968 ; 6(5): 230 -
232.
[HeT, Barker ML, Biesbrock A, et al. (2014 [a])] A randomized controlled clinical trial to as sess 
the desensitizing effect of a stannous fluoride dentifrice. Am J Dent; 27(2): 106 -110. 
[HeT, Barker ML, Biesbrock AR, et al. (2014 [b])] A Clinical Study to Assess the Effect of a 
Stabilized Stannous Fluoride Dentifrice on Hypersensitivity Relative t o a Marketed Sodium 
Fluoride/Triclosan Control. J Clin Dent 2014; 25(2): 13 -18.
[HeS, Wang J. (2015 [a])]Development of the chinese version of the dentin hypersensitivity 
experience questionnaire.  Dentin Hypersensitivity ;Elsevier 2015 :165-175. 
[HeSl, Wang J H.(2015[b])] Reliability and validity of the chinese version of the short form of 
the dentin hypersensitivity experience questionnaire ( DHEQ -15). Quality of Life Research 
2015a; 24(6): 1465 -1469. 
[HeT, Peters J, Goyal CR, et al. (2019)] Clini cal Desensitizing Effect of Bioavailable SnF 2
Dentifrice (Abstract # 2210). IADR 2019 Vancouver, Canada. 
[Heaton LJ, Barlow AP, Coldwell SE. (2013)] Development of labeled magnitude scales for 
the assessment of pain of dentin hypersensitivity. J Orofac Pa in 2013; 27(1): 72 -81. 
[Hines D, Xu S, Stranick M, et al. (2019)] Effect of a stannous fluoride toothpaste on dentinal 
hypersensitivity: In vitro and clinical evaluation. J Am Dent Assoc 2019; 150(4): S47 -S59.
[Holland GR, Narhi MN, Addy M, et al. (1997)] Guidelines for the design and conduct of 
clinical trials on dentine hypersensitivity. J Clin Periodontol 1997; 24(11): 808-13.
[Kanouté A, Ndame Dieng S, Diop M, et al. (2022)] Chemical vs. natural toothpaste: which 
formulas for which properties? A scopi[INVESTIGATOR_17971] . JPHIA 2022 ;13(3):1-13.https://doi.or 
g/10.4081/jphia.2022.1945.
[Kenward MG, Roger J H. (1997)] Small sample inference for fixed effects from restricted 
maximum likelihood. Biometrics 1997 ; 53(3): 983-997.
[Kim JY,et al. ( 2021 )] Clinical and In-Vitro Studies of Our New SnF 2Toothpaste. [ADDRESS_798611]/AADR/CADR General Session . 
[Konradsson K, Lingström P, Emilson CG, et al. (2020)] Stabilized stannous fluoride 
dentifrice in relation to dental caries, dental erosion and dentin hy persensitivity: A systematic 
review. Am J Dent 2020; 33(2): 95 -105.
[Laster L, Laudenbach KW, Stoller NH. (1975)] An evaluation of clinical tooth mobility 
measurements. J. Periodontol 1975 ;46:603-607.
[Leight R, Sufi F, Gross R, et al. (2008 )] Dentinal hypersensitivity: A [ADDRESS_798612]-to-reach molar teeth. J ClinDent 2008; 19(4): 147-53.
[Linde A, Goldberg M. (1993)] Dentinogenesis. Crit Rev Oral Biol Med 1993; 4(5): 679 -728.
[Lobene RR, Weatherford T, Ross NM, et al. (1986)] A modified gingival index for use in 
clinical trials. Clin Prev Dent 1986 ;8:3-6.
[Machuca C, Baker S, Sufi F, et al. ( 2014)] Derivation of a short form of the de ntine 
hypersensitivity experience questionnaire. J Clin Periodontol 2014; 41:46-51.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 86of 113
[Magloire H, Bouvier M, Joffre A. (1992)] Odontoblast response under carious lesions. Proc 
Finn Dent Soc 1992; 88(Suppl 1): 257 -274. 
[Makin SA. (2013)] Stannous fluoride dentifrices. Am J Dent 2013 ;26 Spec No A:3A –9A.
[Martins CC, Firmino RT, Riva JJ, et al. (2020)] Desensitizing Toothpastes for Dentin 
Hypersensitivity: A Network Meta -analysis. J Dent Res 2020; 99: 514 -22.
[Martins CC, Riva J J, Firmino RT, et al. (2022)] Formulations of desensitizing toothpastes for 
dentin hypersensitivity: a scopi[INVESTIGATOR_17971]. J Appl Oral Sci 2022; 30: e20210410. 
https://doi.org/10.1590/1678 -7757 -2021 -0410.
[Marto C, Baptista PA, Nunes T, et al. (2020)] Evaluati on of the efficacy of dentin 
hypersensitivity treatments -A systematic review and follow -up analysis. J Oral Rehab 2020; 
46: 952 -90. 
[Mason S, Kingston R, Shneyer L, et al . (2017) ]. Clinical study to monitor dentinal 
hypersensitivity with epi[INVESTIGATOR_100748] a desensitising dentifrice. BDJ open2017; 3(1): 1-6.
[Mason S, Burnett GR, Patel N, et al. (2019)] Impact of toothpaste on oral health -related quality 
of life in people with dentine hypersensitivity. BMC Oral Health 2019; 19: 1 -11. 
[Miller S, Truong T, Heu R, et al. (1994 )] Recent advances in stannous fluoride te chnology: 
antibacterial efficacy and mechanism of action towards hypersensitivity. Int DentJ 1994; 44
(Suppl.1): 83 -98.
[Mjör IA. (2002)] Clinical Management and Tissue Changes Associated with Wear and 
Trauma, in Pulp -Dentin Biology in Restorative Dentis try 2002: 80 -83. ISBN: 0 -[ZIP_CODE] -412-8.
[NiLX, He T, Chang A, et al. (2010)] The desensitizing efficacy of a novel stannous -containing 
sodium fluoride dentifrice: An 8 -week randomized and controlled clinical trial. Am J Dent 
2010; 23(SpI[INVESTIGATOR_602996]): 17B -21B.
[NiL, He T, Chang J, et al. (2011)] De -sensitizing effect of a stannous containing sodium 
fluoride toothpaste (Abstract #2825). IADR 2011 San Diego, [LOCATION_004].
[Parkinson CR, Willson RJ (2011)] A comparative in vitro study investigating the occlusion 
and mine ralization properties of commercial dentifrices in a four -day dentine disc model. J. 
Clin. Dent 2011; 22(3): 74 -81. 
[Parkinson C, Hughes N, Jeffery P, et al. (2013)] The efficacy of an experimental dentifrice 
containing 0.454% w/w stannous fluoride in providing relief from the pain of dentin 
hypersensitivity: an 8 -week clinical study. Am J Dent 2013; 26(SpI[INVESTIGATOR_602995]): 25A -31A.
[Parkinson CR, Jeff ery P, Milleman JL, et al. (2015[a])] Confirmation of efficacy in providing 
relief from the pain of dentin hypersensitivity of an anhydrous dentifrice containing 0.454% 
with or without stannous fluoride in an 8 -week randomized clinical trial. Am J Dent; 28 (4): 
190-196. 
[Parkinson et al (2015 [b])] RCTs of Stannous Fluoride Toothpaste Antimicrobial Activity; 
Evaluation of the Plaque Glycolysis and Regrowth Model. J Dent Res 2015; 94B: Abstract # 
34. BSODR Cardiff, [LOCATION_006].
[Pashley DH (1994 )]Dentine permeability and its role in the pathobiology of dentine 
sensitivity. Arch Oral Biol 1994; 39:S73-80.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 87of 113
[Pereira JC, de Carvalho Sales -Peres SH, Francisconi -dos-Rios LF, et al. (2015)] Current and 
novel clinical approaches for the treatment of dentin hypersensitivity. Dentine Hypersensitivity: 
Advances in Diagnosis, Management, and Treatment 2015: 101-32.
[Pollard AJ,Khan I, Davies M, et al. (2023)] Comparative efficacy of self -administered 
dentifrices for the management of dentine hypersensitivity -A systematic review and network 
meta -analysis .JDent2023; 130: 104433 .
[Polson AM, Caton JG, Yeaple RN, et al. (1 980)]Histological determination of probe tip 
penetration into gingival sulcus of humans using an electronic pressure -sensitive probe. J Clin
Periodontol 1980 ; 7(6): 479 -88.
[Porritt JM, Sufi F, Baker SR. (2016)] Utilising daily diaries to examine oral health experiences 
associated with dentin hypersensitivity. BMC Oral Health 2016; 16:1-11.
[Rees JS.(2000)] The prevalence of dentine hypersen sitivity in general dental practice in the 
[LOCATION_006]. J Clin Periodontol 2000 ;27:860–865.
[Robinson PG.(2014)] Dentin hypersensitivity: Developi[INVESTIGATOR_007] a person -centred approach to oral 
health .Academic Press; 2014.
[Samant A, Malik C, Chabra S, et al. (1976)] Gingivitis and periodontal disease in pregnancy. 
J Periodontol 1976; 47(7): 415 -8.
[Schiff T, Dotson M, Cohen S , et al. (1994 )] Efficacy of a dentifrice containing potassium 
nitrate, soluble pyrophosphate, PVM/MA copol ymer, and sodium fluoride on dentinal 
hypersensitivity: atwelve -week clinical study. J Clin Dent 1994; 5: 87 -92. PMID: 8534380.
[Schiff T, Saletta L, Baker R, et al. (2005)] Desensitizing effect of a stabilized stannous 
fluoride/sodium hexametaphosphate d entifrice. Compend Cont Ed Dent; 26([ADDRESS_798613].1): 35 -40.
[Schiff T, He T, Sagel L, et al. (2006)] Efficacy and safety of a novel stabilized stannous 
fluoride and sodium hexametaphosphate dentifrice for dentinal hypersensitivity. J Contemp 
Dent Pract 2006 ;7:1-8.
[Seltzer S, Bender I. (1975)] The Dental Pulp: Biologic Considerations in Dental Procedure s, 
2ndEdition, Philadelphia, PA: JBLippi[INVESTIGATOR_100251]1975 .
[Sharma N, Roy S, Kakar A, et al. (2010)] A clinical study comparing oral formulations 
containing 7.5% calcium sodium phosphosilicate (NovaMin), 5% potassium nitrate, and 0.4% 
stannous fluoride for t he management of dentin hypersensitivity. J Clin Dent; 21(3): 88 -92.
[ShiY, Chen H, Sun L. (2012)] Dentin Tubule Occlusion with a Novel SnCl 2/NaF/Silica 
Dentifrice (Abstract #1354). AADR Annual Meeting 2012 Tampa, [LOCATION_012].
[Splieth CH, Tachou A. (2013)] Epi[INVESTIGATOR_602997]. Clin Oral Invest 
2013; 17: 3 -8. 
[van Berckel MM, Bosma NH, Hageman MG, et al. (2017)] The correlation between a 
numerical rating scale of patient satisfaction with current management of an upper extremity
disorder and a general measure of satisfaction with the medical visit. Hand 2017; 12(2): 202-
206.
[Vinaya KR, Shubhashini N, Seshan H, et al. (2010)] A clinical trial comparing a stannous 
fluoride based dentifrice and a strontium chloride based dentifrice in alleviating dentinal 
hypersensitivity. J Int Oral Health; 2(1): 37 -50.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 88of 113
[West N, Addy M, Jackson R, et al. ( 1997 )] Dentine hypersensitivity and the placebo response: 
A comparison of the effect of strontium acetate, potassium nitrate and fluoride tooth pastes. J
ClinPeriodontol 1997; 24(4): 209-15.
[West NX.(2008) ]Dentine hypersensitivity: preventive and therapeutic approaches to 
treatment. Periodontol 2000 ;48(1) :31-41.
[West NX, Sanz M, Lussi A, et al. (2013) ]Prevalence of dentine hypersensitivity and study of 
associated factors: a European population -based cross -sectional study. J Dent2013; 41(10) :
841-851.
[West N, Seong J, Davies M .(2014)] Dentine hypersensitivity. Monogr Oral Sci 2014 ; 25: 108 -
122.
[West NX, Seong J, Davies M . (2015)] Management of dentine hypersensitivity: efficacy of 
professionally and self‐administered agents. J Clin Periodontol 2015; 42:S256 -S302.
[West N, Davies M, He T, et al. (2019)] Effects of bioavailable SnF 2dentifrice on erosion and 
sensitivity: meta -analysis (Abstract #2323). IADR 2019 Vancouver, Canada.
[West NX, He T, Zou Y, et al. (2021)] Bioavailable gluconate chelated stannous fluoride 
toothpaste meta -analyses: Effects on dentine hypersensitivity and enamel erosion. J Dent 2021; 
105: 103566.
[West NX(2022)] Position paper by [CONTACT_603080]. Available on request .
[White DJ, Lawless M, Fatade A, et al. (2007)] Stannous fluoride/sodium hexametaphosphate 
dentifrice increases dentin resistance to tubule exposure in vitro. J Clin Dent 2007 ; 18(2): 55 -
59.
[Yang S, Ying K, Wang F, et al. (2016)] Desensitizing effect of stannous fluoride -containing 
toothpaste for patients with dentine hypersensitivity: a meta-analysis. West China J Stomatol; 
34(2): 150 -155.
[Zsiska M. (2012)] Dentinal tubule occlusion with stannou s fluoride and KNO 3/Gantrez 
dentifrices. J Dent Res; 91: 744.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798614]
CSM Clinical Study Manager
CSR Clinical Study Report
DH Dentin Hypersensitivity
DHEQ Dentin Hypersensitivity Experience Questionnaire
EAR Erosion/Abrasion/Attrition
eCRF Electronic Case Report Form
EDC Electronic Data Capture
EudraCT European Clinical Trials Database
FDA Food and Drug Administration ([LOCATION_002] )
g Gram
GCP Good Clinical Practice
GDS Global Data Sheet
GRASE Generally Recognized as Safe and Effective
[COMPANY_004]CH GlaxoSmithKline Consumer Healthcare
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Conference on Harmonisation
IND Investigational New Drug 
IRB Institutional Review Board
IRT Interactive Response Technology
LMS Labelled Magnitude Scale
LSLV Last Subject Last Visit 
MedDRA Medical Dictionary for Regulatory Activities
MGI Modified Gingival Index
mITT Modified Intention -to-Treat
ml Milliliter
mm Millimeter
MMRM Mixed Model with Repeated Measures
MoA Mode of Action
N/A Not Applicable
NRS Numeric Rating Scale
OHrQoL Oral Health -Related Quality of Life
OHT Oral Hard Tissue300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798615] Operating Procedure
TEAE Treatment Emergent Adverse Event
US [LOCATION_002]
VAS Visual Analogue Scale300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 91of 113
15.2 Dentin eHypersensitivity Experience Questionnaire (Example 
DHEQ -48)
SECTION ONE
The following questions are about your sensitive teeth, and the impact it has on your everyday life.
From now on in this questionnaire we are going to call what you feel as ‘sensations in your teeth’ or 
‘sensations’ .
300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 92of 113
300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798616] it has on your everyday life.
300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798617] month to what extent would you agree 
or disagree with the following statements (Please tick only one response for each question).
Strongly 
agree 
(7) Agree 
(6) Agree a 
little 
(5) Neither 
agree 
nor
disagree 
(4) Disagree 
a little 
(3) Disagree 
(2) Strongly 
disagree 
(1) 
1) Having sensations in my teeth 
takes a lot of the pleasure out of 
eating and drinking. 
2) There have been times when I 
can’t finish my meal because of 
the sensations. 
3) It takes a long time to finish 
some foods and drinks because of 
sensations in my teeth. 
4) There have been times when I 
have had problems eating ice 
cream because of these 
sensations. 
The following questions are about the ways in which the sensations in your teeth have 
forced you to change things in your daily life.Thinking about yourself over the last month
to what extent would you agree or disagree with the following statements (Please tick only one 
response for each question).
Strongly 
agree 
(7) Agree 
(6) Agree a 
little 
(5) Neither 
agree nor
disagree 
(4) Disagree  
a little 
(3)Disagree 
(2) Strongly 
disagree 
(1) 
5) I have to change the way I eat 
or drink certain things. 
6) I have to be careful how I 
breathe on a cold day. 
7) I have to leave some cold 
foods or drinks to warm up 
before I can have them. 
8) I have to cool some foods or 
drinks down before I can have 
them. 
9) I have to cut up some fruits 
before being able to eat them. 
10) I have to wear a scarf over 
my mouth on cold days. 
300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798618] month to what extent 
would you agree or disagree with the following statements (Please tick only one response f or
each question).   
Strongly 
agree 
(7) Agree 
(6) Agree a 
little 
(5) Neither 
agree nor
disagree 
(4) Disagree  
a little 
(3) Disagree 
(2) Strongly 
disagree 
(1) 
11) I have avoided very cold 
drinks or foods. 
12) I have avoided very hot 
drinks or foods. 
13) When eating some foods I 
have made sure they don’t 
touch certain teeth. 
14) I have changed the way I 
brush my teeth. 
15) When eating some foods I 
have made sure I bite in small 
pi[INVESTIGATOR_6928]. 
16) There are other foods I 
have avoided. 
Thefollowing questions are about the way the sensations affect you when you are with other 
people or in certain situations . Thinking about yourself over the last month to what extent 
would you agree or disagree with the following statements (Please tick only one response for 
each question).
Strongly 
agree 
(7) Agree 
(6) Agree a 
little 
(5) Neither 
agree nor
disagree 
(4) Disagree  
a little 
(3) Disagree 
(2) Strongly 
disagree 
(1) 
17) Because of the sensations I 
take longer than others to finish 
a meal. 
18) I have to be careful what I 
eat when I am with others 
because of the sensations in 
my teeth. 
19) I hide the way I am eating 
when I am with others because 
of the sensations in my teeth. 
20) I am unable to fully take 
part in conversations because 
of the sensations in my teeth. 
300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 96of 113
21) Going to the dentist is hard 
for me because I know it is 
going to be painful as a result 
of sensations in my teeth. 
The following questions are about the way the sensations in your teeth make you feel.
Thinking about yourself over the last month to what extent would you agree or disagree with 
the following statements (Please tick only one response for each question).
Strongly 
agree
(7)Agree
(6)Agree a 
little
(5)Neither 
agree 
nor
disagree
(4)Disagree 
a little
(3)Disagree
(2)Strongly 
disagree
(1)
22) I’ve been frustrated because I 
can’t find anything that deals with 
the sensations I have in my teeth. 
23) I’ve been anxious that 
something I eat or drink might 
cause sensations in my teeth. 
24) The sensations in my teeth 
have been irritating. 
25) I have been annoyed with 
myself because I did something 
that I knew caused these 
sensations. 
26) I felt guilty because I might 
have contributed to the sensations 
I am having with my teeth. 
27) The sensations in my teeth 
have been annoying. 
28) The sensations in my teeth 
have been embarrassing. 
29) I have been anxious because 
of the sensations in my teeth. 
The following questions are about what the sensations in your teeth mean for you. Thinking 
about yourself over the last month to what extent would you agree or disagree with the 
following statements (please tick only one response for each question).
Strongly 
agree 
(7) Agree 
(6) Agree a 
little 
(5) Neither 
agree nor
disagree 
(4) Disagree  
a little 
(3) Disagree 
(2) Strongly 
disagree 
(1) 
30) I find it difficult to accept 
that I am a person who has 
these sensations in my teeth. 
300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 97of 113
31) Having these sensations in 
my teeth makes me feel 
different from others. 
32) Having these sensations in 
my teeth makes me feel old. 
33) Having these sensations in 
my teeth makes me feel 
damaged. 
34) Having these sensations in 
my teeth makes me feels as 
though I am unhealthy. 
The last five questions ask about how much the sensations in your teeth affect your life 
overall . 
Excellent 
(1) Very
good 
(2) Good  
(3) Fair 
(4) Poor 
(5) Very poor 
(6) 
35) Overall how would you rate the 
health of your mouth, teeth and gums?
Very Much
(4)Quite a bit
(3)Somewhat
(2)A little
(1)Not at all
(0)
36) Overall how much do the sensations in 
your teeth bother you?
37) Overall, how much do the things you 
do to manage the sensations bother you?
38) Overall, how much do the sensations 
in your teeth affect your quality of life?
39) Overall, how much do the things you 
do to manage the sensations in your teeth 
affect your quality of life?
300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 98of 113
15.3 Labelled Magnitude Scales : Intensity, Duration, Tolerability & 
Description (Example LMSs )
NOT TO SCALE
300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 99of 113
NOT TO SCALE
300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 100of 113
15.4 LMS Training Exercise (Example)
STUDY STAFF INSTRUCTIONS 
Subjects will be given a hard copy of the instructions for completing the LMS s; the investigator
(or designee )should read the ‘Subject I nstructions ’aloud while the subject reads along. 
Subjects should be encouraged to ask questions if they are unsure about anything they read.
The subject will then complete the LMS training exercise, and t he investigator (or designee )
will determine whether the subject understands how to use the LMS based on the irtraining 
exercise responses and the guidance below. 
Interpretation of the Line Scale Training Exercise 
The objective of th e training exercise is NOT to determine whether the subject can provide 
specific ‘correct’ answers but to determine ifthey understand the concept of LMS completion . 
The following gener al assessment criteria are suggested .
•Is the subject placing their marks only on the verbal descriptors? If so, remind them they 
should usethe entire scale, including areas of the line between descriptors. 
•Is the subject placing their marks in the same place on all four LMSs . If so, explain 
again that each LMS measure sa different aspect of their response (intensity, duration, 
their ability to tolerate it, and how they would descri be it) and this likely produce marks 
in different places on each scal e. 
•The s ubject should indicate their response by [CONTACT_40009] ‘X’on the LMS . If they are 
circling descriptors ormaking unclear marks, remin dthem of the correct way to record 
their response . 
If the subject appear sunable to complete theLMS s(intensity, duration, tolerability and 
description) with appropriate responses, the investigator (or designee )should talk through the ir
grading of the first two scenarios. If the marks are generally correctly ordered but far from their 
likely true positi ons, askthe subject to verbalize why they placed the marks where they did. 
However, the investigator/ designee should be careful not to pressure the subject to change their 
responses. Start with an item the subject rated ‘well’, ask about that , then conti nue by [CONTACT_603081]. 
If the investigator (or designee) deems a subject unable to provide appropriate responses to the 
LMS training questions, it is unlikely they will provide reliable LMS responses following 
application of the evaporative (air) stimulus . The subject should be withdrawn.300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ADDRESS_798619] INSTRUCTIONS 
The purpose of this training exercise is to introduce you to four different linescale syou will be 
asked to useduring the study . Each one hasdifferent words positioned along the line that can 
be used to rate the feeling sor sensations people can experience in their mouths.
There are no right or wrong answers. 
Read the description of each example sensation or feeling carefully , then try to remember or 
imagine what each onefeels like. If you haven’t experience d exactly what is described, try to 
think of something similar. As you think about theexample , think about the word on the line 
that best describes what that sensation feels like. You can ‘fine tun e’your rating to best reflect 
that experience by [CONTACT_603082] s next to it, up or down the 
scale. 
INDICATE HOW YOU WOULD RATE THE FEELING DESCRIBED BY [CONTACT_603083] 
‘X’ON THE LINE. 
YOU CAN PLACE YOUR MARK ANYWHERE ALONG THE LINE , EXACTLY ON A 
DESCRIPTIVE WORD OR BETWEEN WORDS. 
Please turn to the next page for the first example in this exercise. 300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 102of 113
Let’s start with this example. 
The touch of a pi[INVESTIGATOR_602998]. 
Have you ever experienced this feeling or sensation before? Yes / No (Please circle one)
First please rate the INTENSITY of this feeling or sensation. 
Mark the scale below with an ‘X’to indicate the best description of that feeling or sensation. 
Remember, you can mark anywhere on the line, including between the descriptive words. 
NOT TO SCALE 
Please turn to the next page. 
300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 103of 113
Still thinking about the touch of a pi[INVESTIGATOR_602998] , please rate the DURATION of this 
feeling or sensation. 
Mark the scale below with an ‘X’to indicate the best description of that feeling or sensation. 
Remember, you can mark anywhere on the line, including between the descriptive words.
NOT TO SCALE 
Please turn to the next page. 
300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 104of 113
Still thinking about the touch of a pi[INVESTIGATOR_602998] , please rate how much you are able to 
TOLERATE with this feeling or sensation. 
Mark the scale below with an ‘X’to indicate the best description of that feeling or sensation. 
Remember, you can mark anywhere on the line, including between the descriptive words. 
NOT TO SCALE 
Please turn to the next page. 
300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 105of 113
Finally, still thinking about the touch of a pi[INVESTIGATOR_602998] , please give a rating that 
DESCRIBES the kind of feeling or sensation this is. 
Mark the scale below with an ‘X’to indicate the best description of that feeling or sensation. 
Remember, you can mark anywhere on the line, including betwe en the descriptive words. 
NOT TO SCALE 
Please turn to the next page. 
300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 106of 113
Let’s try this example. 
The pain from biting your tongue. 
Have you ever experienced this feeling or sensation before? Yes / No (Please circle one)
First please rate the INTENSITY of this feeling or sensation. 
Mark the scale below with an ‘X’to indicate the best description of that feeling or sensation. 
Remember , you can mark anywhere on the line, including between the descriptive words. 
NOT TO SCALE 
Please turn to the next page. 
300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 107of 113
Still thinking about the pain from biting your tongue , please rate the DURATION of this 
feeling or sensation. 
Mark the scale below with an ‘X’to indicate the best description of that feeling or sensation. 
Remember, you can mark anywhere on the line, including between the descriptive words.
NOT TO SCALE 
Please turn to the next page. 
300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 108of 113
Still thinking about the pain from biting your tongue , please rate how much you are able to 
TOLERATE with this feeling or sensation. 
Mark the scale below with an ‘X’to indicate the best description of that feeling or sensation. 
Remember, you c an mark anywhere on the line, including between the descriptive words.
NOT TO SCALE 
Please turn to the next page. 
300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 109of 113
Finally, still thinking about the pain from biting your tongue , please give a rating that 
DESCRIBES the kind of feeling or sensation this is. 
Mark the scale below with an ‘X’to indicate the best description of that feeling or sensation. 
Remember, you can mark anywhere on the line, including between the descriptive words. 
NOT TO SCALE 
Please turn to the next page. 
300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 110of 113
Let’s try one last example. 
The pain of a persistent toothache. 
Have you ever experienced this feeling or sensation before? Yes / No (Please circle one)
First please rate the INTENSITY of this feeling or sensation. 
Mark the scale below with an ‘X’to indicate the best description of that feeling or sensation. 
Remember, you can mark anywhere on the line, including between the descriptive words. 
NOT TO SCALE 
Please turn to the next page. 
300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 111of 113
Still thinking about the pain of a persistent toothache , please rate the DURATION of this 
feeling or sensation. 
Mark the scale below with an ‘X’to indicate the best description of that feeling or sensation. 
Remember, you can mark anywhere on the line, including between the descriptive words. 
NOT TO SCALE 
Please turn to the next page. 
300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 112of 113
Still thinking about the pain of a persistent toothache , please rate how much you are able to 
TOLERATE with this feeling or sensation. 
Mark the scale below with an ‘X’to indicate the best description of that feeling or sensation. 
Remember, you can mark anywhere on the line, including between the descriptive words. 
NOT TO SCALE 
Please turn to the next page. 
300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI
Haleon
Clinical Protocol
Protocol Number :[ZIP_CODE] 3
Property of Haleon -Confidential
May not be used, divulged, p ublished or otherwise disclosed without the consent of Haleon
Clinical Protocol Template v 10.0
Page 113of 113
Finally, still thinking about the pain of a persistent toothache , please give a rating that 
DESCRIBES the kind of feeling or sensation this is. 
Mark the scale below with an ‘X’to indicate the best description of that feeling or sensation. 
Remember, you can mark anywhere on the line, including between the descriptive words. 
NOT TO SCALE 
You have finished the training exercise and are now re ady to take part in the main part 
of the study. 
If you have any questions about this training , please ask the member of staff training you.
If you feel that you understand how to use these scales, please tellthemember of staff too . 
Thank you for your time!
300103 Protocol  06 Feb 2024 | TMF-248202 | 1.3
CCI